Activation of proestrogens from hops by human intestinal bacteria: conversion of isoxanthohumol into the potent phytoestrogen 8-prenylnaringenin by Possemiers, Sam
 
  
 
 
 
 
 
 
 
Promotoren: Prof. dr. ir. W. Verstraete 
 Vakgroep Biochemische en Microbiële Technologie 
 Laboratorium voor Microbiële Ecologie en Technologie (LabMET) 
 Universiteit Gent 
 
 Prof. dr. ir. John Van Camp 
 Vakgroep Voedselveiligheid en Voedselkwaliteit 
 Onderzoeksgroep Levensmiddelenleer en Humane Voeding 
 Universiteit Gent 
 
Decaan: Prof. dr. ir. H. Van Langenhove 
 
Rector:  Prof. dr. P. Van Cauwenberge 
 
 
 
The work presented in this dissertation was performed at the Laboratory of Microbial Ecology 
and Technology (LabMET), Ghent University (Ghent, Belgium) and in the Unité de l’Ecologie 
et Physiologie du système Digestif (UEPSD), Institut National de la Recherche Agronomique 
(INRA, Jouy-en-Josas, France). 
 
This work was supported by a fellowship (aspirant) of the Fund for Scientific Research – 
Flanders (Fonds voor Wetenschappelijk Onderzoek (FWO) – Vlaanderen). 
 ir. Sam POSSEMIERS 
 
ACTIVATION OF PROESTROGENS FROM HOPS BY 
HUMAN INTESTINAL BACTERIA:  
 
 
 
CONVERSION OF ISOXANTHOHUMOL INTO THE POTENT 
PHYTOESTROGEN 8-PRENYLNARINGENIN 
 
 
Thesis submitted in fulfillment of the requirements for the degree of 
Doctor (PhD) in Applied Biological Sciences  
  
Titel van het doctoraat in het Nederlands: 
 
ACTIVATIE VAN PRO-OESTROGENEN UIT HOP DOOR HUMANE INTESTINALE 
BACTERIEN: OMZETTING VAN ISOXANTHOHUMOL IN HET KRACHTIGE FYTO-
OESTROGEEN 8-PRENYLNARINGENINE 
 
 
 
 
 
 
 
 
 
 
To refer to this thesis: 
Possemiers, S. (2007). Activation of proestrogens from hops by human intestinal bacteria: 
conversion of isoxanthohumol into the potent phytoestrogen 8-prenylnaringenin. PhD thesis, 
Ghent University, Belgium 
 
 
 
 
ISBN 978-90-5989-170-8 
 
 
The author and the promotors give the authorization to consult and copy parts of this work for 
personal use only. Every other use is subjected to copyright laws. Permission to reproduce 
any material contained in this work should be obtained from the author. 
 i 
NOTATION INDEX 
Abs: absorbance 
ADME: Concept of bioavailability based on absorption, distribution, metabolism and excretion 
AF: activation function 
ANOVA: analysis of variance 
BHI: brain heart infusion 
BMD: bone mineral density 
BMI: body mass index 
BW: body weight 
CAM: complementary and alternative medicine  
CAU: corrected absorbance units 
CFU: colony forming units 
CoA: coactivator 
CPRG: chlorophenol red β-D-galactopyranoside 
CVD: cardiovascular disease 
CYP: cytochrome P450 enzyme 
DAD: diode array detector 
DBD: DNA binding domain 
DGGE: denaturing gradient gel electrophoresis 
DHD: dihydrodaidzein 
DMSO: dimethylsulfoxide 
DMX: desmethylxanthohumol 
EC50: 50 % effect concentration 
END: enterodiol 
ENL: enterolactone 
ER: estrogen receptor 
ERE: estrogen response element 
ESI: electrospray ionization 
E2: 17β-estradiol  
GC: gas chromatography 
GF: germ-free 
GRAS: generally recognized as safe 
HMA: human microbiota associated 
HPLC: high-performance liquid chromatography 
HRT: hormone replacement therapy 
Notation index 
 ii 
HSP: heat shock protein 
IBD: inflammatory bowel disease 
IC50: 50 % inhibition/induction concentration 
IF: induction-fold of cell proliferation 
IX: isoxanthohumol 
LBD: ligand binding domain 
LC-MS/MS: liquid chromatography – mass spectrometry/ mass spectrometry 
LDL: low-density lipoprotein 
LOD: limit of detection 
MAPK: mitogen-activated protein kinase 
MAT: matairesinol 
MDS: multidimensional scaling 
MPB: methane producing bacteria 
MWS: Million Women Study 
NMR: nuclear magnetic resonance 
O-DMA: O-desmethylangolensin 
PCR: polymerase chain reaction 
6-PN: 6-prenylnaringenin 
8-PN: 8-prenylnaringenin 
ROS: reactive oxygen species 
SCFA: short chain fatty acids 
SDG: secolariciresinol-diglucoside 
SECO: secolariciresinol 
SERM: selective estrogen receptor modulator 
SHIME: simulator of the human intestinal microbial ecosystem 
SRB: sulfate reducing bacteria 
Tmax: time after ingestion when maximum plasma concentrations are observed 
TWINSHIME: setup in which two SHIME models are operated in parallel 
UDP: uridine diphosphate 
UGT: UDP-glucuronosyl transferases 
UPGMA: Unweighted Pair Group Method with Arithmetic mean 
UV-VIS: ultraviolet-visible 
WHI: Women’s Health Initiative 
X: xanthohumol 
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CHAPTER 1 
Literature review 
1.1 A historical perspective 
1.1.1 The history of hop use 
Hops (Humulus lupulus L.) are known since ancient times and nowadays mainly used in 
the beer industry because of the unique feature that the plant produces large amounts of 
favorable secondary metabolites. These compounds are excreted in yellow glandular 
trichomes, termed lupulin glands, that cover the bracteoles of the female inflorescences (hop 
cones) (Figure 1.1). Although several hundreds of metabolites are being produced in these 
unique glands, the most important compounds for the brewing industry are the bitter acids, 
which give beer its typical bitter flavor and ensure foam and bacterial stability, and the hop 
essential oils, which give beer its typical “hoppy” aroma (Verzele, 1986). 
 
 
Figure 1.1. In commercial hop production, female hop vines are trained to climb strings up to 5-10 m 
high (up left). On lateral arms, the plants produce the typical female inflorescences, called hop cones 
(down left). Covering the bracteoles of these cones, the plant produces numerous yellow glandular 
trichomes (right). In these trichomes, called lupulin glands, hops can efficiently secrete large amounts 
of specific secondary metabolites. At harvest, the vines are cut down and the cones are stripped off. 
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However, despite its long history of cultivation, the use of hop in beers is not as old as 
the history of hop itself. Prior to the use in beer, hops were cultivated as early as 736 by 
German monks for medicinal purposes (Moir, 2000). Probably one of the first historical 
applications of hops was the treatment of insomnia, stress and anxiety because of its mild 
sedative effects. Even nowadays, about 1 % of the cultivated hops is still used for these 
purposes, usually in combination with other plants such as valerian or melissa (Gyllenhaal et 
al., 2000; Morin et al., 2005). Some other reported applications include stimulation of gastric 
juice production, the use as diureticum or to clean the blood and as bacteriostatic and anti-
inflammatory agent (Neve, 1991). Yet, records of the use of hops would even go back to the 
Egyptians where they would be used as a medicinal plant and a few descriptions of hops as 
a decoration for gardens were found in documents of the 6th century BC. Burgess (Burgess, 
1964) writes that hop sprouts were already used as a salad in the first century AD. And hop 
sprouts were also eaten by the less wealthy in medieval times as a substitute for asparagus. 
Next to this, hop stems were used in some cases to make cloth and paper and in a number 
of other traditional applications. 
The history of beer dates back to at least 1750 BC when the Sumerians discovered how 
to ferment cereals into beer (Ross et al., 2002). Several Roman sources also report the beer 
drinking culture of the German and Celtic tribes (Behre, 1999). However, beer in those days 
was totally different compared to our interpretation. Whereas barley is (mostly) the typical 
ingredient in current beers, all different cereals, including rice and maize, were used in 
ancient times. Although yeast is necessary to ferment the cereal, the importance was only 
recognized as late as the 16th century. Before, the success of beer production depended on 
yeast spores, carried in the air and infecting the brew by chance (Behre, 1999).  
Hops were probably first added to beer in the 12th century by German monks (Burgess, 
1964; Neve, 1991). In those days, it was popular to use a variety of fruits, herbs and spices 
to flavor beer, giving beer a sweet taste (so-called gruit beer). In northern central Europe and 
north-west Europe, Myrica gale L. (sweet gale or bog myrtle) was used since ancient times 
as principal beer additive (Behre, 1999). Initially the bitter taste from hops was not 
particularly appreciated (Verzele and De Keukeleire, 1991) and in England, which did not 
grow hop in those times, London brewers were even prosecuted when using hops. However, 
when the production of beer increased in the 14th century and the brewers started to export 
their beer, the importance of hops in beer was more and more appreciated. Because of the 
bacteriostatic properties of hops, which Myrica lacked, hopped beers could be preserved 
much longer than gruit beer and the use of hops allowed the brewers to market their beers 
further from its production site (Burgess, 1964). Whereas sweet gale was still the principal 
additive in the area of its natural occurrence, hops were used more often in other regions, 
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giving these brewers the important advantage of better preservation. When finally rumors 
were spread that drinking beer from sweet gale was harmful and could lead to blindness and 
even death, the use of Myrica completely declined (Behre, 1999). The enacting of the 
‘Reinheitsgebot’ (Purity Law) by Wilhelm IV, the lord of Bayern, eventually made from hops a 
standard ingredient in beer. Many aspects of this law, ordering that beer must be made from 
barley, water and hops, were adapted by other countries and since the 19th century, the main 
application of hops is to make beer. 
However, whereas the world beer production increased eightfold since 1900, the world 
hop production does not show the same trend (Figure 1.2). The size of the world hop crop 
reflects the demand of the brewers in general, but it also demonstrates the decline in 
hopping rates due to a lowering of bitterness levels in beers, the use of hops with higher α-
acid levels and the use of more and more sophisticated hop products (Moir, 2000). Whereas 
three countries, the USA, Germany and China, account for 75 % of world hop production, 
beer is traditionally made in many countries. Yet, especially in the last decade, highest 
increases are noted in China, where production increased with 52 % since 2000, with the 
result that Chinese beer production already amounts 20 % of the total.   
 
 
Figure 1.2. Evolution of the world beer and hop production between 1900 and 2006 and regional beer 
and hop production in 2006 [after: Moir et al. (2000) and http://www.hopsteiner.com] 
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1.1.2 Prenylflavonoids in hops  
As hops are now mainly used for beer production, beer is the most important dietary 
source of hop compounds. Prenylated flavonoids are found in a limited number of plant 
families, of which the Moraceae-Cannabaceae (with Humulus lupulus L.), Leguminosae and 
Asteraceae host about 80 % of the ca. 1100 known prenylflavonoids (Barron and Ibrahim, 
1996). However, as none of the other plants can be identified as rich nutritional sources of 
prenylated flavonoids in the Western diet, beer may very well represent the most important 
dietary source of prenylflavonoids.  
Within the female hop cone, xanthohumol (X) is the principal flavonoid (Figure 1.3), 
present in high concentrations in the lupulin glands (0.1-1 % of cone dry weight) (Stevens et 
al., 1999) with large differences depending on the variety and flowering stage (De Keukeleire 
et al., 2003). This prenylated chalcone is accompanied by at least 13 related chalcones, 
present in 10- to 100-fold lower concentration, from which desmethylxanthohumol (DMX) is 
the most important (Stevens and Page, 2004).  
 
 
Figure 1.3. The main prenylflavonoid in the female hop cone is the prenylchalcone xanthohumol 
(X) next to low concentrations of desmethylxanthohumol (DMX). During extraction of the hop cones 
and further processing, the chalcones can isomerize into the prenylflavanones isoxanthohumol (IX), 8-
prenylnaringenin (8-PN) and 6-prenylnaringenin (6-PN). 
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The hop chalcones are accompanied by a number of prenylated flavanones, from which 
isoxanthohumol (IX), 8-prenylnaringenin (8-PN) and 6-prenylnaringenin (6-PN) are the most 
important. Although concentrations of these flavanones have been determined in different 
hop varieties (Stevens et al., 1997; Rong et al., 2000), some authors question whether the 
array of prenylflavonoids are in part the result of decomposition during drying and storage 
(Hänsel and Schulz, 1988; Stevens et al., 1997). The presence of chalcone isomerases, 
enzymes which convert chalcones into the corresponding flavanones by ring closure, has 
been shown in hops, although not in the lupulin glands (Stevens et al., 1997). Yet, even 
without the presence of a chalcone isomerase, chalcones might isomerize chemically. X has 
one free hydroxyl available for ring closure, yielding the prenylflavanone IX, whereas DMX 
has two free hydroxyl groups that can participate in cyclization, yielding two flavanones 8-PN 
and 6-PN. This could explain the small amounts of the flavanones in comparison to X and 
DMX in hops (Stevens et al., 1997). Furthermore, it has been shown that the exposure to 
alkali during the extraction and purification process further favor the isomerization, yielding 
higher prenylflavanone amounts (Verzele et al., 1957). Therefore, some authors now 
consider 8-PN as an artifact, rather than a real compound present in hops (Chadwick et al., 
2004; Overk et al., 2005). 
 
1.1.3 Renewed interest in hops as a source of prenylflavonoids 
Renewed interest in the alternative use of hops arose at the end of last century when 
hops were acknowledged to be a source of prenylflavonoids with possible health beneficial 
effects, mainly related to its estrogenic properties (Milligan et al., 1999). However, even 
before this discovery a recurring suggestion has been for many years that hops have a 
powerful estrogenic activity. Already in 1953, Koch and Heim reported that hops contain “the 
equivalent of 20 – 300 µg 17β-estradiol/g” (Koch and Heim, 1953). In those days, hops were 
picked by hand and the need for massed labor at harvest time led to the migration of many 
whole families from the entire region surrounding the hop region to the hop fields. According 
to folk legends, women who started picking hops regularly began to menstruate 2 days after 
arriving to pick hops, indicating the presence of an estrogenic substance. Although lacking 
detail, Koch and Heim were the first to show that hop indeed has estrogenic activity based on 
an in vivo assay with castrated female rodents. Other reports stated that brewery sludge 
baths, containing about 30 % hop extracts were taken in Germany for the treatment of 
gynecological disorders (Fenselau and Talalay, 1973). However, the lack of identification of 
the responsible compound resulted in contradictory reports whether or not hops would really 
show estrogenic activity. 
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A first attempt for structure identification was made by Verzele et al. (1957; 1986), who 
isolated the chalcone xanthohumol (X) from hops and, without any proof, attributed the 
estrogenic properties of hops to this compound. However, the real identification of the 
structure was only established in 1988 by Hänsel and Schulz (1988). Before, in 1972, 
Nastainczyk reported in his PhD thesis the isolation of a “proestrogen” from hops which could 
be isomerized to a mixture he called the “hop estrogen” (Chadwick et al., 2006). Hänsel and 
Schulz showed that a new chalcone, DMX, was Nastainczyk’s proestrogen, which can be 
isomerized into a mixture of 8-PN and 6-PN. Finally, the definitive unambiguous identification 
was made in 1999 when Miligan et al. (1999) identified 8-PN as a potent phytoestrogen 
present in hops (Figure 1.4). 
 
 
Figure 1.4. Relative estrogenic potency of prenylflavonoids from hops, as determined by the 
stimulation of alkaline phosphatase activity in Ishikawa Var I cells. [after Milligan et al. (1999)]. The 
activity of the latter enzyme was assessed after 72 h by monitoring the hydrolysis of p-nitrophenyl 
phosphate into p-nitrophenol at 405 nm. The lower the concentration range of the test compound in 
which the typical sigmoidal curve is formed in the graph, the higher its estrogenic potency.  
 
1.2 Estrogenic properties of 8-PN 
1.2.1 Molecular action of estrogens 
Estrogen (derived from Greek words oistros, ‘mad desire’ and gennan, ‘to create, to 
produce’) is the generic term for a family of C18-steroid hormones, more particularly the 
female sex hormones. Both in males and females, many aspects of normal development, 
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differentiation and homeostasis are regulated by these estrogens, with 17β-estradiol (E2) as 
the most important hormone (Figure 1.7). The physiological effects of this group of molecules 
are mediated by ligand-activated nuclear transcription factors, belonging to the nuclear 
receptor gene family (Murdoch and Gorski, 1991). The existence of a protein responsible for 
specific binding of E2 in the uterus was recognized about 40 years ago (Jensen and 
Jacobson, 1962) and a quarter of a century later, the human estrogen receptor (ER) was 
cloned (Green et al., 1986; Greene et al., 1986). During the following decade, this receptor 
was believed to be the single mediator of the estrogenic response. In 1996 however, a novel 
ER was discovered in the rat prostate (Kuiper et al., 1996) and named ERβ to distinguish it 
from the other receptor, ERα. Now, even a third receptor has been identified in fish (Hawkins 
et al., 2000). 
ERs are normally located in the nucleus but they can move to the cytoplasm, where they 
are complexed with heat shock proteins (hsp) (Figure 1.5). This interaction would help fold 
the ER protein properly and protect the hydrophobic hormone binding domain from 
inappropriate interactions (Kuiper et al., 1997). In the classical mechanism of ER action, E2 
diffuses through the cell membrane, distributes throughout the cell, and binds to the ER, 
located in the nucleus bound to heat shock protein 90 (hsp90). The binding induces a 
conformational change in the receptor, resulting in the dissociation of hsp90 and the 
formation of a stable dimer complex of 2 receptors. The E2/ER complex then binds to specific 
DNA-binding sites, called estrogen response elements (ERE) located in the promoter region 
of responsive genes. Gene transcription is further induced by the binding of coactivators 
(CoA) (Darwish et al., 1991; Pettersson and Gustafsson, 2001; Pearce and Jordan, 2004; 
Lewis and Jordan, 2005). 
Although ERα and ERβ genes are located on different chromosomes (6 and 14) (Enmark 
et al., 1997), both receptors show very similar structures, possessing 6 distinct domains 
(Figure 1.5). The amino-terminal A/B domain encodes a hormone-independent 
transcriptional activation function (AF-1). Domain C corresponds to the DNA binding domain 
(DBD), which is responsible for specific binding of the receptors to ERE (or ERE-like 
sequences) in the promoter of target genes. Domain D is the hinge region. The carboxy-
terminal E/F domains encode the ligand binding domain (LBD). This region consists of 12 α-
helices, which form a hydrophobic pocket responsible for E2 binding. The LBD also harbors a 
second transcriptional activation function domain (AF-2), which activates transcription in 
response to E2 or synthetic agonists by recruiting and binding coactivators (Fairall et al., 
1993; Schwabe et al., 1993; Brzozowski et al., 1997).  
The DNA-binding domain is the most highly conserved region between ERα and ERβ 
with 96 % identity. Therefore, both receptors may interact with similar EREs (Pettersson and 
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Gustafsson, 2001). Also in the LBD, both reactors possess moderate (53 %) sequence 
identity. This indicates that they might interact differently with different ligands, although the 
affinity with E2 is similar (Kuiper et al., 1997). The major functional domain difference is 
contained within the N-terminal region (AF-1), which is probably inactive in ERβ (Hall and 
McDonnell, 1999). 
 Many studies have investigated differences in distribution patterns and biological 
responses between both receptors. Some reasons for different biological responses include 
ligand affinity for a specific receptor, the expression of receptor specific activators and the 
formation of heterodimers (Hall and McDonnell, 1999; Pettersson and Gustafsson, 2001; 
Pearce and Jordan, 2004). Another factor would be differences in tissue distribution (Figure 
1.6) (Kuiper et al., 1997; Jefferson et al., 2000; Taylor and Al-Azzawi, 2000; Levin, 2001; 
Mutembei et al., 2005). Even within tissues, differences may occur between cellular 
subtypes, as noted for the uterus and prostate (Sar and Welsch, 1999; Zhang et al., 2002). 
 
 
Figure 1.5. The conventional mechanism of interaction with the estrogen receptor (ER) and the 
different domains in the protein structure of human ERα and ERβ. 17β-estradiol (E2) diffuses into the 
cell and binds to ERα or ERβ. Bound ERs dissociate from heat shock proteins (hsp), dimerize and 
undergo conformational changes. With the aide of coactivators, the complex binds to specific DNA 
regions leading to gene activation. ERα and ERβ have similar structural domains, among which a 
DNA binding (DBD) and ligand binding domain (LBD) [after Lewis et al. (2005)]. 
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However, the traditional view of estrogen action explains inadequately the extensive 
range of estrogen actions. For instance, many effects of E2 occur within seconds or minutes, 
which is too fast for transcriptional events (Migliaccio et al., 1993). Now it is clear that ER 
receptors are also located on the plasma membrane, coupled to an intracellular signal 
transduction pathway (Pietras and Czego, 1977; Kelly and Levin, 2001; Toran-Allerand, 
2004). Although it has been described that ERα and ERβ can delocalize to the plasma 
membrane (Razandi et al., 1999), other estrogen responsive receptors might exist (Das et 
al., 1997; Nadal et al., 2000). 
Finally, it has been shown that ERs can be activated even without presence of E2. For 
instance, growth factors and proteinase K can activate ERα by phosphorylation dependent 
on the Ras-MAPK (mitogen-activated protein kinase) pathway. Phosphorylation would occur 
on serine residues in the AF-1 region (Bunone et al., 1996). The process would also occur 
with ERβ (Tremblay et al., 1999). This way, estrogen-like effects may be produced, even in 
the absence of E2. 
 
 
Figure 1.6. Overall tissue distribution of ERα and ERβ [after Pearce et al. (2004)]. 
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1.2.2 Estrogens and the menopause 
1.2.2.1 Physiological role of estrogens 
In females, E2 is mainly produced in the granulose of the mature ovary through 
conversion of testosterone supplied by the thecal cells. The responsible enzyme is the P450 
enzyme aromatase (Payne and Hales, 2004). Synthesis of estrogens also occurs in adipose 
tissue, skeletal muscle, skin, hair follikels and bone. Much of the current knowledge about 
the role of ERα and ERβ is derived from studies with ER deficient mice. This demonstrated 
that both ERs are necessary for proper ovarian function, whereas ERα is critical for uterine 
physiology and the normal development of the mammary gland and bone maintenance. They 
may play redundant roles in cardioprotection (Rosenfeld et al., 2001; Pearce and Jordan, 
2004). Although not completely clear, there are indications that ERα most often displays 
proliferative action, whereas ERβ would be anti-proliferative in many tissues and might exert 
protective effects against the onset of colon and breast cancer (Gustafsson, 1999). 
Therefore, the ratio of both receptors within the tissue might be important and ERβ targeted 
drugs might have future clinical applications.   
Although categorized as a female sex hormone, E2 also has important physiological roles 
in men. In adult men, estrogens are produced by the adrenals, testes and adipose tissue. 
Mice studies showed that ERα is required for male fertility (Rosenfeld et al., 2001). This may 
be due to direct effects in the testis as well as indirect effects by mediation of the 
hypothalamus-pituitary axis (Akingbemi, 2005). Moreover, a man with a mutation in the ERα 
gene showed signs of osteoporosis, reduced maturation of the epiphyses, early 
atherosclerosis and linear growth persisted into adulthood, showing the importance of E2 
interaction with ERα also in men (Smith et al., 1994; Sudhir et al., 1997). 
1.2.2.2 Menopause 
In view of general women’s health, estrogens are required for the function of the 
reproductive system, development of the healthy breast, they have beneficial effects on the 
heart and ensure the maintenance of the bone density. Moreover, these compounds would 
influence the brain centers that maintain body temperature and they enable the vaginal lining 
to stay thick and lubricated (Lewis and Jordan, 2005). The period when women are most 
confronted with the true value of estrogens is at the onset of the menopause, when 
endogenous estrogen production diminishes.  
For up to 75 % of menopausal women, one of the most apparent effects of this loss of 
estrogens are so called vasomotor symptoms, which can negatively impact overall quality of 
life (Avis et al., 1997). The etiology of these symptoms is probably caused by instability of the 
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thermoregulatory center of the hypothalamus, induced by falling estrogen and progesterone 
levels (MacLennan et al., 2001), although estrogen effects in other parts of the body may 
also be involved (Bowe et al., 2006). This leads to sudden, transient vasodilatation in the skin 
blood vessels, indicated as hot flushes and night sweats. Other consequences of estrogen 
loss include an increase in bone loss (osteoporosis), dementia and a rise in low-density 
lipoprotein (LDL) cholesterol and other cardiovascular changes, which increase the risk of 
cardiovascular diseases (CVD).  
To counteract these symptoms, it is generally acknowledged that the most efficient 
treatment is the administration of estrogens alone or in combination with progestogens (van 
der Mooren and Kenemans, 2004). This treatment, referred to as Hormone Replacement 
Therapy (HRT), would reduce both the frequency and severity of hot flushes, with 
combination of estrogens and progestogens as most efficient therapy (MacLennan et al., 
2001). Moreover, positive effects on bone metabolism (Lindsay et al., 1984) and CVD (Grady 
et al., 1992) were noted. However, many studies, such as the Nurses study, also indicated 
important negative side effects of HRT (Stampfer et al., 1991). Rapid effects may include 
breast tenderness, nausea and vaginal bleeding (MacLennan et al., 2001). Yet, the most 
important negative association is the noted increased risk of breast cancer. According to the 
hormonal model of breast cancer causation, E2 stimulates mitosis of breast epithelium, which 
may be augmented by progesterone (Key et al., 2001). The longer the breast is exposed to 
estrogens (e.g. by HRT), the higher the risk would be for errors in the DNA replication, 
possibly leading to tumor development (Lewis and Jordan, 2005). Yet, until recently, the 
consensus was that the benefits of HRT far outweighed the risks. 
Recent large scale studies such as the Women’s Health Initiative (WHI) (Writing Group 
for the Women's Health Initiative, 2002) and Million Women Study (MWS) (Million Women 
Study, 2003), drastically changed this vision. In its fifth year, the WHI study was prematurely 
terminated because of a too excessive increase of breast cancer, CVD, and Alzheimer’s 
disease due to combination HRT. Similarly, the MWS reported increased risk of fatal breast 
cancer. This had a significant impact on the attitude of physicians and patients toward HRT, 
and in the first months post-WHI 93 % of the patients tried to quit treatment (Ettinger et al., 
2003). Nowadays, there are signs that the rush away from HRT is slowing; and the trend is 
toward a more cautious approach to HRT, especially towards patients with a history of breast 
cancer (Rippy and Marsden, 2006). Moreover, it is now assumed that the contradicting WHI 
results on CVD and dementia should be interpreted with caution. Protective effects of 
estrogen treatments on CVD and dementia would only occur when the treatment is started at 
the early menopause (45-55 y), whereas the WHI participants were too old (50-79 y) and fell 
outside the window of opportunity (Haimov-Kochman and Hochner-Celnikier, 2006).    
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1.2.3 Phytoestrogens 
As a result of the negative publicity on HRT, the prescription of this treatment drastically 
decreased and many women now turn to alternative strategies to relieve menopausal 
complaints, referred to as complementary and alternative medicine (CAM) and non-
pharmacological interventions (Hoffmann et al., 2005; Wathen, 2006). These include 
changes in diet, exercise/yoga, relaxation, stress management and herbal remedies and 
dietary supplements (Daley et al., 2006), although the effectiveness of CAM therapies is still 
largely questioned (Amato and Marcus, 2003). Yet, one group of dietary supplement does 
show promise for the treatment of menopausal symptoms, i.e. supplements containing 
phytoestrogens (Kronenberg and Fugh-Berman, 2002).  
1.2.3.1 Groups of phytoestrogens 
Phytoestrogens are naturally occurring hormone-like compounds found in a wide range 
of plants, which have a unique diphenolic structure (Adlercreutz and Mazur, 1997). Due to 
their structural similarity to the female hormone E2, phytoestrogens have the ability to bind to 
ERs (Magee and Rowland, 2004). The explanation for the unique ability of ERs to bind a 
variety of steroids and other compounds may lay within the fact that the hormone-binding 
pocket of ERs is relatively large (Bourguet et al., 1995), with the result that E2 does not 
occupy the entire cavity. As previously mentioned, the LBD is formed by the structural 
orientation of 12 helices (H1-H12). Upon binding of E2, H12 is repositioned in such a way that 
the interaction of the ER with coactivators is facilitated, inducing biological activity 
(Pettersson and Gustafsson, 2001). However, although a wide range of other molecules fit 
into the large LBD pocket, the translocation of H12 differs depending on the structure of the 
compound in the LBD, not always completely exposing the coactivator interaction site on the 
ER. This would explain the contradiction between the high binding affinity of ERs for a variety 
of compounds and the low response-inducing properties of most of them (Pike et al., 1999).  
The presence of these hormone-like compounds in plants was first realized over 60 
years ago, when fertility problems were observed in sheep that had been grazing pastures 
containing red clover, having high amounts of the isoflavones formononetin and biochanin A 
(Bennets et al., 1946; Rossiter and Beck, 1966). Later it became clear that molecules with 
estrogenic activity are present in a broad range of plants. Already in 1954, 53 plant species 
were listed to express estrogenic activity (Bradbury and White, 1954). In the eighties the list 
already contained over 300 species (Price and Fenwick, 1985) and the number keeps 
increasing (Zhang et al., 2005; Agradi et al., 2006). However, the principal phytoestrogens in 
human diet are restricted to a limited number of molecules (Figure 1.7).  
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The isoflavones daidzein and genistein, mainly present in the human diet in various soy 
products, are by far the most studied phytoestrogens (Setchell et al., 2003; Turner et al., 
2003; Chen and Rogan, 2004; MacGregor et al., 2005; Messina et al., 2006). Next to this, 
lignans are also considered as ubiquitous in human diet (Raffaelli et al., 2002). Whereas the 
highest concentrations are found in flaxseed (Johnsson et al., 2000), the most important 
dietary sources of lignans are whole-grain cereals, legumes and various vegetables and 
fruits (Adlercreutz and Mazur, 1997; Mazur et al., 2000). To date, secoisolariciresinol (SECO) 
and matairesinol (MAT) were most often considered as the most relevant dietary lignans 
(Boker et al., 2002; Valsta et al., 2003). However, this was recently refuted by Milder et al. 
(2005; 2005), who showed that two other compounds, lariciresinol and pinoresinol, contribute 
to 75 % of the total lignan intake. Other groups of phytoestrogens include the coumestans 
(Kelly, 1972; Cos et al., 2003) and stilbenes (Gehm et al., 1997; Song et al., 2006). Whereas 
the former are mainly present in the legumes soy and clover (Franke et al., 1994), the main 
dietary sources of resveratrol are red wine and peanuts (Sobolev and Cole, 1999; Fremont, 
2000). Recently, a new group of phytoestrogens was added to this list when Milligan et al. 
(1999) identified hop (Humulus lupulus L.) as a source of one of the most potent 
phytoestrogens.  
 
 
Figure 1.7. The most relevant dietary groups of phytoestrogens as well as the most representative 
structures. Crucial for ER binding is the presence of a phenol and OH-group at a distance of 1.2 nm. 
Literature review 
 16 
1.2.3.2 Analysis of estrogenic potency 
Estrogenic potency is expressed as the ratio of the activity of a test compound relative to 
that of a reference compound, most often E2. In general, most phytoestrogens are relatively 
weak estrogens, requiring much higher concentrations than E2 to produce an equivalent 
biological response. A variety of experimental methods are used to assess the estrogenicity 
of phytoestrogens, and the results can vary significantly between assays. In general, in vivo 
assays provide a more holistic view of estrogenic activity. These assays incorporate many 
different biological processes, including absorption and metabolism, which influence 
estrogenic activity. Many of the in vitro methods are a simple measurement of direct 
interaction with the ER and are not necessarily predictive of estrogenic activity in vivo. 
In vitro assays include ER binding, ER-dependent transcription systems and proliferation 
of estrogen-dependent cell lines, such as MCF-7 cells (Rasmussen and Nielsen, 2002). The 
relative binding affinity (RBA) of phytoestrogens for ERα or ERβ is defined as the 
concentration of a compound required to inhibit E2 binding with 50 % (Blair et al., 2000). For 
instance, genistein and coumestrol have a high and preferential affinity for ERβ (Kuiper et al., 
1997), whereas enterolactone and resveratrol have low affinities for both receptors (Bowers 
et al., 2000; Mueller et al., 2004). However, as described above, binding to ERs not 
necessarily induces transcriptional activity. Therefore, the transcription potency of 
phytoestrogens, or the efficiency to induce ER dimer binding to DNA, has been assessed 
using cells engineered to express a reporter gene under the control of an ERE, coding for 
enzymes such as β-galactosidase or luciferase. Typical assays use yeast cells transfected 
with ERα (De Boever et al., 2001) or ERβ (Bovee et al., 2004) or ishikawa cells (Markiewicz 
et al., 1993). Finally, the estrogenic effects in estrogen-sensitive tissues are measured 
mostly as the proliferation of estrogen-sensitive cell lines (Rasmussen and Nielsen, 2002). 
These assays showed that, despite the high binding affinity of genistein and coumestrol for 
ERβ, almost similar as E2, the estrogenic potency is much lower compared to E2 (Collins et 
al., 1997; Breinholt and Larsen, 1998). Typical in vivo screens for estrogenic activity involve 
the analysis of female reproductive tissue development, such as the uterotrophic assay 
(Baker et al., 1999). 
1.2.3.3 8-PN 
The unequivocal identification of 8-PN as a phytoestrogen immediately led to numerous 
studies in which the estrogenic activity of 8-PN was elucidated in vitro (Table 1.1). This 
showed that 8-PN was the first ERα selective phytoestrogen with only 25-fold lower affinity 
for the latter receptor than E2 (Overk et al., 2005). Its in vitro biological activity on the ERα 
receptor would be in the range of 5-600 times weaker than E2, making it at least one order of 
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magnitude more potent than the other known phytoestrogens. On the ERβ receptor, it would 
however only be ranked after coumestrol and genistein (Bovee et al., 2004). 
After isomerization of DMX into 8-PN, two enantiomers of 8-PN are formed, 2S(-)-8-PN 
and 2R(+)-8-PN. Preliminary in vitro receptor binding assays showed that 2S(-)-8-PN exhibits 
an overall two- to threefold higher affinity for both receptors compared to 2R(+)-8-PN 
(Schaefer et al., 2003). However, in vivo studies with ovariectomized rats showed no 
differences in effects between 2S(-)-8-PN and racemic 8-PN, indicating that in vivo the 
difference in activity between the enantiomers might not be significant (Hümpel et al., 2005). 
 
1.2.4 8-PN as a SERM to relieve menopausal complaints 
1.2.4.1 Selective estrogen receptor modulators 
The discovery of a second ER and the observation that both types of receptors are 
differentially distributed within various tissues and organs has raised hopes that tissue 
specific estrogens could be found that have beneficial effects on specific targets, without 
influencing negative side effects. Such molecules are called selective estrogen receptor 
modulators (SERMs): they are agonists in some tissues (e.g. bone, liver and cardiovascular 
system) and antagonists in others (e.g. uterus and breast) (Lewis and Jordan, 2005). The 
best known example of SERMs are tamoxifen and raloxifene. Acting as an antagonist in the 
breast, uterus and mammary gland, they would reduce the risk of developing estrogen-
related cancers (Buelke-Sam et al., 1998; Cuzick et al., 2003), without reduction of bone 
density in postmenopausal patients (Love et al., 1992).  
Given the negative publicity about the potential side effects of HRT treatment to relieve 
menopausal complaints, many studies now focus on such SERMs as alternative strategies 
for menopausal estrogen deficiency (Bryant and Dere, 1998). Candidate molecules should 
reduce vasomotor symptoms and prevent osteoporosis, without having negative side effects 
such as cancer development. In view of numerous findings that dietary isoflavones would 
exert potent cancer preventive effects (Adlercreutz and Mazur, 1997; Zheng et al., 1999; 
Magee and Rowland, 2004; Polivkova et al., 2006), phytoestrogens have been proposed as 
ideal candidate SERMs to relieve menopausal complaints.  
Most studies focused on isoflavones and indicated their potential use as SERMs for a 
number of reasons: 
• Isoflavones have differential affinities for ERα and ERβ and both receptors have different 
tissue distribution. Hence, they modulate estrogenic responses depending on the target 
tissue (Gustafsson, 1999). 
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Table 1.1. Relative estrogenic potency of 8-prenylnaringenin on ERα and ERβ in different assays. 
Relative estrogenic potency Reference 
Competitive binding to ERα a  
8-PN (4.1) ≈ G (7) > D (0.12) > IX (7.9e-5) c (Overk et al., 2005) 
C (34) > G (0.7) > D (0.2) > N (n.d.) d (Kuiper et al., 1998) 
Competitive binding to ERβ a  
G (75) > 8-PN (0.88) ≈ D (1.25) > IX (0.027) c (Overk et al., 2005) 
C (100) > G (13) > D (1) > N (0.2) (Kuiper et al., 1998) 
Competitive binding to ER from rat uterine cytosol a  
8-PN (0.7) > G (0.3) (Kitaoka et al., 1998) 
8-PN (2.3) > C (0.8) > G (0.3) (Milligan et al., 1999) 
Yeast estrogen screen ERα b  
8-PN (0.75) > C (0.42) > G (0.025) > D (0.014) > 6-PN 
(<0.0075) i 
(Milligan et al., 1999) 
8-PN (0.4) > IX (0.001) (Coldham et al., 2002) 
8-PN (0.65) > G (0.0091) e (Zierau et al., 2005) 
8-PN (1.0) > C (0.57) > G (0.05) > N ( < 0.001) g, i (Bovee et al., 2004) 
Yeast estrogen screen ERβ b  
C (2.7) > G (1.1) > 8-PN (0.39) > D (0.011) > N ( 0.0052) h (Bovee et al., 2004) 
Ishikawa cell assay b  
8-PN (20) > C (2.6) > G (0.4) > 6-PN (0.16) > D (0.053) (Milligan et al., 1999) 
8-PN (1.08) > G (0.04) ≈ D (0.028) > IX (0.013) c (Overk et al., 2005) 
MCF-7 cell proliferation b  
8-PN (0.17) > G (0.0068) (Kitaoka et al., 1998) 
8-PN (3.3) > C (0.05) = G (0.05) > E (0.033) > D (0.005) f (Matsumura et al., 2005) 
Abbreviations: 8-prenylnaringenin (8-PN), genistein (G), daidzein (D), isoxanthohumol (IX), coumestrol (C), 
naringenin (N), 6-prenylnaringenin (6-PN), equol (E). 
a Determined in competitive binding assays. b The relative estrogenic potency is defined as the % ratio between 
the EC50 of 17β-estradiol (E2) and the EC50 of the compound in each specific test system. c 6-Prenylnaringenin 
and xanthohumol showed no activity. d N.d. : Not determined as complete displacement of the ligand from ERα 
could not be obtained and no EC50 value could be calculated. e Naringenin showed no activity. f Resveratrol 
showed no activity. g Daidzein, enterolactone and enterodiol showed no activity. h Enterolactone and enterodiol 
showed no activity. i The < sign means that this compound did not fully reach a maximum response and therefore 
the EC50 value could not be determined accurately. The real potency will be greater than the value in the table. 
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• Although genistein binds to ERβ in a manner similar to that observed for E2, α-helix 12 
from the ER does not adopt in the typical agonist position, but partially blocks the 
transactivation site. Therefore, genistein acts as a partial agonist (Pike et al., 1999). 
• Isoflavones elicit agonistic effects in absence of E2 with lower potency but in the 
presence of E2 they may block the receptor, thereby acting as antagonist (Magee and 
Rowland, 2004), although recent work did not detect antagonism of genistein in the 
presence of E2 in MCF-7 cells (Schmidt et al., 2005). But even if genistein acts as an 
agonist in breast cancer cells, it does not stimulate their proliferative activity (Diel et al., 
2001; Schmidt et al., 2005).  
• Genistein expressed SERM-like activity in various experimental models (Diel et al., 2001; 
Diel et al., 2001; Caldarelli et al., 2005). 
• Genistein would only induce uterine hyperthrophy at doses more then 10-fold higher than 
the dose needed to prevent bone loss, indicating tissue selectivity (Ishimi et al., 2000). 
 
Next to isoflavones, enterolignans and resveratrol have also been described as mixed 
agonist/antagonist (Bowers et al., 2000; Mueller et al., 2004). Finally, many studies also 
indicate interesting SERM-like activity of black cohosh (Cimicifuga racemosa L.) extracts 
although the active substance remains unidentified up to date (Seidlova-Wuttke et al., 2003). 
Coumestrol however, before the discovery of 8-PN the most potent phytoestrogen, would act 
as a pure agonist with molecular properties very similar as E2 which might question its use to 
relieve menopausal complaints (Diel et al., 2001; Schmidt et al., 2005). 
As 8-PN was identified as an even more potent phytoestrogen than coumestrol and is a 
preferential ERα agonist, it might be questioned whether 8-PN shows SERM-like activity and 
therefore whether it would be a suitable alternative for HRT. And indeed, Diel et al. (2004) 
reported that 8-PN induced significant estrogenic effects in the uterus and liver and found no 
evidence of SERM-like activity in Wistar rats. This was also noted by Miyamoto et al. (1998). 
However, a few years later, the same researchers were the first to report that effects of 8-PN 
were not always similar to E2 (Caldarelli et al., 2005). Using the hormone sensitive carbonic 
anhydrase II enzyme as a marker, they found that 8-PN effects in the uterus and liver were 
much smaller compared to E2 and even less pronounced than genistein. Similarly, whereas 
8-PN only displayed 70-fold weaker estrogenicity at ERα, its estrogenic potency in the 
uterine and vagina growth assay was 20,000-fold lower compared to E2 (Schaefer et al., 
2003). Finally, experiments with the 4-week bone mineral density (BMD) model in 
ovariectomized rats indicated that equipotent bone-protecting doses of 8-PN and E2 showed 
large differences in estrogenic effects on uterus and endometrium (Hümpel et al., 2005). And 
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also in the ERE-luciferase transgenic mouse model a pronounced bone-tissue specific 
estrogenic effect was seen for 8-PN (Hümpel et al., 2005).  
In conclusion, a number of reports show that 8-PN, despite the strong ERα-specific 
agonist activity, may act as a natural SERM with 10-fold higher selectivity for bone tissue 
compared to E2. Therefore, the few existing reports on the effects of 8-PN on two main 
menopause-related symptoms, i.e. osteoporosis and vasomotor symptoms will be discussed 
below. Important to notice is that these data are still very much incomplete, something which 
can also be concluded from reports on other phytoestrogens. Despite the literally hundreds 
of reports on the effects of phytoestrogens on menopausal symptoms, their final efficacy is 
still far from understood (Fitzpatrick, 2003; Krebs et al., 2004).    
1.2.4.2 Effect on bone remodeling 
Bone remodeling is function of the activity of two different cell lines. Osteoblasts, 
responsible for bone formation, respond to osteoclasts, the bone resorbing cells. Estrogens 
have a crucial role in maintaining bone homeostasis, by suppressing osteoclast activity and 
the prevention of bone resorption (Ernst et al., 1989). In menopausal estrogen deficiency, the 
rate of bone resorption due to increased osteoclast activity exceeds the osteoblast bone 
formation, possibly leading to osteoporosis. Osteoporosis is characterized by low bone mass, 
which increases the risk of fractures, especially the hips, spine and wrists (Namkung-Matthai 
et al., 2001). An estimated 75 million people suffer from osteoporosis in Europe, the USA 
and Japan. By 2050, the costs for hip fracture therapy would approach 250 billion dollar in 
the USA, showing the importance of the problem (Soper et al., 2001). Historically, 
osteoporosis has been considered as a disease that typically afflicts postmenopausal 
women. However, although women are four times more likely to develop osteoporosis than 
men, it is estimated that 3-6 % of US men aged 50 and older have symptoms of osteoporosis 
(Looker et al., 1997). Potential reduction of osteoporosis has traditionally been a two-sided 
approach by either attempting to boost bone density in high-risk postmenopausal women by 
improved diet or supplements, or by maximising the build up of bone during the highly 
important pubescent years, as about 35 % of a mature adult's peak bone mass is built up 
during puberty. 
Many studies have investigated the possible application of phytoestrogens to prevent or 
treat osteoporosis, but data are contradictory. Setchell et al. (2003) reviewed the available in 
vitro animal and human data and concluded that the structure and mode of action of 
(isoflavone) phytoestrogens would be ideal for the prevention of bone loss. In vitro studies 
indeed suggest bone sparing activity of for instance isoflavones (Gao and Yamaguchi, 2000; 
Chen et al., 2003) and coumestrol (Tsutsumi, 1995; Kanno et al., 2004). Animal studies have 
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the advantage that any coupling effects between osteoblasts and osteoclasts and their 
progenitor or precursor cells are taken into account and allow for metabolic events which 
may take place (Setchell and Lydeking-Olsen, 2003). The majority of animal studies also 
confirms the positive effects of phytoestrogens on bone remodeling (Arjmandi et al., 1998; 
Ishimi et al., 2000; Seidlova-Wuttke et al., 2003). In contrast, human data are not always as 
convincing about possible effects. Based on the available literature, some factors can be 
indicated which may influence the efficiency of isoflavone effects on the bone:  
• The estrogen status of the test individuals is crucial. Efficiency differs for post- and 
premenopausal women and effects vary throughout the menstrual cycle (Fitzpatrick, 
2003). 
• A number of studies indicate that soy isoflavones favorably affect bone density in 
perimenopausal, rather than postmenopausal women (Newton et al., 2006). This shows 
that phytoestrogens may offer the maximum benefit for prevention rather than treatment 
of osteoporosis. 
• Due to the slow rate of bone turnover, short term studies often fail to see significant 
effects (Setchell and Lydeking-Olsen, 2003). 
 
Only limited data are available on the effects of prenylflavonoids on bone remodeling. 
Interestingly, the first study which was published reported that in vitro xanthohumol and 
humulone (α-acid) acted as surprisingly strong inhibitors of bone resorption with IC50 values 
of about 1 µmol/L and 6 nmol/L respectively (Tobe et al., 1997). However, as both 
components lack appreciable estrogenic activity, their capability to inhibit bone resorption 
seems difficult to explain through estrogenic pathways. Effenberger et al. (2005) investigated 
the effect of X, IX, 8-PN and 6-PN on osteoblast phenotype and gene expression. They 
detected effects of all tested compounds, but for most investigated parameters, 8-PN was 
the most active compound, with activities similar or even stronger than E2. Miyamoto et al. 
(1998) and Hümpel et al. (2005) used the ovariectomized rat model to investigate the 
protective effect of 8-PN on bone loss. Whereas the former authors reported that 30 mg/kg.d 
8-PN was needed for full response, 18 mg/kg.d 8-PN protected the rats from bone loss in the 
latter study, probably due to the longer treatment period (four compared to two weeks). 
Although no human data are available, the pharmacokinetic parameters of 8-PN are claimed 
to be similar in rats and humans, indicating that protective effects might also be expected in 
humans (Hümpel et al., 2005).  
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1.2.4.3 Effect on vasomotor symptoms 
Although hot flushes typically last 0.5 to 5 y after natural menopause, they may persist 
for as long as 15 y in a small percentage of postmenopausal women (Bachmann, 1999). 
Because their severity greatly impacts the quality of life, many women seek medical 
treatment. Recent years, hopes are put on the efficacy of phytoestrogens to control the 
thermoregulation in postmenopausal women. However, despite the numerous trials, the data 
are even much more inconclusive than those about the effects on bone health. Whereas 
some reviews and studies conclude that there are no effects to be expected from isoflavones 
or lignans (Krebs et al., 2004; Lewis et al., 2006), others report positive effects on hot flushes 
without causing negative side effects, especially for women with severe symptoms (Crisafulli 
et al., 2004; Howes et al., 2006). Much research has also been performed towards the 
effectiveness of black cohosh to reduce hot flushes (Kronenberg and Fugh-Berman, 2002; 
Frei-Kleiner et al., 2005), although other reports show no significant improvements of 
vasomotor symptoms (Newton et al., 2006). Its medicinal use was already acknowledged by 
native Americans (Borrelli and Ernst, 2002) and black cohosh still is one of the main herbs 
recommended in many European countries as alternative for HRT (McKenna et al., 2001). Its 
specific mode of action is still largely unknown, but recent work showed an interaction of 
black cohosh compounds with the opiate receptor (Rhyu et al., 2006) and opiate withdrawal 
has been related with menopausal symptoms (Kronenberg and Downey, 1987). Based on 
the available evidence, the North American Menopause Society now suggests that 
phytoestrogens may be helpful for women with frequent hot flushes, but their clinical efficacy 
should further be investigated in clinical trials (Howes et al., 2006). 
A few studies have investigated the relation between 8-PN and hot flushes. Even before 
the discovery of 8-PN, Goetz (1990) already published the results of a human trial in which 
hop was shown effective to control hot flushes. Unfortunately, they used a non-standardized 
hop extract and no relation could be made with the mode of action at that time. A recent 
study published a placebo-controlled trial with a hop extract standardized on 8-PN and 
showed mild favorable effects on vasomotor symptoms and other menopausal discomforts 
(Heyerick et al., 2006). As the hypothalamus and pituitary hormones may be involved in 
thermoregulation, Christoffel et al. (2006) investigated the effects of orally dosed 8-PN on the 
hypothalamo-pituitary-uterine axis in rats. They found that only a high 8-PN dose (68.4 
mg/kg) had significant effect, but at this dose negative effects on the uterus were also 
observed.  
Yet, a study directly looking at effects of 8-PN on body temperature found effective 
concentrations at 7.5 mg/d (Bowe et al., 2006), which is well below the doses causing side 
effects (68.4 mg/d) (Christoffel et al., 2006). In this study, the reversal by 8-PN of the 
  Chapter 1 
 23 
ovariectomy-induced rise in tail skin temperature in rats was investigated, as a model of 
menopausal hot flushes (Figure 1.8). The fact that 5-day oral treatment with 8-PN could 
reverse the skin temperature increase induced by estrogen depletion, indicates that 8-PN 
indeed may be helpful to reduce the severity and/or number of vasomotor symptoms. 
 
 
Figure 1.8. Effects of oral administration of 17β-estradiol (E2; ●; 75 µg/day) or 8-prenylnaringenin (8-
PN; ▲; 7.5 mg/day) on tail skin temperature (TST) in the ovariectomized rat. Control animals were fed 
phytoestrogen-depleted rat diet (■). * P<0.05 E2 vs control on the same day. # P<0.05 8-PN vs control 
on the same day [after Bowe et al. (2006)].  
 
1.3 Other biological activities of hops 
1.3.1 Effect on aromatase activity 
E2 has been implicated in both the initiation and promotion of breast cancer and the 
lifetime estrogen exposure is considered a major risk factor for the disease (Key et al., 2001). 
Two thirds of breast cancers occur in postmenopausal women at a time that circulating 
estrogen levels are low. However, in the breast tissue of these women and especially in 
cancerous tissue, estrogen concentrations are found to be higher, due to the activation of 
less active precursors by the enzymes involved in E2 metabolism (Figure 1.9) (Perel et al., 
1980). Therefore, compounds inhibiting for instance the activity of the aromatase enzyme 
may play an important role in the development of estrogen-dependent cancers, by reducing 
the estrogen concentrations in these tissues (Bonneterre et al., 2001). 
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Next to having direct estrogenic effects by interacting with the estrogen receptor, 
phytoestrogens are also well known to exert indirect estrogen-related effects, e.g. by 
interfering with the circulating estrogen levels. Several studies indicate that isoflavones and 
lignans can inhibit the activity of four key enzymes in this process (Figure 1.9). By inhibiting 
aromatase, 17β-hydroxysteroid dehydrogenase Type 1, sulfatase and sulfotransferase, 
phytoestrogens would therefore have an important influence on the regulation of final 
estrogen levels in different tissues (Basly and Lavier, 2005; Brooks and Thompson, 2005; 
Deluca et al., 2005). This may help to explain their cancer-preventive activity (Cornwell et al., 
2004). 
 
 
Figure 1.9. Different enzymes involved in the synthesis of estrogens [after Brooks and Thompson 
(2005)] 
 
Only one study investigated the effect of hop prenylflavonoids on aromatase activity in a 
carcinoma cell culture, expressing high levels of the enzyme (Monteiro et al., 2006). X, IX 
and 8-PN decreased the aromatase activity, with the latter having the most potent inhibitory 
strength so far reported for polyphenols in these cells (IC50 = 65 nmol/L). This effect would be 
independent of aromatase synthesis and probably mediated by interference with the enzyme 
itself or signaling cascades that regulate its activity.  
 
1.3.2 Anticancer properties 
There is a large body of evidence from both animal experiments and epidemiological 
studies that phytoestrogens have a protective effect against several cancers including breast, 
prostate and colon cancer. Asian populations consuming diets rich in soy isoflavones have a 
lower incidence of these cancers compared to Western populations (Messina et al., 1994). 
However, when Asians migrate to Western countries and adopt to Western diets, the cancer 
risk also increases. A survey of a variety of populations of women also indicates a reduction 
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in breast cancer risk among women with a high intake of phytoestrogens (Ingram et al., 
1997). The way in which phytoestrogens protect may vary depending on the cancer type and 
individual compound and is still subject of debate as many proposed mechanisms are based 
on in vitro research and their relevance will need to be confirmed in humans. For instance, 
genistein is known to inhibit tyrosine kinases, which influence the regulation of cell functions 
such as cell division (Peterson and Barnes, 1996). Genistein has also been shown to inhibit 
the DNA repair enzyme topoisomerase (Peterson, 1995), to induce apoptosis Yeh et al., 
2007) and to act as an antioxidant thus preventing oxidative damage (Ruiz-Larrea et al., 
1997). Enterolactone on the other hand is known to have an anti-estrogenic effect, 
suppressing E2-induced RNA synthesis in rats (Waters and Knowler, 1982).  
Several experimental animal studies have examined the effect of beer and alcohol on 
cancers, mainly colorectal cancers. Whereas tap water or low percent ethanol solutions 
generally did not influence the incidence of carcinogen-related cancers, beer significantly 
reduced the number of tumors in most studies, indicating the presence of compounds with 
anti-carcinogenic properties in beers (Gerhauser, 2005). As beer is an extremely complex 
beverage, it is very difficult to identify all possible ingredients which may be responsible for 
this protective effect. Therefore, the discussion will be limited to the group of prenylflavonoids 
and their effect on the three important stages of carcinogenesis, i.e. initiation, promotion and 
progression. 
1.3.2.1 Tumor initiation 
As a measure to detect anti-initiating properties of prenylflavonoids, most studies focus 
on the modulation of carcinogen metabolism and on the prevention of oxidative damage. 
Many chemicals in the environment act as carcinogens following activation by phase I 
cytochrome P450 (CYP) enzymes. Therefore, ideal cancer preventive agents should inhibit 
the activity of specific CYP enzymes involved in carcinogen activation. In addition, they 
should induce detoxifying phase II enzymes which facilitate the removal of carcinogens. 
Prenylflavonoids seem to fulfill these criteria. Depending on the CYP enzyme, X (CYP1A1 
and CYP1B1) or IX and 8-PN (CYP1A2) where the most potent inhibitors of carcinogen 
activation in a study by Henderson et al. (2000). This was confirmed in other studies 
(Miranda et al., 2000; Gerhauser et al., 2002) and prenylflavonoids inhibited the activation of 
the carcinogen IQ in vitro (Miranda et al., 2000). Only one study reported opposite effects of 
8-PN and IX, after observing a moderate induction of CYP1A1 in primary hepatic cells 
(Gross-Steinmeyer et al., 2004). Prenylflavonoids were also shown to induce quinine 
reductase, an important phase II enzyme which promotes the reduction of quinones, making 
them susceptible for glucuronidation and excretion (Miranda et al., 2000; Dietz et al., 2005).  
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Overproduction of reactive oxygen species (ROS) during conditions of oxidative stress 
results in DNA damage and contributes to tumor initiation. Also, excessive production of nitric 
oxide (NO) during infection and chronic inflammation is believed to initiate cellular injury and 
carcinogenesis, e.g. via nitrosative deamination of DNA bases and induction of lipid 
peroxidation (Gerhauser et al., 2002). In different assays, X was highly effective in 
scavenging ROS (Gerhauser et al., 2002) and hop chalcones, including X, inhibited the 
production of NO by suppression of NO synthase (Zhao et al., 2003). In addition, X showed 
high antioxidant activity in inhibiting LDL oxidation, which is though to play a central role in 
atherosclerosis, with activity higher than α-tocopherol and genistein (Miranda et al., 2000). 
Whereas prenylflavanones also exerted moderate antioxidant activity, their non-prenylated 
counterpart naringenin showed pro-oxidant effects (Rodriguez et al., 2001). 
1.3.2.2 Tumor promotion 
Excessive production of prostaglandins, i.e. hormone-like endogenous mediators of 
inflammation, has been associated with carcinogenesis. Elevated levels stimulate cell 
proliferation and initiate the formation of new blood vessels (angiogenesis). X was shown to 
effectively inhibit the activity of cylclo-oxygenases Cox-1 and Cox-2, which are involved in 
the synthesis of prostaglandins (Gerhauser et al., 2002). By interacting with the estrogen 
receptors, hormones as E2 stimulate cell growth and increase the risk for breast and uterine 
cancer (Reid et al., 1996). X was identified as a pure anti-estrogen in Ishikawa cell cultures, 
which may indicate that X blocks the proliferative activity of E2 (Gerhauser et al., 2006). 
1.3.2.3 Tumor progression 
Characteristic of tumor cells in the progression phase is uncontrolled cell proliferation, 
independent of hormone or growth factor stimulation, and impairment of mechanisms like 
apoptosis and terminal cell differentiation, which normally regulate tissue homeostasis 
(Compagni and Christofori, 2000). X inhibited the proliferation of human breast, colon and 
ovarian cancer cells in vitro (Miranda et al., 1999). This tumor progression preventive activity 
may be the result of acting on a number of targets. On the level of DNA synthesis, X inhibited 
DNA polymerase α activity and the incorporation of thymidine in newly synthesized DNA 
(Gerhauser et al., 2002). It also induced terminal cell differentiation and was shown to kill a 
number of cancer cell types by apoptotic mechanisms (Lust et al., 2005; Pan et al., 2005). 
Tumor invasion is the hallmark of malignancy and therefore, inhibition of invasion is an 
important step in the prevention of cancer progression. Using the chick heart invasion assay, 
X was shown to inhibit the invasion of breast cancer cells (Vanhoecke et al., 2005). Next to 
inducing apoptosis in these cells, X upregulated the E-cadherin/catenin invasion suppressor 
which stimulates cell aggregation. 8-PN also stimulated this complex but was unable to block 
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invasion (Rong et al., 2001). Finally, inhibition of angiogenesis is an important step in the 
prevention of cancer development, as tumors cannot expand beyond a critical mass if not 
enough blood is circulated in the tumor. Both 8-PN (Pepper et al., 2004) and X (Gerhauser et 
al., 2006) inhibited the formation and development of new blood vessels. In conclusion, these 
data show that prenylflavonoids and especially X might have promising applications with 
respect to cancer prevention at the level of tumor initiation, promotion and progression.   
 
1.3.3 Antibacterial activity 
The antibacterial activity of hop compounds has been recognized for decades and was 
one of the main reasons why hopped beers became popular in the second half of the last 
millennium, allowing the brewers to export their beer over longer distances (Burgess, 1964). 
For centuries it was generally believed that hops protect beer from infection by most 
organisms, including pathogens. It was only in the 20th century that Shimwell (1937) showed 
that hop compounds only inhibit the growth of Gram-positive bacteria. In addition, some 
species of lactic acid bacteria are less sensitive to hop compounds and are able to grow in 
beer (Suzuki et al., 2006). The lipophilic region of the cell membrane would represent the 
target side for antibacterial activity and β-acids, followed by α-acids and iso-α-acids have the 
highest activity. Yet, as beer contains mainly iso-α-acids, these compounds would be the 
most important preservatives in beer (Sakamoto and Konings, 2003). Bacterial growth may 
spoil beer by turbidity, acidity and the production of unfavorable smell such as hydrogen 
sulfide. Therefore, new strategies are being developed to minimize the contamination of beer 
and to increase the antimicrobial activity of beer components (Vaughan et al., 2005). 
Next to bitter acids, hop flavonoids might also have antibacterial activity as this has been 
reported for many flavonoids (Basile et al., 1999; Schoefer et al., 2003). In this context, X has 
gained most attention and its broad spectrum anti-infective potential recently has been 
reviewed (Gerhauser, 2005). X was shown to inhibit the Gram-positive bacteria 
Staphylococcus aureus and Streptococcus mutans (Mizobuchi and Sato, 1984; Bhattacharya 
et al., 2003) and a number of fungi (Mizobuchi and Sato, 1984) and exerted antiviral activity 
against different viruses, including the herpes and human immunodeficiency virus (Buckwold 
et al., 2004; Wang et al., 2004).  
Finally, X inhibited the replication of Plasmodium falciparum, the causative agent of 
malaria (Herath et al., 2003; Frölich et al., 2005). Given this broad spectrum anti-infective 
activity, the question arises whether high X intake may influence the bacterial community in 
the gut, especially because a large fraction of the ingested X may reach the colon (see 
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below). However, after a daily administration of 100 mg/kg X to rats for four weeks, Hanske 
et al. (2005) detected no changes in the rat fecal microbiota, using DGGE. 
 
1.3.4 Sedative properties of hops 
As mentioned above, probably one of the first medicinal applications of hops would be 
related to their sedative properties. Further indications of sleep-promoting properties of hops 
were observed among hop pickers by the fact that they tired easily, apparently due to the 
contact with the hop cones (Zanoli et al., 2005). Moreover, a number of reports from the first 
half of the 19th century have indicated that preparations of hops have sedative-like activity in 
frogs, pigeons, mice, goldfish and golden carp (Chadwick et al., 2006). More recent 
investigations found mild sedative effects of hops in rats and mice (Lee et al., 1993). A 
double-blind crossover study of 27 subjects with sleep difficulties taking hops, lemon balm 
and valerian, showed however no sleep enhancement with hops (Lindahl and Lindwall, 
1989). Many herbal preparations therefore combine hops with more potent sedative herbs, 
such as valerian. This combined extract was shown to be effective in the treatment of sleep 
disorders in human volunteers (Vonderheid-Guth et al., 2000). 
Up to now, a conclusive identification of compounds responsible for this activity has not 
been achieved. In 1932, Sikorski and Rusiecki reported that α- and β-acids were strongly 
sedative in birds (Chadwick et al., 2006) and a degradation product of these acids, 2-methyl-
3-butenol, was shown to be sedative in mice (Wohlfart et al., 1983). This metabolite is 
formed during storage of hops and might also be formed in vivo by metabolism of α-acids 
(Hänsel et al., 1982). The important role of α-acids was further indicated by the fact that a 
CO2 extract from hops and an α-acid fraction showed sleep-enhancing properties (Zanoli et 
al., 2005). However, Meissner and Häberlein (2006) suggested that not the acid fraction, but 
rather X may play a role by interaction with specific neural receptors. 
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1.4 Bioavailability of hop prenylflavonoids  
1.4.1 Concept of bioavailability 
The term bioavailability has been the subject of much debate. Originally, the term 
mainly related to the extent and rate of absorption from the gut. Subsequently, the 
importance of distribution, metabolism and excretion were recognized, leading to a 
‘bioconversion and biodelivery’ concept of bioavailability. Current definitions have been 
extended to encompass the concept of ‘bioefficacy’. Therefore, for flavonoids bioavailability 
now refers to the effectiveness of a compound to elicit a biological response in a target tissue 
(Rowland et al., 2003). Ideally, this response should be monitored with a sensitive functional 
marker (e.g. plasma homocysteine for folate). In reality however, no such marker is available 
for flavonoids and bioavailability can only be assessed based on data from absorption, 
distribution, metabolism and excretion (ADME) (Figure 1.10).  
 
 
Figure 1.10. Overview of the human gastrointestinal tract. The bioavailability and subsequent 
biological effect of dietary compounds depends on absorption, distribution, metabolism and excretion. 
In this process, the different parts of the gastrointestinal tract play a crucial role. 
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Flavonoids are widely distributed throughout the plant kingdom with more than 4000 
different flavonoids identified thus far. Their basic chemical structure consists of two benzene 
rings linked by a heterocyclic ring, allowing multiple patterns and substitutions that give rise 
to various subclasses. Despite this similar overall structure, the biochemical and biological 
properties vary considerably with only minor modifications of the flavonoid structure. 
Numerous studies suggest that flavonoids are extensively metabolized by CYP enzymes in 
the intestinal epithelium and liver, giving rise to metabolites with biological activities 
distinctively different from the parent compound (Nielsen et al., 1998; Breinholt et al., 2002), 
Furthermore, flavonoids can be metabolized in the colon by intestinal bacteria (Figure 1.11). 
 
 
Figure 1.11. General scheme of factors influencing the bioavailability of naringenin. After absorption 
from the small intestine, a large proportion is conjugated with glucuronic acid or sulfate and may be 
metabolized in the liver. It can then circulate in the bloodstream or enter into enterohepatic circulation. 
In the colon, the intestinal bacteria can degrade naringenin and its metabolites.  
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Biotransformation of food components has evolved to facilitate the elimination of 
potentially toxic substances through the production of polar, and usually less active, 
metabolites (Coldham et al., 2002). However, in certain cases, biotransformation may confer 
a substantial increase in the biological activity. Therefore, the rest of this chapter will address 
all possible aspects of the bioavailability and biotransformation of prenylflavonoids from 
hops. Special attention will be given to IX, the main prenylflavonoid in beers and hop 
products, in the role of a potential proestrogen by virtue. After all, IX has the potential for a 
very substantial degree of metabolic activation: O-demethylation into 8-PN would increase its 
relative estrogenic potency from 0.001 to 0.4 (Coldham et al., 2002). 
 
1.4.2 Absorption and distribution of flavonoids 
Flavonoids mainly occur in food as glycosides, bound to sugar moieties, but sometimes 
also as aglycones. For instance, naringenin is present in citrus fruits bound to glucose or 
rutinose molecules, but in tomatoes it is present as free naringenin. Many aglycones can 
readily be absorbed in the small intestine and depending on the sugar moiety and position on 
the flavonoid, deglycosilation of flavonoid glycosides can occur by mammalian β-
glucosidases in the small intestine, followed by absorption of the aglycone (Griffiths and 
Smith, 1972; Bugianesi et al., 2002; Manach and Donovan, 2004; Walle, 2004). This is 
indicated by a rapid peak in plasma concentration of the compounds. Others however, such 
as narirutin (naringenin-O-rhamnoglucoside), the predominant naringenin glycoside in 
oranges, reach the colon intact. Here, deglycosilation occurs by bacterial enzymes (Erlund et 
al., 2000; Erlund et al., 2001; Cermak et al., 2006; Wang et al., 2006). Due to extensive 
phase I and II metabolism in the intestinal wall during absorption and in the liver (see below), 
a major fraction of the absorbed flavonoids is excreted back into the intestine through the bile 
as glucuronides and/or sulfates and reaches the colon where bacterial β-glucuronidases and 
sulfatases can release the flavonoid aglycone (Scalbert et al., 2002; Hu et al., 2003; Liu et 
al., 2003; Walle et al., 2004). Absorption of the released aglycone leads to enterohepatic 
circulation, indicated by a second plasma peak (7-10 h post ingestion) (Manach et al., 2004). 
In most cases, flavonoids mainly occur in plasma as phase II conjugates which can be 
excreted in urine or reach specific target organs to exert biological activity. However, 
intracellular metabolism in the tissues has also been noted, influencing the nature of the 
active compound (Shimoi et al., 2001; Youdim et al., 2003; Spencer et al., 2004). 
Few studies have been performed on the pharmacokinetics of hop prenylflavonoids. 
Whereas the absorption of X would be low (Avula et al., 2004; Nookandeh et al., 2004), 8-PN 
is easily taken up from the gut, probably by passive diffusion (Nikolic et al., 2006). After 8-PN 
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administration to rats, dogs and postmenopausal women, rapid almost complete absorption 
(Tmax=1.5 h) was noted, followed however by extensive presystemic elimination (>50 %) via 
the bile. Enterohepatic circulation resulted in a secondary plasma peak (Tmax=7-10 h) (Rad et 
al., 2006). This rapid elimination would be due to extensive phase II metabolism. In vitro tests 
showed that during absorption both glucuronidation on the B ring and sulfation occur, 
whereas hepatic cells almost completely converted 8-PN into the A ring 7-O-glucuronide 
(Nikolic et al., 2006). This was confirmed in vivo as conjugates dominated over free 8-PN in 
both plasma and urine (Schaefer et al., 2005; Rad et al., 2006). Plasma concentrations 
showed a good dose response relation but conjugation was less efficient at high dose. Within 
48 h, respectively 5-10 % and 20-30 % of the ingested dose were excreted in urine and 
feces, in the latter predominantly as free 8-PN (Rad et al., 2006).  
 
1.4.3 Liver metabolism of flavonoids: production of 8-PN from IX 
Liver metabolism of dietary compounds can include a variety of reactions including 
condensation, cyclization, hydroxylation, dehydroxylation, alkylation, O-dealkylation, 
halogenation, dehydrogenation, double-bond reduction, carbonyl reduction and ring 
degradation (Das and Rosazza, 2006). For flavonoids, CYP hydroxylation of the B ring, 
leading to catechol formation, and/or A ring would be the major site of hepatic metabolism 
(Nielsen et al., 1998). For instance, naringenin, the non-prenylated analogue of 8-PN, is 
mainly hydroxylated on the 3’ position, yielding eriodictyol (Breinholt et al., 2002), and also 
for the isoflavone phytoestrogens daidzein and genistein, A and B ring hydroxylation is the 
main route of hepatic metabolism (Kulling et al., 2001; Breinholt et al., 2003; Hu et al., 2003). 
Methylated flavonoids often are demethylated in the liver. The methylated isoflavones 
formononetin and biochanin A are O-demethylated into respectively daidzein and genistein 
(Tolleson et al., 2002; Lania-Pietrzak et al., 2005) and demethylation on both the A and B 
ring has been shown for a number of flavonoids (Nielsen et al., 1998; Breinholt et al., 2003; 
Kagawa et al., 2004; Wen and Walle, 2006). 
However, due to the presence of the prenyl side chain, hepatic metabolism seems to 
be different for prenylflavonoids. Using rat liver microsomes as a model, Yilmazer et al. 
(2001) showed that phase I metabolism of X yielded four metabolites. The formation of three 
of them involved epoxidation of the prenyl group in the A ring, followed by cyclization into 2 
hydroxylated dihydrofurano and one dimethylchromeno analogs of X. The fourth metabolite 
was formed by hydroxylation of the B ring of X, yielding a catechol structure. Using the fungal 
species Pichia membranifaciens and Cunninghamella echinulata as microbial models to 
mimic mammalian liver metabolism, similar dihydrofurano analogues of X were also obtained 
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(Herath et al., 2003; Herath et al., 2003). This is in line with previous findings (Tahara et al., 
1997; Tanaka and Tahara, 1997) and shows that the prenyl group in the A ring of 
prenylflavonoids would be the major site of hepatic phase I metabolism by CYP enzymes 
and not hydroxylation of the B ring. In a recent study on X transformation by human liver 
microsomes, the prenyl group also was the primary site of metabolism (Nikolic et al., 2005). 
However, the most abundant metabolite was no cyclization product of X but trans-X alcohol 
after oxidation of the terminal methyl group of the prenyl chain. The authors attributed this 
first to species differences between rats and humans, but in a later article this was denied 
and concentration effects were postulated as the main cause (Nikolic et al., 2004). Phase II 
glucuronidation of X by UDP-glucuronosyl transferases (UGT) led to the formation of 4’-O 
and 4-O glucuronides, from which the former position appeared to be favored (Ruefer et al., 
2005). In another in vitro study, it was found that specific isoforms of UGT and 
sulfotransferases have high activity towards X (Ruefer et al., 2005). Again, the 4’-O and 4-O 
glucuronides were the predominant metabolites.  
Phase I metabolism of the flavanones IX and 8-PN also mainly took place on the prenyl 
chain. 8-PN metabolism yielded four major metabolites (Nikolic et al., 2004). Two were 
identified as cis- and trans-8-PN alcohol, from which the latter was more abundant and could 
further be oxidized to trans-8-PN aldehyde. The fourth was oxidized on the 3’ position 
yielding 8-prenyleriodictyol. Incubation of human hepatocytes with 8-PN revealed that phase 
II metabolism mainly involved 7-O-glucuronidation on the A ring of 8-PN and its alcohol 
metabolites (Nikolic et al., 2006). IX metabolism showed to be very similar as for 8-PN 
(Nikolic et al., 2005), yielding the cis- and trans-IX alcohol as main metabolites (Figure 1.12). 
Probably, specific CYP enzymes (CYP2C19 and CYP2C8) are involved in the 
prenylflavanone metabolism (Guo et al., 2006).  
The most interesting finding however was that, although not the most abundant, one 
metabolite of IX was identified as 8-PN, indicating demethylation of IX in the liver. Although 
O-demethylation of chalcones (Sanchez-Gonzalez and Rosazza, 2004) and non-prenylated 
analogues of 8-PN on the A ring (Nielsen et al., 1998; Ibrahim et al., 2003) has been shown, 
no demethylation of X into DMX was found (Yilmazer et al., 2001) and previous attempts to 
activate IX into 8-PN with liver enzymes were unsuccessful (Coldham et al., 2002). 
Therefore, although 8-PN was only a minor metabolite in this study, this was the first report 
of the role of IX as a proestrogen, being activated into the potent phytoestrogen 8-PN by 
human liver enzymes such as CYP1A2 (Guo et al., 2006). The importance of this reaction 
could further increase when considering that X could be isomerized in the intestine into IX. 
This extra production of the proestrogen IX was suggested to take place under the acidic 
conditions of the stomach (Nikolic et al., 2005). 
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Figure 1.12. Main phase I and II metabolites of 8-prenylnaringenin (8-PN). Xanthohumol (X) may 
chemically be converted into isoxanthohumol (IX) in the intestine, increasing the IX concentration. 
Phase I metabolism of IX mainly yields cis- and trans-alcohols of the prenyl group but may also be an 
extra source of 8-PN by hepatic O-demethylation of IX. 
 
1.4.4 Metabolism of flavonoids by intestinal bacteria 
While many recent studies focus on the absorption of flavonoids and the importance of 
liver phase I and II metabolism towards their final biological activity, it is often forgotten that a 
major fraction of ingested flavonoids reaches the colon directly or through enterohepatic 
circulation. Here, the aglycones can be absorbed from the colon or act as substrate for the 
indigenous bacterial community with their extensive metabolic potential. In many cases 
bacterial metabolism of polyphenols leads to a decrease in biological activity. However, in 
some cases specific bacterial transformations give products with increased biological 
properties compared to the parent compounds. Therefore, bacterial degradation and specific 
transformation will be discussed separately. 
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1.4.4.1 Microbial biotransformation activity 
For many years, it was believed that the main purpose of the large intestine was the 
resorption of water and salt by the body and the facilitated disposal of waste materials. 
However, the human large intestine harbors a highly complex microbial ecosystem of about 
200 g living cells, at concentrations of 1012 microorganisms per gram gut content, the highest 
recorded for any microbial habitat (Whitman et al., 1998). The use of advanced culture-
independent approaches (Gill et al., 2006; Zoetendal et al., 2004) and new ecological 
theories about evolutionary forces shaping the microbial community in the intestine (Bäckhed 
et al., 2005; Dethlefsen et al., 2006; Ley et al., 2006) have given more insight in the structure 
of this ecosystem. Although 55 and 13 divisions have been described of respectively bacteria 
and archaea, the gut microbiota is dominated by only two bacterial divisions, the 
Bacteroidetes (bacteroides) and Firmicutes (clostridia, eubacteria, …), with lower levels of 
Actinobacteria (bifidobacteria), and by one member of the Archaea, Methanobrevibacter 
smithii. At this level, the intestinal communities of all humans therefore appear quite similar. 
However, within these divisions, a limited number of lineages terminate in broad, shallow 
radiations comprising hundreds of species and thousands of strains, making the microbiota 
of an individual as personalized as a fingerprint (Bäckhed et al., 2005; Ley et al., 2006).  
Driven by selection forces at both microbial and host level, this microbial community has 
coevolved in a mutualistic relation with the human host with important implications for health 
and disease. This involves the stimulation of the gut immune system (Salminen et al., 1998), 
the regulation of cell proliferation (Dethlefsen et al., 2006), the synthesis of vitamins K and B 
(Conly and Stein, 1992), energy salvation (Backhed et al., 2004) and pathogen resistance 
(Hopkins and Macfarlane, 2003). On the other hand, specific community assemblage may 
also be seen as a risk factor contributing to a disease state (Ley et al., 2006). This is shown 
by recent reports linking intestinal bacteria with diseases ranging from allergies (MacDonald 
et al., 2005) to bowel inflammation (Elson et al., 2006) and obesity (Backhed et al., 2007). 
But the intestinal community has also another important role. Taking together the 
genomes of all these bacteria, the microbiome has a coding capacity that vastly exceeds that 
of the human genome and encodes biochemical pathways that humans not have evolved 
(Egert et al., 2006). Thus, the intestinal microbiota can be regarded as a separate organ 
within the human host, that is capable of more conversions than the human liver (Table 1.2). 
Most resident colon microbiota typically perform fermentation of carbohydrates and proteins, 
but it has become clear that many bacterial groups are also capable of transforming 
xenobiotic compounds (Macdonald et al., 1983; Aura et al., 2002). The intestinal microbiota 
thus play an important role in the first-pass metabolism of compounds which are poorly or 
incompletely absorbed by the gut mucosa.  
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Table 1.2. Metabolic potency of human gastrointestinal microbiota [after: Ilett et al. (1990)]. 
Reactions Enzyme Bacterial species / origin of sample 
Hydrolysis   
Glucuronides β-glucuronidase E. coli 
Glycosides β-glucosidase Enterococcus faecalis, Eubacterium rectale, 
Clostridium sphenoides 
Amides Amide hydrolase E. coli, B. subtilis 
Esters Deacetylase Enterococcus faecalis 
Sulfamates Arylsulfotransferase Clostridia, enterobacteria, enterococci 
Reduction   
Azo-compounds Azoreductase Clostridia, lactobacilli 
Unsaturated lacton Unsat. glycoside 
hydrogenase 
Eubacterium lentum 
Aliphatic double 
bounds 
Unsat. Fatty acid 
hydrogenase 
Enterococcus faecalis 
Nitro-compounds Nitroreductase E. coli, bacteroides 
N-oxides N-oxide reductase Human colon 
S-oxides Sulfoxide reductase E. coli 
Ketones Hydrogenase Rat caecum 
Hydroxylamines Nitroreductase Rat GIT 
Dehydroxylation   
Demethylaton Demethylase Enterococci, lactobacilli, clostridia 
Deamination Deaminase Bacteroides, clostridia 
Decarboxylation Decarboxylase Enterococcus faecalis 
Dehydrogenation Dehydrogenase Clostridium welchii 
Dehalogenation Dehalogenase E. coli, Aerobacter aerogenes 
Synthetic reactions   
Esterification Acetyltransferase E. coli 
N-nitrosation  Enterococcus faecalis, E. coli 
Other reactions   
Oxidation Oxidase E. coli, Enterococcus faecalis 
Isomerization Isomerase Eubacterium rectale, clostridium sphenoides 
Fission aliphatic Tryptophase E. coli, Bacillus alvei 
Fission ring C-S lyase Pig GIT, Eubacerium aerofaciens 
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In contrast to the oxidative and conjugative reactions from the phase I and II enzymes in the 
enterocytes and hepatocytes, the bacterial metabolism is more reductive, hydrolytic and 
even of degradative nature with a great potential for both bioactivation as detoxification of 
xenobiotics (Ilett et al., 1990). 
Additionally, the intestinal microbiota also interfere with the human biotransformation process 
through the enterohepatic circulation of xenobiotic compounds. Compounds that have been 
absorbed in the intestine and subsequently detoxified are usually conjugated with polar 
groups (glucuronic acid, glycine, sulfate, glutathion and taurine) in the liver prior to secretion 
with the bile (Ilett et al., 1990). Once released in the intestinal lumen, these conjugates may 
be hydrolyzed again by bacterial enzymes such as β-glucuronidases, sulfatases and 
glucosidases. McBain and MacFarlane (1998) estimated that 1010-1012 bacteria/mL intestinal 
content produce β-glucosidase and 107-1011 produce β-glucuronidase, showing the 
importance of intestinal bacteria in this deconjugation process. This would negate the 
detoxification cycle and delay the excretion of many exogenous compounds since the 
original compounds or phase I metabolites are more prone to intestinal absorption than their 
phase II conjugates. 
1.4.4.2 Epithelial transport 
The capability of intestinal bacteria to produce biologically active metabolites, does not 
necessarily mean that a biological activity is to be expected in the human body. For this, the 
activated compound first has to become bioavailable. An important prerequisite for a 
compound to become bioavailable is that it is subjected to intestinal transport across the 
epithelium. Although the morphology of the large intestine is substantially different from that 
of the small intestine, the colon is lined with epithelial cells, colonocytes, which allow the 
absorption of components across the intestinal wall too. Non-digested food components, 
digestion products, secreted human metabolites and microbial fermentation products may 
(partly) become available for absorption. Hence, the small intestine is not the only site of 
absorption. Although the available surface area for colonic absorption is much smaller than 
that of the small intestine, it may be of significant importance given the possibility that 
microbial metabolites may be produced with increased biological activity. 
In general, the permeability to hydrophilic compounds decreases once the small intestine 
is passed. This can be attributed to the smaller surface area of the colon membrane and the 
increased tightness of the epithelium (Ungell et al., 1998). However, this decreased 
permeability is not always observed for hydrophobic compounds. Depending on the type of 
compound and the species of origin, membrane transport studies show higher permeability 
to hydrophobic compounds in the colon than in the small intestine, and vice versa. A sound 
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explanation for these differences is not yet available but one of the reasons may be that 
epithelial enzymes that are involved in metabolic conversion processes, are responsible. A 
second reason may be the presence of efflux carrier proteins (p-glycoprotein) in the colon 
epithelium, thus interfering with the absorption process.  
1.4.4.3 Degradation of flavonoids in the colon 
Colonic metabolism of dietary flavonoids has been extensively studied and associations 
between urinary excretion of simple phenolic structures, such as hippuric acid derivatives, 
and bacterial flavonoid degradation was shown in many studies (Gonthier et al., 2003; Olthof 
et al., 2003; Mulder et al., 2005; Gao et al., 2006). It is clear that the metabolites are formed 
by microbial action, as lower recovery was found in human and animal studies where 
antibiotics were dosed prior to flavonoid uptake (Gott and Griffiths, 1987; Kohri et al., 2001) 
and as phenolic metabolites were not detected in germ-free rats (Griffiths and Barrow, 1972). 
Bacterial flavonoid degradation follows a very general pattern in which many non-
specific metabolites are formed, such as hydroxylated phenylpropionic acids. The 
consequence is that a relatively small number of phenolic degradation products are formed in 
the colon from the extremely diverse group of natural flavonoids (Rechner et al., 2004). 
Already in 1956 it was shown that flavonoid degradation involves ring fission of the 
heterocyclic C ring (Booth et al., 1956). More studies have elucidated the complete 
degradation pathway (Winter et al., 1989; Braune et al., 2001; Hur et al., 2002; Cermak et al., 
2006). With naringenin as example, the degradation starts with isomerization of the C ring at 
the hetero atom into the corresponding chalcone phloretin (Figure 1.13). After reduction into 
a dihydrochalcone, further splicing takes place at the carbonyl moiety, yielding phloroglucinol 
and 3-(4-hydroxyphenyl)propionic acid. 
A number of bacteria have been identified as capable of degradation of flavonoids 
including Eubacterium ramulus (Schneider and Blaut, 2000; Braune et al., 2001; Schoefer et 
al., 2002; Herles et al., 2004), Eubacterium sp. Strain SDG-2 (Wang et al., 2001), Clostridium 
orbiscindens (Schoefer et al., 2003), Clostridium butyricum (Miyake et al., 1997), Clostridium 
sp. (Hur et al., 2002), Rhizobium sp. (Rao and Cooper, 1994), Eubacterium oxidoreducens 
(Krumholz and Bryant, 1986) and Butyrivibrio sp. (Cheng et al., 1969). As chalcones are 
intermediates in the flavonoid degradation, chalcone degradation leads to similar metabolic 
end products (Braune et al., 2005). The metabolite 3-(4-hydroxyphenyl)propionic acid may 
be dehydroxylated into 3-phenylpropionic acid and the mixture can be absorbed from the 
colon. Both components often are recovered as such or conjugated in urine (Griffiths and 
Smith, 1972; Felgines et al., 2000), but may also be subjected to β-oxidation and glycination 
in the liver, yielding hippuric acid and 4-hydroxyhippuric acid, two of the most commonly 
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recovered flavonoid metabolites in urine (Rechner et al., 2004). In contrast, phloroglucinol 
hardly ever is recovered as final metabolite, as it can be degraded into acetate or acetate 
and butyrate (Krumholz and Bryant, 1986; Brune and Schink, 1992). Although bacteria can 
gain some energy from the degradation, the main rationale would be detoxification, as many 
flavonoids exert antibacterial activity (Basile et al., 1999; Schoefer et al., 2003). 
 
 
Figure 1.13. Degradation of naringenin by intestinal bacteria yields 3-(4-hydroxyphenyl)propionic acid 
and phloroglucinol. Whereas the former may further be transformed to 3-phenylpropionic acid, the 
latter is completely degraded by intestinal bacteria. 
 
Important to note is that colonic degradation of flavonoids is highly variable because of 
two main reasons: 
• Small differences in substitution pattern of flavonoids result in major changes in colonic 
degradation, leading to some general rules in structure-function relationships (Griffiths 
and Smith, 1972; Lin et al., 2003; Manach et al., 2004; Simons et al., 2005). The major 
factor determining rapid degradation is the presence of a 5- and 7-OH on the A ring plus 
a 4’-OH on the B ring. Absence of any of the 3 groups protects the compound from 
cleavage. In contrast, extra presence of OH groups on A, B or C ring and desaturation of 
the C ring have no effect on microbial degradation. Methoxy-groups however, both on A 
or B ring significantly slow bacterial degradation. A good example of these differences is 
the degradation of isoflavones. Genistein, having all necessary OH, is rapidly degraded 
into 2-(4-hydroxyphenyl)propionic acid and phloroglucinol (Schoefer et al., 2002), 
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whereas daidzein, lacking the 5-OH, may be transformed into O-desmethylangolensin 
(O-DMA) but is not fully degraded into phenolic acids (Hur et al., 2002; Schoefer et al., 
2002). Finally, the effect of methoxygroups is shown by the fact that glycitein, having a 6-
methoxy, is degraded slower than genistein (Simons et al., 2005). 
• Large interindividual differences were noted in the degradation of specific flavonoids. For 
instance for naringenin, intestinal bacteria from some individuals did not degrade the 
flavonoid, whereas others accumulated intermediates and some people’s intestinal 
community completely degraded the compound (Rechner et al., 2004). This has led to 
the separation of individuals into high, moderate and low flavonoid degraders (Erlund, 
2004; Simons et al., 2005). 
 
As degradation of flavonoids leads to a decrease in biological activity, especially when 
the structure of the parent compound is necessary to interact with specific targets in the 
human body such as estrogen receptors, knowledge about the intestinal degradation of 
prenylflavonoids from hops is crucial towards the understanding of possible health related 
effects. However, up to now no detailed studies have been reported by other researchers 
about intestinal degradation of prenylflavonoids. Without giving experimental data, some 
authors predict extensive intestinal and hepatic metabolism of 8-PN (Nikolic et al., 2006), 
whereas others state very high metabolic stability of 8-PN (Rad et al., 2006). Two studies 
have described the administration of X to rats and the excretion of X and its metabolites in 
the feces. Nookandeh et al. (2004) administered 1000 mg X/kg body weight and isolated 22 
metabolites from the feces. However 89 % was excreted as unchanged X. Similar results 
were found by Avula et al. (2004) when dosing X at lower concentrations. Both authors 
reported low oral bioavailability and high metabolic stability of X although the former study 
indicated the presence of 22 metabolites. However, as in the first study unrealistically high 
concentrations were dosed and the second study detected but did not identify possible 
metabolites of X, it is impossible to draw any conclusion about intestinal metabolism of X 
based on these studies.   
1.4.4.4 Colonic activation of phytoestrogens 
Next to degrading active dietary compounds into less active metabolites, a number of 
bacterial transformations are also known which lead to the production of metabolites with 
increased biological activity. Of course, deconjugation of glycosides with the release of the 
(active) aglycones is an intestinal activation (Bokkenheuser et al., 1987), but the best 
example of transformations leading to more active metabolites is the activation of 
phytoestrogens inside the intestine (Figure 1.14). Until recently, the two most well known 
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dietary phytoestrogens were the isoflavones and lignans. For these two groups, it is now 
commonly accepted that their biological activity largely depends on the metabolic potential of 
the intestinal bacteria (Rowland et al., 1999; Raffaelli et al., 2002; Wang, 2002; Cos et al., 
2003; Rowland et al., 2003; Turner et al., 2003). 
 
 
Figure 1.14. The most relevant groups of phytoestrogens, the isoflavones, lignans and 
prenylflavonoids, are present in food as less active precursors. Inside the body, they can be activated 
into the respective active metabolites equol, enterodiol + enterolactone and 8-prenylnaringenin. 
Although some transformations are of non-enzymatic origin (C) or catalyzed by human enzymes (H), 
microbial enzymes (M) are crucial for the generation of the final metabolites for most phytoestrogens. 
 
The isoflavones daidzein and genistein (and glycitein) are present predominantly as 
glucosides in most commercially available soy products. Glucosides originating from food 
which escaped deconjugation in the small intestine, as well as phase II glucuronides and 
sulfates excreted in the gut through enterohepatic circulation, can be deconjugated (De 
Boever, 2001; Choi et al., 2002; Tsangalis et al., 2002). It was previously mentioned that 
genistein is much more susceptible to bacterial degradation than daidzein. Many reports 
have shown however that the latter isoflavone not only can partially be degraded into O-
DMA, but may also transformed into equol through the intermediates dihydro- and 
tetrahydrodaidzein. This equol, named after equus (horse) as it was first found in horse urine 
(Marrian and Haslewood, 1932), was shown to be formed exclusively by bacteria as 
antibiotic treatment decreased its production (Blair et al., 2003) and as equol was not 
produced in germ-free rats (Bowey et al., 2003) and a number of bacteria involved in this 
Literature review 
 42 
process have been identified (Hur et al., 2002; Schoefer et al., 2002; Tsangalis et al., 2002; 
Ueno et al., 2002; Wang et al., 2004; Decroos et al., 2005; Wang et al., 2005; Wang et al., 
2005). As many in vitro (Hedlund et al., 2003; Kinjo et al., 2004; Lund et al., 2004; Muthyala 
et al., 2004; Turner et al., 2004; Messina et al., 2006) and in vivo studies (reviewed in 
Atkinson et al. (2005)) indicate that equol would exert increased health beneficial effects, the 
intestinal bacteria have a crucial role in the activation of soy phytoestrogens. 
A similar story is true for lignans. These plant compounds are present in foods as 
inactive glycoside precursors (Liggins et al., 2000) but can be activated inside the human 
intestine into the active mammalian lignans (also called enterolignans) enterodiol and 
enterolactone (Setchell et al., 1981; Setchell et al., 1981; Borriello et al., 1985; Clavel et al., 
2006). The main dietary precursors are identified as secoisolariciresinol (SECO), 
matairesinol and recently lariciresinol and pinoresinol (Milder et al., 2005). In the intestine, 
the latter two are first transformed in SECO which can then be activated into the 
enterolignans. As this transformation again was shown to be performed uniquely by bacteria 
(Bowey et al., 2003) and as the enterolignans would have increased biological activity 
(Banskota et al., 2004; McCann et al., 2005; Kuijsten et al., 2006; Saarinen et al., 2006; 
Zeleniuch-Jacquotte et al., 2006), it can be concluded that intestinal bacteria also determine 
health effects related to lignan intake.  
Both groups of phytoestrogens are also known to share another interesting feature. For 
isoflavones and lignans it is well known that the extent of bacterial metabolism is highly 
variable between individuals. It has been observed that only about 30-50 % of humans have 
the intestinal metabolic potential to produce equol (Lampe et al., 1994; Atkinson et al., 2004; 
Atkinson et al., 2006), separating individuals in equol producers and non-producers, with 
higher prevalence of the producer phenotype in Asian countries (Song et al., 2006) and 
among vegetarians (Setchell and Cole, 2006). O-DMA production would occur in 80-90 % of 
the individuals (Kelly et al., 1993). As wide ranges in the production of the mammalian 
lignans have also been observed (Lampe et al., 1994; Hutchins et al., 2000; Atkinson et al., 
2006), interindividual differences in the intestinal bacterial community result in interindividual 
differences in the exposure to specific phytoestrogen metabolites. 
In view of this microbial production of the estrogenic phytoestrogen metabolites in the 
colon, it is important to note that comparative in vitro permeability studies with small intestinal 
and colon epithelia revealed that the colon epithelium is more permeable to the natural 
estrogen E2 than the small intestinal epithelium (van der Bijl and van Eyk, 2003). This 
indicates that microbially produced phytoestrogens inside the colon lumen may also be 
available for colon epithelium absorption and hence also can elicit a biological response, 
once reaching the target organs upon the uptake in the blood compartment. This is 
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confirmed by the numerous studies detecting equol and enterolignans in serum and urine 
after oral uptake of their precursors. 
Therefore, the question arises whether this might also happen with this new group of 
phytoestrogens from hops. In 2002, it was suggested that IX might act as a proestrogen in 
vivo supposing it could be demethylated into 8-PN after uptake in the human body (Coldham 
et al., 2002) and in 2005, urinary 8-PN excretion was indeed detected after IX consumption 
by healthy men (Schaefer et al., 2005). Although this was attributed to liver metabolism (see 
above), the intestinal microbial community might very well be responsible for this 
transformation, as a number of bacteria have been identified as capable to demethylate 
methoxylated aromates (Table 1.3). Yet, no reports by other research groups confirmed this 
hypothesis. 
 
Table 1.3. A selection of bacteria having O-demethylation capacity. 
Strain Reference 
Desulfitobacterium hafniense (Neumann et al., 2004) 
Sphingomonas paucimobilis (Masai et al., 2004) 
Pseudomonas putida (Furukawa et al., 2003) 
Clostridium coccoides (Kamlage et al., 1997) 
Clostridium formoaceticum (Frank et al., 1998) 
Acetobacterium dehalogenans (Kaufmann et al., 1998) 
Thermoanaerobacter kivui (Kevbrina and Pusheva, 1996) 
Sporomusa ovata (Stupperich et al., 1996) 
Sporomusa sphaeroides (Muller and Bowien, 1995) 
Acetobacterium woodii (Muller and Bowien, 1995) 
Sporomusa paucivorans (Hermann et al., 1987) 
Clostridium aceticum (Lux and Drake, 1992) 
Clostridium formicoaceticum (Lux and Drake, 1992) 
Eubacterium limosum (Hur and Rafii, 2000) 
Peptostreptococcus productus (Clavel et al., 2005) 
Eubacterium aggregans (Mechichi et al., 1998) 
Clostridium methoxybenzovorans (Mechichi et al., 2005) 
Holophaga foetida (Kreft and Schink, 1997) 
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1.5 Estrogenicity of beer: fact or fiction? 
1.5.1 Exposure to 8-PN after beer consumption 
The final content of prenylflavonoids in beer strongly depends on the production process 
and more specifically on the way hops are introduced in the brewing kettle. Hops are either 
introduced as pellets or as extracts. Pellets are basically hop cones which are grinded and 
pressed into a small form, facilitating storage, handling and dosage (Magalhaes et al., in 
press). Hop extraction involves milling, pelleting and remilling, passing a solvent through a 
column to collect the resin components and finally removal of the solvent. Ethanol was one of 
the first solvents used to extract flavor and bitter compounds from hops but has the 
disadvantage of low selectivity resulting in high impurity and solvents are difficult to remove. 
Therefore, the selective and easily removable supercritical CO2 is currently the most 
accepted solvent (Gardner, 1993). However, as hop pellets and extracts differ in the 
concentration of prenylflavonoids, the choice for one form has a crucial impact on the final 
prenylflavonoid content (Table 1.4). Pellets of course still contain all flavonoids and so do 
ethanolic extracts because of the low selectivity of the solvent. On the contrary, polar 
compounds such as flavonoids cannot be excreted with supercritical CO2 leading to very low 
prenylflavonoid concentrations in the extract (Magalhaes et al., in press) and in the final 
beers brewed with these extracts (Stevens et al., 1999; Rong et al., 2000). 
 
Table 1.4. Prenylflavonoid content (g/100 g; average ± standard deviation) in different hop products 
[after Magalhaes et al. (in press)]. 
 Hop product 
 Pellets (type 45) Ethanolic extract CO2 extract 
Xanthohumol 0.62 ± 0.01 3.75 ± 0.05 0.089 ± 0.001 
Isoxanthohumol <LOD 0.17 ± 0.01 <LOD 
 
Although X and (lower amounts of) DMX are the main prenylflavonoids in the hop cone, 
their abundance in beer is much lower in favor of the corresponding prenylflavanones. This is 
also related to the production process. Stevens et al. (1999) showed that upon introducing 
hops, 95 % of the prenylflavonoid fraction consists of X, DMX and 3’-
geranylchalconaringenin. However, during the wort boiling much of the X and all of the DMX 
is converted by thermal isomerization into IX and a mixture of 6-PN and 8-PN. Later in the 
production process the isomerization of X continues leading in their example to a 98 % 
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conversion into IX. Therefore, IX and lower quantities of 6-PN and 8-PN are the main 
prenylflavonoids in beers (Table 1.5). 
Although IX concentrations often are in the range of 1 mg/L depending on the origin of 
the hops and brewing process, the 8-PN concentrations generally are much lower and most 
often below 100 µg/L (Table 1.5). This is in agreement with other groups who quantified 8-PN 
concentrations in Belgian, German and other European beers and found concentrations in 
the range of not detected up to 20 µg/L (Tekel et al., 1999), 21 µg/L (Rong et al., 2000) and 
138 µg/L (Schaefer et al., 2005).  
 
1.5.2 Biological relevance of 8-PN exposure 
There is currently a considerable interest whether moderate beer consumption may 
influence human health (De Keukeleire, 2003). Because of the risks associated with high 
alcohol intake (World Cancer Research Fund, 1997), clinical guidelines generally do not 
recommend the consumption of alcohol containing beverages. However, many studies now 
conclude that moderate beer consumption would protect against these life style-related 
diseases (Klatsky et al., 1997; Cleophas, 1999; Di Castelnuovo et al., 2002) indicating that 
moderate beer consumption should not unconditionally be contemplated as negative. This 
may be related to protective effects of moderate alcohol consumption (Giles and Sander, 
2005), but additional benefits might also be associated with specific non-alcohol components 
in beer, such as isohumulones (Kondo, 2004; Miura et al., 2005; Nozawa et al., 2006).  
In view of the current findings on the potent biological activity of 8-PN, an extra question 
was recently added to this discussion: Are any (positive or negative) endocrine effects to be 
expected related to moderate beer consumption? Much attention has recently been given to 
the presence of endocrine-active substances in the human diet and possible health risks 
(Knight and Eden, 1996; Cassidy and Milligan, 1998; Jefferson and Newbold, 2000; Mazur 
and Adlercreutz, 2000; Chen and Rogan, 2004; Rasier et al., 2006). As previously 
mentioned, 8-PN would be the most potent phytoestrogen currently known with much higher 
activity than other dietary compounds, and therefore this question should indeed be carefully 
considered when assessing health effects of moderate beer consumption.  
Yet, as final 8-PN concentrations in beers are generally below 100 µg/L, the total 
estrogenicity of beers is still 500- to 1000-fold lower than the concentration needed for 
harmful in vivo activity (~100 mg/L) in rat experiments (Milligan et al., 2002). Moreover, many 
beers are now made with CO2 hop extracts instead of whole hops, giving lower 8-PN 
concentrations or even no 8-PN. Therefore, it is generally agreed that with the current 
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knowledge, no detrimental health effects are to be expected through moderate beer 
consumption (Milligan et al., 1999; Milligan et al., 2002; Stevens and Page, 2004).  
 
Table 1.5. Prenylflavonoid contents in beer and dietary supplements. [after Stevens et al. (1999)]. 
Beer (µg/L) a X IX 8-PN 
US major brand    
Lager/pilsner 34 500 13 
Lager/pilsner 9 680 14 
Lager/pilsner 14 400 17 
Lager/pilsner – – – 
Northwest/US microbrews    
American porter 690 1330 240 
American hefeweizen 5 300 8 
Strong ale 240 3440 110 
India pale ale 160 800 39 
Imported beers    
European stout 340 2100 69 
European lager 2 40 1 
European pilsner 28 570 21 
European pilsner 12 1060 8 
Czech lager 28 1350 150 
Czech lager 28 1180 175 
Czech lager 26 1910 116 
Czech draught < 0.2 < 20 < 2.0 
Other    
Non-alcohol beer 3 110 3 
Dietary supplements b    
Breast enhancement 3220-4830 792-1188 103-155 
Menopausal complaints 2500-3000 1000-1500 100 
a Most beers contain no desmethylxanthohumol due to thermal isomerization in the brew kettle. 
b Selection of two commercially available dietary supplements claiming specific beneficial effects. 
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A final remark relates to positive effects of long term exposure to very low concentrations 
of estrogens. Many reports now conclude positive effects on for instance bone density of 
long term exposure to ultra-low doses (0.25 mg/d) of E2 (Prestwood et al., 2003; Kenny et al., 
2005; Appt et al., 2006). Based on the absolute 8-PN concentrations in beer, even these 
kinds of effects probably should not be expected. However, one important factor is often not 
taken into consideration: the aspect of bioavailability and possible biotransformation 
reactions inside the body, influencing the final biological activity of the ingested product.  
 
1.6 Objectives of this research 
At the time this research was started, a number of in vitro data already suggested high 
biological activity of prenylflavonoids and a first hop extract standardized on 100 µg 8-PN 
was recently marketed, claiming positive effects in alleviating menopausal complaints. At the 
same time, some reports already described liver metabolism of prenylflavonoids in vitro and 
a possible role of IX as ‘proestrogen by virtue’ had been suggested. However, despite the 
indications of high biological activity, little was known about the fate of these compounds in 
the human body. It was already known for a long time that hops caused stronger estrogenic 
effects in some women compared to others (Koch and Heim, 1953), indicating an important 
role of the aspect of bioavailability towards the final biological activity. Similarly, first 
indications about the effectiveness of the recently commercialized hop extracts showed that 
some women observed more effects on menopausal complaints after uptake of the product 
compared to others. Yet, in vivo data about prenylflavonoid bioavailability were not available. 
Until 1999, studies about bioavailability of phytoestrogens mainly focused on isoflavones 
and lignans. This showed that, as for many other flavonoids, the biological activity of these 
phytoestrogens largely depends on the activity of the intestinal microbial community present 
in the colon. Upon ingestion of precursors present in food or dietary supplements, intestinal 
bacteria produce metabolites with increased biological activity. However, it was also seen 
that the capacity of this community to form the active compound is highly variable, with the 
result that biological effects after phytoestrogen intake may also vary. 
As nobody ever explored this specific aspect of bioavailability for the newly discovered 
group of prenylflavonoid phytoestrogens, the main objective of this work was to explore the 
possible role of the human intestinal microbial community in determining the bioavailability 
and biological activity of prenylflavonoids from hop. To do this, an integrated in vitro – in vivo 
approach was followed, combining batch incubations with SHIME, rat and human studies.  
Therefore, the outline of this research can be described as follows: 
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(i) Exploration of microbial degradation and activation of prenylflavonoids (chapter 2). In 
this chapter, bacterial metabolism of X, IX and 8-PN will be investigated using in vitro 
batch cultures of human fecal samples and degradation as well as activation will be 
assessed using the Yeast Estrogen Screen. The most important finding of this 
explorative study, i.e. the intestinal activation of IX into 8-PN will be further investigated 
in batch with focus on interindividual differences in this process. Finally, a highly efficient 
8-PN-producing strain of Eubacterium limosum is selected and the possible application 
of the strain to increase 8-PN production in situ in low-producing intestinal communities 
will be explored using batch incubations. 
(ii) In depth study of the intestinal activation of IX into 8-PN (chapter 3). After the first 
exploration of the intestinal production of 8-PN, this chapter will investigate the process 
in detail. Using the Simulator of the Human Intestinal Microbial Ecosystem (SHIME), 
stability of prenylflavonoids in the upper intestine (stomach and small intestine) will be 
investigated as well as the microbial conversion of IX in the different colon regions. 
Interindividual differences in this process will further be investigated by expanding the 
number of fecal samples in batch incubations and a preliminary human intervention trial 
will be described which studies the impact of intestinal activation of IX and variability in 
this process on urinary 8-PN excretion. 
(iii) Study of the intestinal activation of different phytoestrogens (chapter 4). As it became 
clear from previous chapters that interindividual variation in microbial metabolism 
determines the final biological activity of all important groups of phytoestrogens, a 
statistical approach will be used to separate high, moderate and low producer 
phenotypes for each phytoestrogen based on in vitro incubations and specific 
phenotypes will be related with each other and the abundance of specific microbial 
groups. Knowledge about this may help to better evaluate the biological effect of 
combined uptake of different precursors in food and to elucidate some factors 
determining their microbial metabolism. 
(iv) Application of E. limosum as a probiotic in vitro and in vivo (chapter 5). In this final 
research chapter, the strategy of using probiotics to increase the 8-PN production and 
exposure in low-producing individuals will further be explored. To do this, a new model 
system, the TWINSHIME, will be developed, allowing to study the intestinal microbiota of 
two producer phenotypes in parallel in the representative SHIME model. This will be 
validated in vivo in an experiment with two groups of human microbiota associated rats, 
harboring high- and low-8-PN-producing intestinal microbiota. In addition, germ-free rats 
are included in the study to definitively show the unique involvement of intestinal bacteria 
in the activation of IX into 8-PN and to investigate pharmacokinetic parameters. 
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CHAPTER 2 
Activation of proestrogens from hops by intestinal microbiota; 
conversion of isoxanthohumol into 8-prenylnaringenin 
ABSTRACT 
Hop, an essential ingredient in most beers, contains a number of prenylflavonoids, 
among which 8-prenylnaringenin (8-PN) would be the most potent phytoestrogen currently 
known. Although a number of health effects are attributed to these compounds, only a few 
reports are available about the bioavailability of prenylflavonoids and the transformation 
potency of the intestinal microbial community. To test these transformations, four fecal 
samples were incubated with xanthohumol (X), isoxanthohumol (IX) and 8-PN. Upon 
incubation with IX, present in strong ales up to 4 mg/L, 36 % was converted into 8-PN in one 
fecal sample and the estrogenic properties of the sample drastically increased. In an 
experiment with 12 fecal cultures, this conversion was observed in 1/3 of the samples, 
indicating the importance of interindividual variability in the intestinal microbial community. 
Eubacterium limosum was identified to be capable of this conversion (O-demethylation) of IX 
into 8-PN, and after strain selection a conversion efficiency of 90 % was achieved. Finally, 
strain supplementation to a non-converting fecal sample led to rapid and high 8-PN 
production at only 1 % (v/v) addition. Up to now, the concentration of 8-PN in beer was 
considered too low to affect human health. However, these results show that the activity of 
the intestinal microbial community could more than tenfold increase the exposure 
concentration. Since prenylflavonoids are present in many beers with IX being the major 
constituent, the results raise the question whether moderate beer consumption might 
contribute to increased in vivo levels of 8-PN and even influence human health.  
 
Key words: Hop, isoxanthohumol, 8-prenylnaringenin, prenylflavonoids, intestine, bacteria, 
Eubacterium limosum, beer, phytoestrogens, O-demethylation 
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(2005). Activation of proestrogens from hops ( Humulus lupulus L.) by intestinal microbiota; 
Conversion of isoxanthohumol into 8-prenylnaringenin. Journal of Agricultural and Food Chemistry, 
53: 6281-6288. 
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INTRODUCTION 
Hops (Humulus lupulus L.) have been used for centuries as an essential raw material in 
beer brewing providing bitterness and flavor to beer. In the last few years, the plant has 
gained increasing attention as a source of prenylflavonoids, a subclass of polyphenols. 
These are present in the lupulin glands, found in the female hop cones. In this group, two 
prenylchalcones xanthohumol (X) and desmethylxanthohumol (DMX) and three 
prenylflavanones isoxanthohumol (IX), 8-prenylnaringenin (8-PN) and 6-prenylnaringenin (6-
PN) now receive much attention because of their possible health-promoting properties. X has 
been identified as a strong cancer chemopreventive agent (Gerhauser et al., 2002), while 8-
PN has been shown to be one of the most potent phytoestrogens identified so far, with 
considerably higher activity than the well-known soy phytoestrogens (Milligan et al., 1999; 
Schaefer et al., 2003). These interesting properties have led to intense research aiming at 
deciphering various bioactivities. 8-PN showed in vivo estrogenic activity (Milligan et al., 
2002; Diel et al., 2004), prevented bone loss in rats (Miyamoto et al., 1998), inhibited 
angiogenesis (Pepper et al., 2004) and metastasis (Rong et al., 2001) and exhibited 
antiandrogenic activity (Zierau et al., 2003). 
There is considerable interest in whether human exposure to phytoestrogens has either 
health risks or benefits (Cassidy and Milligan, 1998; Barnes, 2003; Magee and Rowland, 
2004). In case of hop prenylflavonoids, beer is the main dietary source, with an estimated 
daily intake of about 0.14 mg prenylflavonoids (Stevens et al., 1999). However, the 
concentrations detected in beer (and therefore, the average intake) significantly depend on 
the brewing process, as strong ales contain up to 4 mg/L. Although X is present as a 
predominant prenylchalcone (up to 1 % (m/m)) (De Keukeleire et al., 2003), most of it is 
transformed into IX by thermal isomerization during wort boiling. As a result, IX is the major 
prenylflavonoid found in beer in concentrations from 500 µg/L (lager/pilsner) up to 4 mg/L 
(strong ale) (Stevens et al., 1999; Rong et al., 2000). DMX is equally converted into 8-PN 
giving final concentrations in beer up to 100 µg 8-PN/L and IX vs. 8-PN ratios between 20 
and 40. But despite the high activity of 8-PN, the total estrogenicity of beers is still 500- to 
1000-fold lower than the concentration needed for harmful in vivo activity (~100 mg/L) in rat 
experiments (Milligan et al., 2002). Moreover, many beers are now made using hop extracts 
instead of whole hops, giving lower concentrations of 8-PN or even no 8-PN. Therefore, it is 
generally agreed that with the current knowledge, no detrimental health effects due to 
estrogens in beer are to be expected through moderate beer consumption (Milligan et al., 
1999; Milligan et al., 2002; Stevens and Page, 2004). Besides beer, a number of hop-based 
dietary supplements are marketed, but contents may vary (Coldham and Sauer, 2001).  
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In order to exert in vivo effects claimed in vitro, dietary flavonoids need to be absorbed 
from the gut and reach their targets unchanged. However, up to now no peer-reviewed data 
with regard to the bioavailability of prenylflavonoids are available. In general, monomeric 
flavonoids reach the small intestine unchanged (Spencer, 2003), where absorption from the 
gut in the mesenteric circulation can take place. In vitro studies indicated extensive liver 
biotransformation of X (Yilmazer et al., 2001; Yilmazer et al., 2001), IX (Nikolic et al., 2005) 
and 8-PN (Nikolic et al., 2004) upon absorption. However, the extent of dietary polyphenol 
absorption in the small intestine is rather limited (10-20 %), and important enterohepatic 
circulation often occurs (Spencer et al., 1999; Kuhnle et al., 2000), thereby implying that a 
large proportion reaches the colon. Naringenin, the non-prenylated analogue of 8-PN, 
showed intensive microbial biotransformation in the intestine, including ring cleavage and 
dehydroxylation (Rechner et al., 2004), followed by absorption and urinary excretion 
(Felgines et al., 2000). The extent of degradation strongly depended on compound 
concentration and individual composition of the gut microbiota of the different human 
subjects. On the other hand, when X was fed to rats it was mainly recovered in unchanged 
form from the feces (89 %) (Nookandeh et al., 2004). 
As a source of 8-PN, IX and X, moderate beer consumption leads to the intake of 
bioactive compounds, which could either act beneficially or be harmful depending on the final 
concentration reaching the target organs in the human body. In many cases, the 
bioavailability of phytoestrogens is strongly influenced by the composition and activity of the 
gut microbial community (Bowey et al., 2003; Rowland et al., 2003; Turner et al., 2003). As 
the microbiota can activate as well as degrade these components, the focus of the present 
study is to investigate the role of the microbial community towards the in vivo estrogenic 
properties of beer or food supplements containing hops by investigating the 
biotransformation or the breakdown of X, IX and 8-PN in fecal cultures and to evaluate 
interindividual differences. Understanding these processes is a crucial step towards the 
estimation of the final bioactivity of dietary flavonoids derived from hops and the evaluation of 
possible effects associated with such intake. 
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MATERIALS AND METHODS 
Chemicals 
X was isolated from spent hops (i.e. the residue which remains after liquid or supercritical 
carbon dioxide extraction of hop cones, NateCO2, Wolnzach, Germany) via methanol/ethyl 
acetate (9/1, v/v) extraction, flash chromatography fractionation, and purification by semi-
preparative chromatography on a Varian Omnisphere C18 column (250 mm x 21.4 mm, 10 
µm, Varian, St.-Katelijne-Waver, Belgium) using a Gilson 322 Pump (Gilson, Middleton, 
USA) with a Gilson UV-VIS 156 detector and a Gilson 206 Fraction Collector. IX was 
prepared from X by isomerization under reflux in a 5 % ethanolic KOH solution. IX was 
purified from the reaction mixture by semi-preparative HPLC. 8-PN was prepared by 
prenylation of naringenin with 2-methylbut-3-en-2-ol in dioxane in the presence of boron 
trifluoride (Jain et al., 1978). All chemicals were obtained from Sigma-Aldrich (St. Louis, 
Missouri, USA). Using semi-preparative high-performance liquid chromatorgaphy (HPLC), 8-
PN was purified from a fraction resulting from flash chromatography and containing both 8-
PN and 6-PN and a B-ring prenylated naringenin. The identities of X, IX and 8-PN were 
confirmed by comparison of 1H NMR and 13C NMR data (Varian 300 MHz) with literature 
values (Stevens et al., 1997) and the purities were assessed to be more than 99 % by HPLC. 
 
Fermentation conditions 
Bacterial cultures 
Fecal samples were obtained from 12 healthy subjects between the age of 20 and 35 
and designated A to L. None of the subjects had a history of gastrointestinal disease and had 
not taken antibiotics during 3 months prior to sample delivery. Fecal slurries of 20 % (w/v) 
fresh fecal samples were prepared by homogenizing the feces with phosphate buffered 
saline (0.1 mol/L, pH 7) containing 1 g/L sodium thioglycolate as reducing agent. The 
particulate material was removed by centrifugation (1 min, 500 x g).  
Eubacterium limosum DSM 20543 was obtained from the German Collection of 
Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany). 
Culture medium 
All fermentation experiments were performed in Brain Heart Infusion broth (37 g/L, 
Oxoid, Hampshire, USA) with 0.5 g/L L-cystein HCl. Fecal bacteria as well as E. limosum 
require anaerobic conditions (low redox potential) for growth. Therefore, resazurin (2 mg/L) 
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was added as a redox indicator. A pink color indicates a high redox (>−80 mV) and a 
colorless solution shows a low redox potential (<−80 mV), i.e. anaerobic. The redox potential 
in the large intestine typically ranges between -150 and -280 mV. The medium was 
autoclaved at 121 °C for 15 min.  
Prior to addition to the autoclaved growth medium in the fermentation vessels, stock 
solutions of the different prenylflavonoids (X, IX, 8-PN) were prepared in dimethylsulfoxide 
(DMSO) in a concentration of 5 g/L. Changing the solvent from DMSO to ethanol did not 
influence the outcome of the experiments (data not shown). 
Fermentation 
The fermentation volume was either 25 or 50 mL. In case of the fecal fermentation 
experiments, each batch culture consisted of 90 % Brain Heart Infusion medium, 10 % fecal 
slurry and 25 mg/L of X, IX or 8-PN (5 µL stock solution/mL batch culture) (Figure 2..1). 
Culture experiments with E. limosum were performed by adding 100 µL bacterial stock to the 
Brain Heart Infusion medium and 25 mg/L of X, IX or 8-PN (5 µL stock solution/mL batch 
culture). Each batch was sealed with rubber tops and anaerobiosis was obtained by flushing 
the flasks with N2 during 20 cycli of 2 min 700 mbar overpressure and 900 mbar 
underpressure. Cultures were incubated at 37 °C on a shaker for the duration of the 
experiment. At given time points, samples were taken using syringes. All experiments were 
performed in triplicate. Prior to the start of the experiment, all fecal samples were tested for 
background concentrations of prenylflavonoids that could be present in the sample itself, but 
none were detected.  
 
 
Figure 2.1. Experimental design of this study 
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Chemical analysis 
Extraction protocol 
Two extraction procedures were compared to reach the best recovery of prenylflavonoids 
from fecal cultures: solid-phase extraction using Bond Elut® C18 silica columns (3 mL, 200 
mg, Varian, St.-Katelijne-Waver, Belgium) and liquid/liquid extraction with ethyl acetate. The 
latter protocol gave the best results with recoveries of > 90 % for X, IX and 8-PN and it was 
further optimized. Samples originating from fecal cultures were diluted 5-fold in acidified H2O 
(pH 2) prior to extraction. Samples from E. limosum incubations were used as such. A 1 mL 
sample was added to 4 mL acidified H2O (pH 2) and 5 mL ethyl acetate in a test tube. After 
rigorously vortexing, the samples were centrifuged at 3000 x g for 10 min. Three milliliters of 
the ethyl acetate phase were transferred to a new test tube and dried under N2 stream. 
Finally, the extracts were dissolved in exactly 500 µL methanol, transferred into HPLC vials 
and stored at -20 °C prior to analysis. 
HPLC analysis 
Quantitative analyses were effected by HPLC using a Waters 2695 Alliance Separations 
Module (Waters, Milford, USA) equipped with a Waters 996 Photodiode Array Detector and 
Waters Millenium Software v3.20. A C18 reversed-phase column (Varian, Omnisphere, 250 x 
4.6 mm, 5 µm) was used in combination with a gradient composed of solvent A (water 
acidified with 0.025 % (v/v) formic acid) and solvent B (methanol acidified with 0.025 % (v/v) 
formic acid). Gradient profile: 0-3 min: 45 % B in A, 3-32 min: from 45 % B in A to 95 % B in 
A, 32-37 min: 95 % B in A, 37-45 min: 95 % B in A to 45 % B in A, 45-47 min: 45 % B in A. 
The sample size was 20 µL, the flow-rate 1 mL/min, and the column temperature 35 °C. 
Detection was done simultaneously at 295 nm (for IX, 8-PN and 6-PN) and at 370 nm (for X) 
using diode array detection. Peaks were identified by comparison of the retention times with 
those of authentic isolated reference compounds, as well as by inspection of the respective 
UV spectra. External 5-point calibration curves were established for X, IX, 8-PN and 6-PN 
(R2 > 0.999). Concentrations were calculated based on peak area integration. An extra 
confirmation of the identity of the compounds in the samples was achieved based on the 
typical fragmentation patterns in LC-MS/MS analysis using a Waters Quattro micro with 
electrospray ionization (Stevens et al., 1997). 
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In vitro estrogenicity testing 
To test the estrogenic activity of the prenylflavonoids and their metabolites, we used a 
modified protocol from De Boever et al. (2001) that was based on the protocol developed by 
Routledge and Sumpter (1996) for the yeast estrogen bioassay. In brief, Saccharomyces 
cerevisiae was transformed with the human estrogen receptor (ERα) gene, together with 
expression plasmids containing responsive elements and the lacZ reporter gene (encoding 
the enzyme β-galactosidase). The estrogenic activity of the samples was expressed as 
percentage equivalence to 10 nmol/L 17β-estradiol (E2) which elicited a 100 % response in 
the estrogen receptor bioassay. The bioassays were performed in 96-well plates in which 10 
µL of the test compounds were incubated with 240 µL of the genetically modified yeast 
(absorbance of 0.25 at 610 nm). Serial dilutions of the test compounds were made in 
dimethylsulfoxide which allowed generating dose-response curves for dose (ordinate) versus 
activity (abscissa). The data were fitted by a 4-parametric logistic model using the Marquardt-
Levenberg algorithm (Sigmaplot 4.0, SPSS, Chicago, Illinois, USA) (De Boever et al., 2001). 
 
Conversion of isoxanthohumol into 8-prenylnaringenin 
 58 
RESULTS 
Biotransformation of hop prenylflavonoids 
Incubation of X, IX and 8-PN with human fecal samples 
The capacity of the cultures obtained from fecal samples A, B, C and D (further referred 
to as cultures A-D) to degrade or transform the hop prenylflavonoids X, IX and 8-PN was 
tested by incubating the cultures with 25 mg/L of each individual compound for a period of 8 
days. Results are presented as molar % recovery of X, IX or 8-PN, relative to the dosed 
amount (Table 2.1). X proved to be relatively stable with a recovery of above 65 %. In all 
cultures incubated with X, IX was detected (few %). However, as this was also observed 
after incubation of autoclaved fecal material with X (data not shown), no bacterial 
mechanisms are involved in the isomerization of X into IX. In culture C, also 5 % of 8-PN was 
recovered. In cultures A, B and D, IX was very resistant to transformation as more than 80 % 
was recovered. In culture C however, the bacterial community was able to transform IX into 
8-PN, as IX strongly disappeared and about 35 % of 8-PN was recovered. This 
transformation did not occur when testing autoclaved fecal material. Remarkably, 90 % of the 
initial amount of 8-PN was degraded in cultures A and D, while more than 50 % of 8-PN was 
still recovered in cultures B and C. These results indicate that different fecal cultures are 
characterized by varying capacities to transform the hop prenylflavonoids. 
 
Table 2.1. Microbial transformation of xanthohumol (X), isoxanthohumol (IX) and 8-prenylnaringenin 
(8-PN) after incubation with fecal samples A-D a. 
Start X IX 8-PN 
 % Recovery % Recovery % Recovery 
 X IX 8-PN X IX 8-PN X IX 8-PN 
A 74.9(10.7) 5.9(0.8) n.d. b n.d. 90.1(6.3) n.d. n.d. n.d. 11.2(0.5) 
B 80.5(2.5) 9.1(2.4) n.d. n.d. 83.0(5.1) n.d. n.d. n.d. 67.2(13.1)
C 73.6(3.1) 2.2(0.1) 5.3(0.2) n.d. 19.0(2.9) 36.4(7.4) n.d. n.d. 54.6(2.7) 
D 65.4(4.2) 11.7(1.6) n.d. n.d. 86.0(4.5) n.d. n.d. n.d. 7.6(1.3) 
a The compounds were incubated for 8 days at a concentration of 25 mg/L and results are presented as average 
(SD) molar percentage recovery of X, IX or 8-PN relative to the dosed amount of flavonoid. b N.d.: Not detected. 
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Microbial conversion of IX into 8-PN by fecal cultures 
The most interesting data obtained from Table 2.1 are the results from culture C. A 
considerable amount of IX was transformed into 8-PN, showing the role of IX as a 
proestrogen which can be activated by the intestinal microbial community. To further 
investigate these transformations, cultures E to L were incubated with 25 mg/L IX and 
samples were taken after 72 h (Figure 2.22.2). In cultures E, J and K varying amounts of 8-
PN (grey bars) were recovered and, especially in cultures J and K, a lower recovery of IX 
(black bars) was found in comparison to the non 8-PN-producing cultures. These results 
stress the significance of the difference in microbial community composition and activity, 
since conversion of IX into 8-PN was evident in only 4 of 12 cultures. 
 
 
Figure 2.2. Transformation of isoxanthohumol (IX) by human fecal cultures. Samples E-L were 
incubated with 25 mg/L IX for 3 days. Results are presented as average (+ SD) concentration of IX 
and 8-prenylnaringenin (8-PN) recovered (n=3). When no bars are displayed, no 8-PN was detected. 
 
In vitro estrogenic response of the incubations 
As 8-PN is known to have strong estrogenic activity, the conversion of IX into 8-PN and 
the degradation of 8-PN were monitored by measuring the estrogenic response of the 
incubations of cultures A-D with IX and 8-PN at time zero and after 8 days (Figure 2.3). As 
no increase of the estrogenic response was detected for the cultures A, B and D upon 
incubation with IX, data are not shown. In contrast, high estrogenic activity was determined in 
culture C, strongly indicating transformation of IX into an estrogen-active reaction product.  
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Figure 2.3. Average (+ SD) estrogen response of 8-prenylnaringenin (8-PN) incubated fecal samples 
A, B, C, D and of isoxanthohumol (IX) incubated fecal sample C, as measured at day 0 and after 8 
days of incubation. Estrogen response of 8-PN and 17β-estradiol (E2) are also shown (n=3). 
 
The estrogenic response of all cultures incubated with 8-PN decreased after the 
incubation because the dose-response curve shifted to higher concentrations. This suggests 
the degradation of 8-PN into non-estrogenic derivatives. The strongest decrease was seen in 
culture A as the EC50-value rose from 120 to 800 nmol/L. Lowest decrease was seen for 
culture B, while for cultures C and D a shift of 0.5 log-units of the EC50-values was detected. 
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As HPLC analysis showed that more than 90 % of the initially dosed 8-PN disappeared in 
culture D, a more pronounced shift in estrogenic activity was expected for this sample. 
Therefore, the higher remaining activity could be due to other degradation products with 
estrogenic activity. In this experiment, 8-PN was 25-fold less active than E2 based on their 
EC50-values. 
 
Incubation of X, IX and 8-PN with Eubacterium limosum 
As E. limosum is an intestinal bacterium capable of O-demethylation and degradation of 
flavonoids, this species was tested for its capacity to transform or degrade X, IX or 8-PN. To 
investigate long-term stability, the bacterium was incubated with 25 mg/L of each compound 
for a period of 13 days. Results are presented as molar % recovery of X, IX or 8-PN, 
relatively to the dosed amount of individual compound (Table 2.2). Again, conversion of X 
into IX was a spontaneous process, as similar results were obtained with autoclaved 
bacterial cultures. E. limosum was able to transform IX into 8-PN, but, since incubated 8-PN 
could almost fully be recovered after 13 days, further degradation did not occur. The small 
proportion of 6-PN recovered, is probably due to isomerization of 8-PN via DMX as 
intermediate. 
 
Table 2.2. Transformation of xanthohumol (X), isoxanthohumol (IX) and 8-prenylnaringenin (8-PN) by 
Eubacterium limosum a.  
Start % Recovery 
 X IX 8-PN 6-PN 
X 85.0(2.6) 16.9(3.5) n.d. b n.d. 
IX n.d. 51.4(4.6) 36.4(11.6) n.d. 
8-PN n.d. n.d. 98.3(1.0) 0.4(0.1) 
a The compounds were incubated for 13 days at a concentration of 25 mg/L and results are presented as average 
(SD) molar percentage recovery of X, IX, 8-PN or 6-prenylnaringenin (6-PN). b N.d.: Not detected. 
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Production of 8-PN by Eubacterium limosum 
Transformation kinetics 
To investigate the transformation kinetics of the conversion of IX into 8-PN, the same E. 
limosum was incubated with IX in 3 parallel experiments and the concentrations of IX (black 
symbols) and 8-PN (white symbols) were monitored for a period of 13 days (Figure 2.4). 
Although incubation conditions were nearly identical, the 8-PN production already started 
after 3 days in incubation 3, while a very long lag phase (10 days) was noted in incubations 1 
and 2. Moreover, the transformation rate was higher in incubation 1 than in incubation 2. This 
shows that transformation kinetics differed depending on the grown E. limosum culture. 
 
 
Figure 2.4. Three parallel incubations of Eubacterium limosum with 25 mg/L isoxanthohumol (IX). 
Disappearance of IX (black symbols) and production of 8-prenylnaringenin (8-PN) (white symbols) 
were monitored over a period of 13 days. 
 
Strain selection 
Because of the differences in transformation rate, it was attempted to select the most 
efficient IX-converting strain performing 3 successive selection rounds. This consisted of 6 
parallel incubations of E. limosum with 25 mg/L IX and incubation for 8 days. Next, the 
culture which produced the highest amount of 8-PN was selected and used as inoculum for 
the next round of 6 parallel incubations (Table 2.3). While in the first selection round the 
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lowest production was only 2 %, an increase of up to 82 % was apparent after 3 selection 
steps and the most efficient culture transformed all the dosed IX into 8-PN. The mean 
production of all 6 incubations in each round increased from 22.5 % up to 90.5 % and the 
standard deviation decreased from 20 % to 7 % after the selection procedure. This means 
that, after only 3 rounds, a strain was selected, which converted almost all IX (high mean) 
and was also stable (low standard deviation). 
 
Table 2.3. Selection of 8-prenylnaringenin (8-PN) producing Eubacterium limosum by three repeated 
incubations a. 
 Molar % IX ⇒ 8-PN conversion 
 I II III 
Lowest 2.1 24.3 82.1 
Highest 46.5 79.4 102.5 
Mean 22.5 57.9 90.5 
SD 19.3 19.6 6.9 
a Six strains were incubated for 8 days with 25 mg/L isoxanthohumol (IX) and the best IX converting strain was 
used for the next selection round. Lowest and highest 8-PN production as well as mean (+ SD) for each selection 
round are listed. 
 
Eubacterium limosum supplementation to fecal cultures 
From Table 2.1 and Figure 2.2, it was concluded that interindividual differences 
ultimately determined the capacity to transform IX into 8-PN. Therefore, we supplemented 
the most efficient E. limosum strain from the selection experiments to the non-producing 
culture B to examine the capacity of this strain to start up production of 8-PN in the complex 
environment of an intestinal suspension. The strain was added to the culture in proportions 
ranging from 0 % up to 100 %. The mixture was incubated with IX for a period of 7 days 
(Table 2.4) and the concentration of 8-PN was monitored every other day. The results show 
that, with increasing supplementation of E. limosum, the production of 8-PN increased. The 
pure E. limosum culture gave a 100 % conversion of IX into 8-PN but, even at 1 % 
supplementation, half of the dosed IX was already transformed into 8-PN after only 1 day. 
Remarkably, a maximum concentration of 8-PN was reached for all incubations on the first 
day, which indicates that all the available IX was immediately converted. No further 
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transformation of 8-PN was detected as the concentration of 8-PN at days 1 and 7 were not 
significantly different (Student T-test, P>0.05).  
 
Table 2.4. Supplementation of Eubacterium limosum to culture B in proportions ranging from 0 % 
(only fecal sample) up to 100 % (only E. limosum culture) and incubation with 90 µmol/L 
isoxanthohumol (IX) (n=3) a. 
 Time (days) 
 0 1 3 5 7 
% suppl. 8-PN production (µmol/L) 
0 0.0(0.0) 0.0(0.0) 0.0(0.0) 0.0(0.0) 0.0(0.0) 
1 0.0(0.0) 49.0(3.1) 36.8(8.3) 48.1(14.0) 46.4(8.9) 
5 0.0(0.0) 41.1(12.6) 38.9(14.7) 40.1(10.2) 37.3(10.6) 
25 0.0(0.0) 38.7(7.4) 36.8(4.3) 38.5(20.6) 31.6(10.7) 
50 0.0(0.0) 76.2(20.2) 61.2(9.5) 59.2(21.6) 50.1(16.9) 
75 0.0(0.0) 74.0(18.6) 63.2(15.5) 60.4(14.1) 60.4(13.8) 
100 0.0(0.0) 88.5(3.8) 74.7(6.8) 83.7(18.4) 75.7(2.7) 
a Results are presented as average (SD) 8-prenylnaringenin (8-PN) production. As culture B did not convert IX 
into 8-PN, the 8-PN production was linked to the supplemented strain. The non-converted IX remained present as 
unchanged component throughout the incubation period. 
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DISCUSSION 
In this study, the conversion of hop prenylflavonoids by human intestinal microbiota was 
investigated. These plant derived compounds, are considered as one of the four principal 
groups of phytoestrogens in food and are mainly ingested through beer consumption. 
Because 8-PN concentrations in beer are generally very low, possible health effects due to 
exposure to these substances are usually considered negligible. However, this view could 
change when considering that IX, which is quantitatively the most important prenylflavonoid 
in beer may act as a proestrogen in food due to microbial O-demethylation. This could lead 
to enhanced concentrations of 8-PN and to a possibly important exposure after beer 
consumption. However, there seem to be important interindividual differences, as only 1/3 of 
the tested human fecal samples showed IX activation. The intestinal bacterium Eubacterium 
limosum was able to perform this conversion and after strain selection the bacterium rapidly 
converted all IX into 8-PN. Strain supplementation to non-converting fecal samples led to 
rapid and efficient 8-PN production, even at low ratios.  
The possibility that IX would act as a proestrogen was recently detected in vivo by 
Schaefer et al. (2005). After dosing 10 mg IX to two men, increased 8-PN concentrations, 
corresponding to up to 5 % conversion, were detected in urinary samples. According to the 
authors, this in vivo activation would be an oxidative demethylation process in the liver, 
based on the findings of Nikolic et al. (2005). Although the prenyl chain of IX was the primary 
target of liver modifications, the latter researchers also recovered small amounts of 8-PN 
after the incubation of IX with liver microsomes. This contradicts with the findings of Coldham 
et al. (2002) who could not find IX activation by the liver. But the liver is not the only 
transformation site inside the human body. The human colon contains ~1012 
microorganisms/cm³, with an enormous metabolic potential. Bacterial enzymes may catalyze 
many reactions including hydrolysis, dehydroxylation, demethylation, ring cleavage and 
decarboxylation. The importance of this microbial community in the metabolism of 
phytoestrogens has been clearly established. Decroos et al. (2005) recently isolated a 
microbial consortium capable of transforming the soy phytoestrogen daidzein into equol and 
Wang et al. (2000) found two bacteria responsible for the conversion of lignans. Moreover, 
several intestinal bacteria possess ß-glucosidases, which are necessary for the hydrolysis of 
phytoestrogen glucosides (Rowland et al., 2003). Therefore, the gut microbiota are now 
considered as an important factor influencing phytoestrogen bioavailability (Turner et al., 
2003).  
Our results confirm a similar activity related to the group of prenylflavonoids, since IX can 
be converted into the potent phytoestrogen 8-PN. These transformation products can 
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subsequently be absorbed from the colon, as it is established for soy isoflavones (Wiseman, 
1999), to exert biological activity inside the body. While 8-PN was only one out of a large 
number of liver transformation products of IX (Nikolic et al., 2005), the human intestinal 
microbiota selectively converted IX into 8-PN with high conversion efficiencies (>35 %). 
These results show that the impact of microbial activities on in vivo conversion of IX will most 
likely be more pronounced than possible liver transformations. However, as only 1/3 of the 
samples converted IX, interindividual variability in microbial community activity could strongly 
influence this in vivo conversion. Finally, Schaefer et al. (2005) noted that urinary 8-PN 
excretion after beer consumption was slower than expected (up to several days), which could 
very well be due to delayed conversion of IX into 8-PN in the intestine, followed by 
absorption and renal excretion. Enterohepatic circulation is another important factor 
determining the retention of IX and 8-PN. 
Up to now little is known about intestinal transformations of prenylflavonoids. Nookandeh 
et al. (2004) dosed 1000 mg X/kg body weight to rats and isolated 22 metabolites from the 
feces. The majority (89 %) of the recovered flavonoids was unchanged X, which is in 
agreement with our data, as we detected only very minor degradation of X. The rest was 
composed of small amounts of different metabolites including some IX. Avula et al. (2004) 
performed a similar experiment with rats and detected mainly unchanged X next to a number 
of unidentified metabolites. However, no published data were available with regard to the 
availability of IX and 8-PN to gut microbiota. In our experiments with fecal samples, IX was 
either partially transformed into 8-PN or remained very stable during the incubations. 8-PN 
on the other hand, was more sensitive to degradation as, in some experiments, 90 % of the 
dosed amount disappeared. One possible explanation for this difference in stability between 
IX and 8-PN is the protective effect of the methoxy group on the A ring of IX, as this is the 
only structural difference with 8-PN. In general, the first step in the degradation of flavonoids 
is the opening and scission of the heterocyclic ring (Manach et al., 2004) and the absence of 
a free hydroxyl in positions 5, 7 or 4’ would protect the compound from this cleavage 
(Griffiths and Smith, 1972; Lin et al., 2003). An important consequence regarding optimum 
bioavailability could be a slow release of 8-PN from IX in the colon and absorption through 
the gut epithelium, taking into account that 8-PN is prone to undergo decomposition.  
To identify possible microbial degradation pathways of prenylflavonoids, a comparison 
can be made with naringenin, lacking the prenyl side chain. This flavanone has been 
extensively studied and is mainly present in citrus fruits in a glycosidic form (Erlund et al., 
2001) and in tomatoes as aglycone (Bugianesi et al., 2002). Degradation of naringenin by 
intestinal bacteria starts with heterocyclic ring cleavage, followed by dehydroxylation yielding 
phloroglucinol and 3-phenylpropionic acid (Rechner et al., 2004). The extent of this 
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degradation strongly depended on the nature of the fecal sample, which resembles the 
results obtained after the incubation of the fecal samples with 8-PN. This again shows that 
interindividual differences in the microbial community of the intestine are decisive on the fate 
of 8-PN and related flavonoids in the human body.  
Microbial O-demethylation (8-PN from IX) is known for a number of anaerobic bacteria 
that can even use methyl ethers for respiratory growth. These bacteria either use fumarate 
(Desulfitobacterium) as electron acceptor (Neumann et al., 2004) or are so-called 
homoacetogens converting CO2 into acetate (Diekert and Wohlfarth, 1994). Eubacterium 
limosum is a homoacetogenic bacterium, which is frequently isolated from human feces 
(Eggerth, 1935). It is known to be involved in the biotransformation of specific isoflavonoids 
(Hur et al., 2002) and a related Eubacterium strain was identified as a producer of the lignan 
enterodiol (Wang et al., 2000). Instead of trying to isolate a bacterium with the ability to 
demethylate IX into 8-PN, we investigated the activity of this E. limosum. The strain proved to 
be able to produce 8-PN and did not further degrade it, as this compound could be 
completely recovered following the incubation of E. limosum with 8-PN. After strain selection, 
the bacterium even quantitatively converted IX into 8-PN after only 1 day of incubation. 
Because IX can easily be produced from X, a microbial fermentation process of IX could 
facilitate efficient large scale production of 8-PN. On the other hand, strain supplementation 
to a non-converting fecal sample led to rapid and high IX conversion. This could imply that 
co-supplementation of IX and a transforming bacterium leads to a ‘slow release’ 8-PN 
production in situ in the intestine, after which the produced 8-PN can be absorbed and 
transported to its targets. 
Several reports now correlate possible health benefits with intentional phytoestrogen 
uptake (Magee and Rowland, 2004). Yet, at the same time questions rise whether 
environmental exposure to phytoestrogens could impose health risks such as endocrine 
disruption. Moreover, overall health effects may result from a combination of phytochemicals 
with multiple and perhaps additive or interfering activities. Up to now, only isoflavones and 
lignans are considered relevant phytoestrogens in the human diet (Magee and Rowland, 
2004), especially because 8-PN concentrations in beer are considered to be too low for 
positive or negative health effects (Milligan et al., 2002; Stevens and Page, 2004). However, 
the intestinal microbial community may have a crucial role in the in vivo conversion of IX into 
8-PN. Ultralow-dose estrogen therapy at a dose of only 0.25 mg 17β-estradiol (E2) per day 
over a period of 3 years significantly improved bone density compared with placebo without 
significant effects on endometrial thickness (Prestwood et al., 2003). According to our 
results, in some humans at least 35 % of the ingested IX may be converted into 8-PN. Taking 
into account an accumulation factor of 2 based on slow elimination of 8-PN (Schaefer et al., 
Conversion of isoxanthohumol into 8-prenylnaringenin 
 68 
2005), a daily consumption of 1 L of beer containing 2 mg IX/L, would lead to a daily 8-PN 
burden of 1.4 mg. As 8-PN is only about 10 times less active compared to E2, the daily 
exposure of about 0.14 mg E2 equivalents is in well within the range of positive biological 
activity (e.g. protective effect on bone metabolism) without negative side effects (e.g. 
proliferation of the endometrium). Although this example is very simplified and does not 
account for differences in bioavailability, it clearly indicates the intriguing role of the gut 
microbial community in the exposure to biologically active compounds. As microbial O-
demethylation of IX could readily lead to a tenfold increase of the ingested 8-PN, supposing 
an IX vs. 8-PN ratio in beer of 30 (Stevens et al., 1999), large population studies are 
warranted in order to acquire insight into the in vivo bioavailability of hop prenylflavonoids 
throughout the intestine and the extent of microbial transformations in the colon. Such 
studies are essential to validate our findings on the capacity of individuals to produce 8-PN 
from IX, giving rise to possible health effects of IX consumption.  
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CHAPTER 3 
Activation of isoxanthohumol into 8-prenylnaringenin in vitro and in 
the human intestine 
ABSTRACT 
Hops, an essential beer ingredient, are a source of prenylflavonoids, including 8-
prenylnaringenin (8-PN), one of the most potent phytoestrogens. As 8-PN concentrations in 
beers are generally low, its health effects after moderate beer consumption were considered 
negligible. However, human intestinal microbiota may activate isoxanthohumol (IX), present 
up to 4 mg/L in beers, into 8-PN. Depending on interindividual differences in the intestinal 
transformation potential, this conversion could easily increase the 8-PN exposure tenfold 
upon beer consumption. Here, we present a further investigation of the process both in vitro 
and in vivo. In vitro experiments with the dynamic SHIME model showed that hop 
prenylflavonoids pass the stomach and small intestine unaltered and that activation of IX into 
8-PN only occurs in the distal colon, with up to 80 % conversion. In vitro incubations of 51 
fecal samples from female volunteers with IX enabled us to separate the fecal microbiota into 
high (8 out of 51), moderate (11 out of 51) and slow (32 out of 51) 8-PN producers, clearly 
illustrating an interindividual variability. Three women were selected from the respective 
groups and they received a daily dose of 5.59 mg IX for a period of 4 days. A significant 
correlation (P<0.01) between intestinal IX activation and urinary 8-PN excretion was 
observed. These data show that intestinal conversion of IX upon moderate beer consumption 
can lead to 8-PN exposure values which might fall within the range of human biological 
activity. 
 
Keywords: phytoestrogens, hops, 8-prenylnaringenin, intestinal bacteria, SHIME 
 
Redrafted after: Possemiers, S., S. Bolca, C. Grootaert, A. Heyerick, K. Decroos, W. Dhooge, D. De 
Keukeleire, S. Rabot, W. Verstraete and T. Van de Wiele (2006). The prenylflavonoid isoxanthohumol 
from hops (Humulus lupulus L.) is activated into the potent phytoestrogen 8-prenylnaringenin in vitro 
and in the human intestine. Journal of Nutrition, 136: 1862-1867. 
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INTRODUCTION 
Phytoestrogens are plant constituents which structurally or functionally mimic female 
estrogens. Some display selective estrogen receptor modulating (SERM) activity and could 
therefore play a beneficial role in the prevention of osteoporosis, menopausal complaints or 
cancers (Ososki and Kennelly, 2003). Multiple studies now indicate negative side effects of 
Hormone Replacement Therapy (HRT) (Rossouw et al., 2002; Million Women Study 
Collaborators, 2003), an effective method for treating various menopausal symptoms 
(Brzezinski and Debi, 1999; Wagner et al., 2001). As there is a rapidly growing body of 
literature on the health beneficial role of phytoestrogens, many women now turn to 
phytoestrogens as a more natural or ‘herbal’ alternative for HRT (Gainford et al., 2005; 
MacGregor et al., 2005). 
For centuries, hops (Humulus lupulus L.) have primarily been used as essential 
ingredient in the beer brewing process. Yet, hops have been studied since 1953 as a 
possible source of estrogenically active compounds (Koch and Heim, 1953) and 8-
prenylnaringenin (8-PN) was identified as a very potent phytoestrogen (Milligan et al., 1999). 
Nowadays, in vitro and animal data suggest that 8-PN might exhibit several biological 
activities (Zierau et al., 2003; Diel et al., 2004; Pepper et al., 2004; Effenberger et al., 2005; 
Hümpel et al., 2005), and hop-containing dietary supplements are marketed to reduce 
menopausal complaints and used for breast enhancement (Coldham and Sauer, 2001).  
An important factor influencing the bioavailability and activity of phytoestrogens is their 
metabolic fate upon ingestion. In general, after reaching the colon, flavonoids are partially 
degraded depending on their structure, thereby leading to lower bioavailability (Simons et al., 
2005). However, microbial transformation in the colon may also increase the biological 
activity of the ingested compounds, a process which has been described for different 
phytoestrogens (Rowland et al., 1999). For hop prenylflavonoids, a similar phenomenon was 
recently observed. Isoxanthohumol (IX) is the prevailing prenylflavonoid in beers, being 10 to 
30 times more abundant as 8-PN (Stevens et al., 1999). Recently, Schaefer et al. (Schaefer 
et al., 2005) noted the activation of IX into the phytoestrogen 8-PN inside the human body, 
which they associated with liver metabolism. Our previous research indicated that the 
intestinal microbial community might be responsible for this production of 8-PN upon IX 
consumption (Possemiers et al., 2005).  
Up to now, hop prenylflavonoids were not considered as relevant phytoestrogens in the 
human diet, as 8-PN concentrations in beer were considered too low to affect human health. 
However, microbial O-demethylation of IX in the human intestine could readily 10-fold 
increase intestinal 8-PN concentrations (Possemiers et al., 2005), leading to the uptake of 
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active estrogen doses after moderate beer consumption which might fall within the range of 
biological activities (Prestwood et al., 2003). Therefore, the importance of this microbial 
process was further investigated in vitro in the Simulator of the Human Intestinal Microbial 
Ecosystem (SHIME) (Figure 3.1), in which the transformation of IX into 8-PN was studied in 
the different parts of the human gut. Based on 51 fecal samples, interindividual differences 
were assessed and a small in vivo trial was set up to relate the in vitro activation data with 
the excretion of 8-PN upon IX consumption. 
 
 
 
Figure 3.1. Schematic representation of the Simulator of the Human Intestinal Microbial Ecosystem 
(SHIME) and its corresponding laboratory setup. 
Production of 8-prenylnaringenin in vitro and in vivo 
 74 
MATERIALS AND METHODS 
Chemicals 
The isolation of xanthohumol (X) from spent hops, isomerization of X into IX and 
chemical synthesis of 8-PN were performed as described earlier by Possemiers et al. (2005). 
Stock solutions of the different prenylflavonoids (X, IX, 8-PN) were prepared in 
dimethylsulfoxide (DMSO) in a concentration of 5 g/L.  
 
Simulator of the Human Intestinal Microbial Ecosystem (SHIME) 
Experimental design 
The reactor setup was adapted from the SHIME, representing the gastrointestinal tract of 
the adult human, as described by Molly et al. (1993). The SHIME consists of a succession of 
five reactors simulating the different parts of the human gastrointestinal tract (Figure 3.1). 
The first two reactors were of the fill-and-draw principle to simulate different steps in food 
uptake and digestion, with peristaltic pumps adding a defined amount of SHIME feed (140 
mL 3x/day) and pancreatic and bile liquid (60 mL 3x/day), respectively to the stomach (V1) 
and duodenum (V2) compartment and emptying the respective reactors after specified 
intervals. The last three compartments were continuously stirred reactors with constant 
volume and pH control. Retention time and pH of the different vessels were chosen in order 
to resemble in vivo conditions in the different parts of the gastrointestinal tract. The overall 
residence time of the last three vessels, simulating the large intestine, was 76 h. Upon 
inoculation with fecal microbiota, these reactors simulate the ascending (V3), transverse (V4) 
and descending (V5) colon. Inoculum preparation, retention time, pH, temperature settings 
and reactor feed composition were previously described by Possemiers et al. (2004). The 
fecal sample to start this SHIME run was derived from an individual which was known to 
have an IX-converting intestinal community. After reactor start up, the system was allowed to 
stabilize for three weeks with standard SHIME feed before the start of the experiment 
(Possemiers et al., 2004). 
Stability in the upper intestine 
In order to test the stability of IX, X and 8-PN in the upper intestine, the compounds were 
added to the SHIME feed (in 3 separate experiments) and transferred through the system 
towards the first colon compartment as described previously (Possemiers et al., 2004). 
Samples were taken before and after each incubation step. The specific cyclization of X to 
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form IX was also monitored in water containing 0.05 % HCl (pH 2) and incubation at 37 °C 
for 1 h. 
Batch experiments 
All fermentation experiments were performed in Brain Heart Infusion (BHI) broth (37 g/L, 
Oxoid, Hampshire, USA) with 0.5 g/L L-cystein HCl under anaerobic conditions, according to 
Possemiers et al. (2005). Three weeks after the inoculation of the SHIME system, a 5 mL 
sample was withdrawn from the SHIME reactors 3, 4 and 5 and transferred to penicillin flasks 
containing 45 mL BHI. At the start of the incubation, about 70 µmol/L of X, IX or 8-PN (5 µL 
stock solution/mL batch culture) was added to each flask. Cultures were incubated at 37 °C 
for 6 d. At the start and after 1, 2, 3 and 6 d samples were taken using syringes. All 
experiments were performed in triplicate. 
SHIME run 
The SHIME experiment consisted of three phases: a 2 wk control period in which 
standard feed was dosed to the SHIME, a treatment period (d15 until 29) in which 70 µmol/L 
IX was supplemented to the SHIME feed and finally a 1wk wash-out period in which the 
SHIME was fed again with standard SHIME feed. During these phases, samples from the 
different colon reactors were taken at different time intervals and analyzed for 
prenylflavonoids, short chain fatty acids and microbial community composition. 
HPLC analysis 
The prenylflavonoids were extracted by liquid/liquid extraction using ethyl acetate 
(Possemiers et al., 2005).  
Quantitative analyses were effected by HPLC using a Waters 2695 Alliance Separations 
Module (Waters, Milford, USA) equipped with a Waters 996 Photodiode Array Detector and 
Waters Millenium Software v3.20 (Possemiers et al., 2005). An extra confirmation of the 
identity of the compounds in the samples was achieved based on the typical fragmentation 
patterns in LC-MS/MS analysis using a Waters Quattro micro with electrospray ionization 
(Stevens et al., 1997). 
In vitro estrogenicity testing 
The estrogenic properties of the prenylflavonoids was assessed using a receptor 
bioassay based on a genetically modified Saccharomyces cerevisiae, according to the 
protocol developed by Routledge and Sumpter (1996). In brief, Saccharomyces cerevisiae, 
transformed with the human estrogen receptor (ERα) gene, together with expression 
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plasmids containing estrogen receptor responsive elements and the lacZ reporter gene 
(encoding the enzyme β-galactosidase), were incubated in medium containing test 
compounds or samples and the chromogenic β-galactosidase substrate chlorophenol red β-
D-galactopyranoside (CPRG). β-Galactosidase expression is quantified through the 
conversion of CPRG into chlorophenol red, measured at 540 nm. Dose response curves for 
β-galactosidase activity were obtained using corrected absorbance units (CAU): CAU = 
(Abs540)compound –[(Abs620) compound –(Abs620)blank]. The best fitting curve was calculated using 
SigmaPlot for Windows, version 4 (SPSS, Heverlee, Belgium) by a four parameter logistic 
regression using the Marquardt-Levenberg algorithm (De Boever et al., 2001). 
Evaluation of microbial activity and structure 
Liquid samples (10 mL) from each colon reactor were collected and frozen at -20 °C for 
subsequent analysis. Microbial activity was monitored by its short chain fatty acid (SCFA) 
production. The SCFA were extracted from the samples with diethyl ether and determined 
with a Di200 gas chromatograph (GC; Shimadzu, ’s-Hertogenbosch, The Netherlands) 
(Nollet et al., 1997). 
Microbial structure of the SHIME community was determined by Real Time PCR. Total 
DNA extractions of 1 mL liquid SHIME sample were performed using the method described 
by Boon et al. (2003). Using an ABI Prism SDS 7000 instrument (Applied Biosystems, Foster 
City, USA) and the qPCRTM core kit for SybrTM Green I (Eurogentec, Liege, Belgium), 10 
times diluted general bacterial DNA as well as specific DNA from Lactobacillus spp., 
Bifidobacterium spp., Atopobium spp. and the Clostridium coccoides - Eubacterium rectale 
group, were quantified by Real Time PCR. The 16S rRNA genes for all members of the 
bacteria were amplified by PCR using primer PRBA338f and P518r (Boon et al., 2003). 
Primer sets, annealing temperature and Mg concentration used to quantify DNA of specific 
groups were described by Rinttilä et al. (2004). Their PCR protocol was adapted to: 2 min at 
50 °C; 5 min at 95 °C and 40 cycles of 20 s denaturation at 94 °C, 30 s primer annealing at 
the specific temperature and 1 min primer extension at 60 °C. Standard curves were 
constructed with DNA from representative species of the different groups in a concentration 
range from 1010 to 102 DNA copies/µL and DNA from at least 10 non-target species was 
used as negative control to test amplification specificity. All reactions were specific for target 
species.  
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Interindividual differences in the conversion of isoxanthohumol 
Study design 
Fifty-one healthy women (aged from 24 up to 55 years old) voluntarily participated in this 
study. None of them had a history of gastrointestinal disease and had not taken antibiotics 
during 3 months prior to the study. All participants delivered a fecal sample for incubation 
purposes. Samples were homogenized in phosphate buffer (20 % w/v) and incubated in 
triplicate in BHI broth (10 % v/v) with 70 µmol/L IX for 72 h according to Possemiers et al. 
(2005) and the conversion of IX into 8-PN was assessed.  
Based on the results of this in vitro study, 3 participants were selected (aged 24, 25 and 
26 years) and designated A, B and C. As indications exist of a possible link between obesity 
and intestinal microbial composition (Bäckhed et al., 2004), possibly affecting processes 
such as 8-PN production, BMIs of the subjects (21, 18 and 21) are indicated to show that the 
individuals were chosen from a representative population. Before the study, the participants 
delivered a fresh fecal sample, which was incubated for 13 d, with samples being taken at 
the start and after 3, 8 and 13 d. Then, for 4 consecutive days these participants ingested 
each morning a capsule containing 5.59 ± 0.97 mg IX and cellulose. Subjects consumed 
their habitual diets but were asked not to drink beer at least 5 d before and during the study. 
The study was given approval by the Ethics Committee of the Ghent University Hospital (EC 
UZG 2005/022) and a written informed consent was obtained from each participant. 
Sample collection and preparation  
Blank urine samples were collected prior to the study and participants made four 24-hour 
urine collections during the study. The urine volumes were quantified and aliquots were 
stored at –20 °C. To a 15 mL sample, 15 mL sodium acetate buffer (0.1 mol/L, pH 5.0) and 
300 µL β-glucuronidase/arylsulphatase (Sigma Aldrich, St. Louis, Missouri, USA) were 
added. The samples were vortex-mixed and incubated for 1 h at 37 °C, followed by solid-
phase extraction.  
The solid-phase extraction C18 silica columns (Bond Elut®, 500 mg, Varian, St.-Katelijne-
Waver, Belgium) were pre-conditioned with 5 mL methanol, 5 mL water, and 5 mL sodium 
acetate buffer, consecutively. After sample application, the cartridges were rinsed with 5 mL 
water and the flavonoids were eluted with 2 mL methanol on a VacMaster 20 sample 
processing unit (IST, Mid Glamorgan, UK). The solvent was evaporated under nitrogen gas 
and the residue was redisolved in 100 µL methanol, transferred into HPLC vials and stored at 
-20 °C prior to analysis. Recoveries of IX and 8-PN were 99.7 ± 7 % and 99.4 ± 6 % 
respectively. 
Production of 8-prenylnaringenin in vitro and in vivo 
 78 
Statistical analysis 
Normality of the data and equality of the variances were assessed using the Kolmogorov-
Smirnov test and the Hartley test, respectively. Comparison of means on non-normally 
distributed data was evaluated with the non-parametric Kruskal-Wallis test. Comparison of 
normally distributed data was performed with ANOVA; when ANOVA indicated significant 
differences, means were compared using the Student-Newman-Keuls multiple comparison 
test. Comparison of the SHIME IX concentrations with the theoretical mean IX concentration 
was performed with a One-sample Student’s T-test. The incubation data from the 51 fecal 
samples were separated into different groups of 8PN production levels using the Two Step 
Cluster analysis protocol. Statistical significance was set at P<0.01. Calculations were 
performed using the Statview® software (version 5.0, SAS Institute, Cary, NC, USA). 
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RESULTS 
Transformation of hop prenylflavonoids in the SHIME 
Stability in the upper intestinal tract 
None of the compounds was significantly (ANOVA, P>0.01) affected during the passage 
through the upper gut, indicating that, without taking absorption from the small intestine into 
account, IX, X and 8-PN reach the large bowel unaltered upon oral ingestion. 
Intestinal transformation of IX and 8-PN 
In a preliminary experiment to test the activation of IX and possible degradation of 8-PN in 
the different compartments of the intestinal tract, the SHIME was inoculated with a fecal 
sample in which the conversion of IX into 8-PN had already been established, and samples 
from the simulated ascending (V3), transverse (V4) and descending (V5) colon 
compartments were incubated in batch with IX or 8-PN. In the ascending colon compartment, 
no conversion occurred (Figure 3.2).  
 
 
Figure 3.2. Conversion of isoxanthohumol (IX) (grey symbols) into 8-prenylnaringenin (8-PN) (black 
symbols) in samples taken from the simulated ascending (V3), transverse (V4) and descending (V5) 
colon of the SHIME (batch experiment), presented as mean (+ SD) concentration (n=3). For each 
curve, data with different letters (a, b, c and d) are significantly different (P<0.01). 
 
In the distal colon parts (V4 and V5) however, a significant (P<0.001) transformation of IX 
was observed with a respective conversion of 20 ± 8 % and 46 ± 23 % of the incubated IX 
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into 8-PN after 6d. For this specific microbial community, almost no degradation of 8-PN 
occurred (Figure 3.3). Only in the transverse colon, a significant (P<0.01) degradation of 16 ± 
3 % of the originally incubated 8-PN was observed after long term incubation.  
 
 
Figure 3.3. Degradation of 8-PN in samples taken from the simulated ascending (V3), transverse (V4) 
and descending (V5) colon of the SHIME (batch experiment), presented as mean (+ SD) concentration 
(n=3). For each curve, data with different letters (a, b, c and d) are significantly different (P<0.01). 
 
Activation of IX into 8-PN in the SHIME 
During the treatment period, the IX concentration in the first colon vessel (circles) 
increased towards a steady-state concentration of about 45 µmol/L and no conversion of IX 
into 8-PN occurred in this part (Figure 3.4 A and B). Through the overflow connection 
between V3 and V4, the IX concentration in the simulated transverse colon (squares) also 
rapidly reached a steady state concentration of about 14 µmol/L. However, this concentration 
was much lower compared to V3 because IX was partially converted into 8-PN (± 29 µmol/L). 
Finally, in the simulated descending colon (triangles) very low IX (± 6 µmol/L) and high 8-PN 
concentrations were recovered (± 56 µmol/L). When IX supplementation was stopped, the 8-
PN concentration decreased at a slower rate than the IX concentration in both V4 and V5.  
To evaluate whether the increase in 8-PN conversion towards the distal end of the colon 
also led to a parallel increase of the estrogenic properties of the SHIME matrix, filter sterile 
SHIME supernatant was tested in the yeast estrogen screen (Figure C). A transient increase 
of the estrogenic properties of V4 and especially V5 was noted and after the wash-out 
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period, the estrogenic values were similar to the values at the start of the experiment. Due to 
the filter sterilization of the samples for the YES-test, a fraction of the 8-PN was lost, 
indicated by the smaller increase of the estrogenic response in V4, compared to the HPLC 
data. Being highly correlated with the HPLC data (R²=0.8156, P<0.001), these results show 
that at least a fraction of the produced 8-PN is available for biological activity. 
Taking into account the mass balance of incoming and outgoing IX concentrations, the 
theoretical IX concentrations in the respective colon compartments of the SHIME were 
calculated over the course of the IX supplementation and wash-out periods. Conversion of IX 
into 8-PN was not considered and the theoretical steady state IX concentration in each colon 
compartment was 45 µmol/L. The sum of the IX and 8-PN concentrations in the ascending 
and transverse colon compartments corresponded to the theoretical IX concentrations 
(Student’s t-test, P>0.01), indicating that IX was only converted to 8-PN and that the latter 
was not further degraded by the colon microbiota. In the descending colon however, the sum 
of the IX and 8-PN concentrations were higher than the theoretical IX concentration 
(Student’s t-test, P<0.01), indicating an accumulation in the latter colon compartment. These 
data showed that IX was microbially converted to 8-PN for 65 % in the transverse and for 85 
% in the descending colon compartment.  
Effect on microbial community activity and structure 
In V3, only acetic (25 mmol/L), butyric (2 mmol/L) and propionic acid (7 mmol/L) were 
produced. In V4 and V5, next to acetic (respectively 37 and 45 mmol/L), butyric (6 mmol/L) 
and propionic acid (14 mmol/L) also small amounts of isobutyric, isovaleric and valeric acid 
were recovered in the range of 2 mmol/L. However, all fatty acid concentrations remained 
constant throughout the experimental period (42 d), indicating no changes in the microbial 
activity due to the supplementation of IX (ANOVA for repeated measurements, P>0.01). 
Whereas the abundance of Lactobacillus spp. and Atopobium spp. remained constant in the 
range of 1 to 5 %, a significant increase (ANOVA for repeated measurements P<0.01) in the 
abundance of the C. coccoides - E. rectale group and Bifidobacterium spp. from 
approximately 5 % to 20 % was noted in the transverse and descending colon. 
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Figure 3.4. Conversion of isoxanthohumol into 8-prenylnaringenin in the ascending (V3), transverse 
(V4) and descending (V5) colon of the SHIME (continuous experiment) after feeding IX from d15 until 
d29. Data are presented as mean (+ SD) concentrations of IX and 8-PN and as equivalent 
concentrations of 17β-estradiol after quantification of the estrogenic properties of the SHIME 
supernatant (n=3).  
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Interindividual differences in the conversion of IX into 8-PN 
Incubation of fecal bacteria with IX 
The 51 fecal samples were incubated with IX immediately after defecation and 8-PN 
production was monitored after 72 h (Figure 3.5). Statistical analysis showed that 3 
significantly different (P<0.01) groups were formed, separating individuals in high (8/51), 
moderate (11/51) and slow (32/51) IX converters, with a mean 8-PN production of 
respectively 78. 8%, 48.5 % and 6.9 %. 
 
 
Figure 3.5. Conversion of isoxanthohumol (IX) into 8-prenylnaringenin (8-PN) by intestinal bacteria 
from 51 different human individuals. The individuals were arranged by increasing 8-PN production and 
results are presented as mean % (+ SD) IX conversion into 8-PN (n=3). Three groups (designated I, II 
and III) with significantly different means (P<0.01) were identified by Two Step Cluster Analysis. 
 
Based on these results, a high, moderate and slow IX-converting individual were selected 
(designated A, B and C) and new fecal samples were incubated (Table 3.1). This confirmed 
that individual A rapidly converted all incubated IX into 8-PN, whereas the microbial 
community from person B only partially activated IX and IX remained unaltered in incubation 
C throughout the entire incubation period.  
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Recovery of IX and 8-PN in urine 
Although only IX was consumed, high amounts of 8-PN (190 µg/d on d4) were detected 
in the urine of individual A (Table 3.1). Based on the quantification of IX in the urine, 8-PN 
constituted 13 ± 2 % of the total amount of urinary excreted prenylflavonoids on d1 up to 41 ± 
1% on d4. In contrast, much lower 8-PN ratios were recovered in the urine of women B (on 
d3 and 4) and C (only on d4). Clearly, in parallel with the in vitro incubations, interindividual 
differences determine the activation of IX, as quantified by the 8-PN excretion. Moreover, as 
the highest IX-converting fecal sample was derived from individual A with the highest urinary 
8-PN excretion, the in vitro and in vivo data were significantly correlated (R²=0.6417, 
P<0.01), indicating the importance of the microbial community in this process. 
 
Table 3.1. Relation between in vitro isoxanthohumol (IX) conversion in fecal samples and in vivo 
exposure to 8-prenylnaringenin (8-PN) after a 4d IX consumption (5.59 mg/d) by 3 individuals a. 
  Individual 
 Time (d) A B C 
3 100.0 (5.4) 7.8 (1.3)   n.d. b 
8 100.0 (0.9) 30.8 (1.7) n.d. 
Fecal  
data c 
13 100.0 (0.7) 39.7 (5.1) n.d. 
1 13.1 (2.5) n.d. n.d. 
2 23.1 (0.1) n.d. n.d. 
3 19.4 (0.2) 8.4 (0.4) n.d. 
Urinary 
excretion c 
4 40.6 (0.6) 13.9 (2.1) 4.5 (0.8) 
a Fecal data are presented as mean (SD) % conversion of IX into 8-PN (n=3) and in 24h-pooled urine samples, 
the ratio (± SD) of 8-PN relative to IX+8-PN was quantified (n=3). b N.d.: 8-PN not detected. c The urinary 
excretion of 8-PN was significantly correlated with the intestinal microbial activation potential of IX, as expressed 
by the % 8-PN production in the fecal samples on day 13 (R²=0.6417, P<0.01). 
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DISCUSSION 
Using the SHIME, it was shown that IX and other prenylflavonoids remain unaltered after 
passage through the stomach and small intestine. The microbial transformations in the colon 
were site-specific, as activation of IX into 8-PN only occurred in the distal parts with up to 80 
% conversion. Analysis of 51 fecal samples separated individuals in high, moderate and slow 
IX converters. As only 1/3 of the individuals were identified as moderate or high 8-PN 
producers and as a small in vivo trial indicated a clear relationship between the urinary 8-PN 
excretion and the intestinal microbial transformation potential of IX, interindividual differences 
in the microbial IX transformation potential may have a crucial impact on the 8-PN exposure 
after IX consumption.  
In general, monomeric flavonoids reach the small intestine unaltered (Spencer, 2003). 
Our results confirm these data, since IX, 8-PN and X were fully recovered after passage 
through the simulated stomach and small intestine. Nikolic et al. (2005) however, reported a 
cyclization of X into IX in 0.05 % HCl following a first order kinetic, indicating that X may also 
act as a proestrogen due to transformation into IX in the acid stomach. As X was neither 
transformed into IX in our simulated stomach nor in a repetition of the latter researcher’s 
experiment, X was further not considered in this research.  
The SHIME is an ideal model to study the activation of IX into 8-PN, allowing to study the 
microbial community and its activity into great detail in the different parts of the intestine, 
differing in community structure and activity (Molly et al., 1993; De Boever et al., 2000; 
Possemiers et al., 2004). The conversion of IX was limited to the simulated transverse and 
descending colon, leading to a strong increase in the estrogenic properties in this part. 
Schaefer et al. (2005) noted that urinary 8-PN excretion after beer consumption was slower 
than expected (up to several days). Our data indicate that this is probably due to delayed 
conversion of IX into 8-PN, as beer is an important source of IX and the ingested IX first has 
to reach the distal colon, possibly after absorption and enterohepatic recirculation, a transfer 
which can take up to 48 h (Cummings, 1997). Since comparison of the actual 8-PN 
concentrations with the theoretical IX concentration in the SHIME indicated a retention of 8-
PN in the colon, the exposure to 8-PN could further be prolonged. 
As the uptake of prenylflavonoids may also affect the intestinal microbiota itself, shifts in 
the community structure or activity during the SHIME experiments were investigated. No 
changes in SCFA profiles were noted, but a relative increase of the C. coccoides - E. rectale 
cluster and Bifidobacterium spp. was noted. Although further research is necessary, the 
mentioned cluster contains a number of homoacetogenic bacteria with enzyme systems for 
the demethylation of methoxylated phenols (Diekert and Wohlfarth, 1994). Furthermore, 8-
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PN exerted antibacterial activity in vitro (data not shown), indicating that differences in 
sensitivity to 8-PN could explain possible shifts in community structure. 
Simons et al. (2005) studied the degradation of different flavonoids by intestinal bacteria 
and separated the subjects into high, moderate and slow degraders. The statistical analysis 
of the 51 fecal samples indicates that this separation is also important with respect to the 
demethylation of IX. As only 1/3 of the subjects could produce moderate or high amounts of 
8-PN, an important part of the population would not benefit from this reaction. In parallel with 
the noted interindividual differences in the conversion of daidzein into equol (Rowland et al., 
1999), these results stress the importance of the gut microbial community towards the final 
biological activity of phytoestrogens, a factor which should not be neglected when 
determining the final active dose inside the body.      
Based on the in vitro data concerning interindividual variability, a preliminary in vivo trial 
was designed as proof of principle of the importance of the gut microbiota towards in vivo 
exposure to 8-PN. To one individual from the high, moderate and low IX-converting groups, 
IX was administered for 4 d and a fresh stool sample was obtained to confirm their intestinal 
transformation potential. The excretion of 8-PN was significantly correlated with the in vitro 
data from the fecal samples. From day one on, a large fraction of the prenylflavonoids 
excreted by subject A consisted of 8-PN, whereas 8-PN was only detected from days 3 and 4 
for B and C. Nevertheless the small size of this trial, the careful selection of the individuals 
based on the in vitro data encourages further research in this domain, as the importance of 
the microbial activation reaction was further confirmed.  
Until recently, possible health effects after moderate beer consumption related to 8-PN 
presence were considered negligible, as concentrations in beers are generally very low. 
Furthermore, for hop containing supplements only the 8-PN content is taken into account. 
This study shows that this approach may no longer be valid as IX can act as a proestrogen in 
beers and supplements. As woman A excreted up to 40 % 8-PN after IX consumption, even 
a 50 % loss in the feces could still lead to an 8-PN exposure in the range of 1 to 2 mg/d after 
daily moderate beer consumption which could fall within the range of biological activity. 
Further in vivo trials are being carried out to evaluate the possible health effects of moderate 
beer consumption or supplements.  
We conclude that human exposure to the biologically active 8-PN not only depends on 
the initial 8-PN concentrations in beers but rather on the combination of exposure to IX and 
the microbial bioactivation potential in the gut.  
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CHAPTER 4 
Metabolism of isoflavones, lignans and prenylflavonoids by 
intestinal bacteria: producer phenotyping and relation with 
intestinal community 
ABSTRACT 
Many studies have investigated the importance of the intestinal bacterial activation of 
individual phytoestrogens. However, human nutrition contains different phytoestrogens and 
the final exposure depends on the microbial potential to activate all different groups within 
each individual. In this work, interindividual variations in the bacterial activation of the 
different phytoestrogens were assessed. Incubation of feces from 100 individuals with 
SoyLife® EXTRA, LinumLife™ EXTRA and isoxanthohumol indicated that individuals can be 
separated into high, moderate and low O-desmethylangolensin (O-DMA), equol, enterodiol 
(END), enterolactone (ENL) or 8-prenylnaringenin producers respectively, but that the 
metabolism of isoflavones, lignans and prenylflavonoids follows separate, independent 
pathways. However, O-DMA and equol production correlated negatively, whereas a positive 
correlation was found between END and ENL production. In addition, END production 
correlated negatively with Clostridium coccoides – Eubacterium rectale counts. Furthermore, 
O-DMA production was correlated with the abundance of methanogens, whereas equol 
production correlated with sulfate reducing bacteria, indicating that the metabolic fate of 
daidzein may be related to intestinal H2 metabolism.  
 
Keywords: Isoflavones, lignans, prenylflavonoids, intestinal bacteria, gut, methanogens, 
sulfate reducing bacteria 
 
Redrafted after: Possemiers S., S. Bolca, E. Eeckhaut, H. Depypere and W. Verstraete (2007). 
Metabolism of isoflavones, lignans and prenylflavonoids by intestinal bacteria: producer phenotyping 
and relation with intestinal community. FEMS Microbiology Ecology, in press. 
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INTRODUCTION 
There is currently a considerable interest whether dietary consumption of phytoestrogens 
has any health benefits or risks (Cornwell et al., 2004; Magee and Rowland, 2004; Sirtori et 
al., 2005; Wathen, 2006). The presence of these hormone-like compounds in plants was first 
observed some 60 years ago, when fertility problems were observed in sheep that had been 
grazing pastures containing red clover, having high amounts of the isoflavones formononetin 
and biochanin A (Bennets et al., 1946; Rossiter and Beck, 1966). Later it became clear that 
molecules with estrogenic activity are present in a broad range of plants (Ososki and 
Kennelly, 2003; Zhang et al., 2005; Agradi et al., 2006). Yet, the principal phytoestrogens in 
human diet are restricted to a limited number of molecules.  
The isoflavones daidzein and genistein, present in human diet in various soy products, 
are by far the most studied phytoestrogens (Setchell et al., 2003; Turner et al., 2003; Chen 
and Rogan, 2004; MacGregor et al., 2005; Messina et al., 2006). Next to this, lignans are 
also considered ubiquitous in human diet (Raffaelli et al., 2002). Whereas the highest 
concentrations are found in flaxseed (Johnsson et al., 2000), the most important dietary 
sources are beverages (37 %), vegetables (24 %) nuts and seeds (14 %) bread (9 %) and 
fruits (7 %) (Adlercreutz and Mazur, 1997; Mazur et al., 2000). To date, secoisolariciresinol 
(SECO) and matairesinol (MAT) were often considered as the most relevant dietary lignans 
(Boker et al., 2002; Valsta et al., 2003). This was recently refuted by Milder et al. (2005), who 
showed that two other compounds, lariciresinol and pinoresinol, contribute to 75 % of the 
total lignan intake. Recently, a new group of phytoestrogens was added to this list. In 1999, 
Milligan et al. (1999) identified hop (Humulus lupulus L.) as a source of one of the most 
potent phytoestrogens, called 8-prenylnaringenin (8-PN). However, 8-PN concentrations in 
hops and end products, such as beer and dietary supplements, generally are low (Stevens et 
al., 1999; Coldham and Sauer, 2001).     
Interestingly, all these phytoestrogens have in common that their final biological activity 
depends on intestinal bacterial metabolism (Rowland et al., 1999; Turner et al., 2003; 
Possemiers et al., 2005; Lampe et al., 2006). Already in 1932, equol was described as an 
important metabolite of daidzein (Marrian and Haslewood, 1932), and later its bacterial origin 
was definitively proven (Blair et al., 2003; Bowey et al., 2003). Moreover, clinical studies 
indicate that equol would have increased beneficial health effects compared to daidzein 
(Atkinson et al., 2005). Alternatively, daidzein may be converted into the less active O-
desmethylangolensin (O-DMA) (Kelly et al., 1993). Similarly, it is known since 1979 that 
intestinal bacteria can convert the inactive plant lignans into the mammalian lignans 
(‘enterolignans’) enterodiol (END) and enterolactone (ENL) (Setchell and Adlercreutz, 1979; 
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Setchell et al., 1980; Stitch et al., 1980) and biological effects of lignan intake depend on the 
bacterial production of these enterolignans (Wang, 2002; Lampe et al., 2006). Finally, it was 
recently shown that hops contain an inactive precursor, isoxanthohumol (IX), which can be 
activated by intestinal bacteria into 8-PN (Possemiers et al., 2005; Possemiers et al., 2006). 
As the IX to 8-PN ratio in hop products generally is 10-30, intestinal activation of IX 
drastically increases the exposure to 8-PN and intestinal metabolism will also for this group 
determine the in vivo biological activity.    
However, these compounds also have a second general characteristic. It has been 
observed that only a part of humans have the intestinal metabolic potential to produce equol 
(Lampe et al., 1994; Atkinson et al., 2004; Atkinson et al., 2006) and wide ranges in the 
production of the enterolignans also have been observed (Lampe et al., 1994; Hutchins et 
al., 2000; Atkinson et al., 2006). As recent work showed that intestinal 8-PN production only 
occurs in 1/3 of humans (Possemiers et al., 2006), it is clear that substantial interindividual 
differences exist in the production of all the final active metabolites, which ultimately may be 
associated with differences in health benefits. 
Many studies have investigated possible health effects of individual groups of 
phytoestrogens present in our diet (Mazur and Adlercreutz, 2000; Chen and Rogan, 2004; 
Rasier et al., 2006; Wathen, 2006). It is clear that human nutrition always contains mixtures 
of different compounds and in view of the previous findings on intestinal activation of 
phytoestrogens, the final evaluation of health effects related to dietary phytoestrogens 
depends on the intestinal potential to activate all different groups of molecules within each 
individual. As to our knowledge no studies have been published on the relation between the 
capacity to activate isoflavones, lignans and prenylflavonoids within one person, an in vitro 
experiment with intestinal bacteria from 100 individuals was designed. Evaluation of equol, 
O-DMA, enterodiol, enterolactone and 8-PN production on all samples allows to investigate 
interindividual differences and will make it possible to assess the direct exposure to bioactive 
estrogen metabolites after food intake. Moreover, the microbial activation of each compound 
was correlated with intestinal community composition and activity, by evaluation of the 
correlation with the abundance of the Clostridium coccoides – Eubacterium rectale cluster, 
the methane producing (MPB) and sulfate reducing bacteria (SRB) and with β-glucosidase 
activity.   
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MATERIALS AND METHODS 
Chemicals 
SoyLife® EXTRA, an isoflavone extract from soy germs, and LinumLife™ EXTRA, a 20 % 
lignan extract from flax, were provided by Acatris NV (Giessen, the Netherlands). SoyLife® 
EXTRA contained 32.4 mg daidzein/g powder and LinumLife™ EXTRA contained 216 mg 
SECO-diglucoside (SDG)/g powder. The isolation of xanthohumol (X) from spent hops, 
isomerization of X into IX and chemical synthesis of 8-PN were performed as described 
earlier (Possemiers et al., 2005). Stock solutions of IX were prepared in absolute ethanol in a 
concentration of 14 mmol/L.  
 
Collection and incubation of fecal samples 
Fecal samples were obtained from 100 female subjects between the age of 44 and 76 
years (average 57) with a BMI between 16.2 and 37.6 kg/m2 (average 24.3). None of the 
subjects had a history of gastrointestinal disease nor had taken antibiotics during 3 months 
prior to sample delivery. Fecal slurries of 20 % (w/v) were prepared by homogenizing the 
feces with phosphate buffered saline (0.1 mol/L, pH 7) containing 1 g/L sodium thioglycolate 
as reducing agent. The particulate material was removed by centrifugation (2 min, 400 × g). 
All 100 samples were separately incubated with SoyLife® EXTRA, LinumLife™ EXTRA or IX. 
All incubation experiments were performed in Brain Heart Infusion broth (37 g/L, Oxoid, 
Hampshire, USA) with 0.5 g/L L-cystein HCl. Fecal bacteria require anaerobic conditions (low 
redox potential) for growth. Therefore, resazurin (2 mg/L) was added as a redox indicator. 
For samples incubated with SoyLife® EXTRA or LinumLife™ EXTRA, respectively 4 g/L and 2 
g/L powder were added to the culture medium. This corresponds to respectively 510 µmol/L 
daidzein and 630 µmol/L SECO. After transferring the medium to fermentation vessels (45 
mL), each batch was sealed with rubber tops and anaerobiosis was obtained by flushing the 
flasks with N2 during 20 cycli of 2 min at 700 mbar overpressure and 900 mbar 
underpressure. After this, the fermentation vessels were autoclaved at 121 °C for 15 min.  
The final fermentation volume (50 mL) consisted of 90 % Brain Heart Infusion medium 
and 10 % fecal slurry, introduced with needles into the anaerobe fermentation vessels. For 
the incubations with IX, the compound was added at the start of the incubation in a final 
concentration of 70 µmol/L. Cultures were incubated at 37 °C on a shaker for 72 h (IX and 
SoyLife® EXTRA) or 120 h (LinumLife™ EXTRA). Samples were taken at the beginning and 
the end of each experiment, using syringes. All experiments were performed in triplicate.  
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Chemical analysis 
Extraction procedures 
Samples incubated with SoyLife® EXTRA: The samples (1 mL) were mixed with 1 mL 
sodium acetate buffer (0.1 mol/L, pH 5). The isoflavones were extracted twice with 5 mL 
diethyl ether. The solvent was evaporated at room temperature under N2 stream and the 
residue was dissolved in 200 µL methanol, transferred into HPLC vials and stored at -20 °C 
prior to analysis. 
Samples incubated with LinumLife™ EXTRA and IX: The samples from the fecal 
incubations with LinumLife™ EXTRA and IX were extracted according to the procedure 
previously described (Possemiers et al., 2005). In brief, samples incubated with IX were 
diluted 5-fold in acidified H2O (pH 2) prior to extraction. Then, a 1 mL sample was added to 4 
mL acidified H2O (pH 2) and 5 mL ethyl acetate in a test tube. After rigorously vortexing, the 
samples were centrifuged at 3000 × g for 10 min. Three milliliters of the ethyl acetate phase 
was transferred to a new test tube and dried under N2 stream. Finally, the extracts were 
dissolved in exactly 500 µL methanol, transferred into HPLC vials and stored at -20 °C prior 
to analysis. 
HPLC analysis 
Samples incubated with SoyLife® EXTRA: Quantitative analyses of daidzein, O-DMA and 
equol were performed by HPLC-UV using a Waters 2695 Alliance separations module 
(Waters, Milford, Massachusetts, USA) equipped with a Waters 996 photodiode array 
detector and Waters Millenium software v3.20 as reported by Maubach et al. (2003). 
Ultraviolet detection was done at a wavelength corresponding to the most intense absorption 
maximum of each analyte i.e. 248 nm for daidzein, 230 nm for equol, and 277 nm for O-
DMA.  
Samples incubated with LinumLife™ EXTRA: Quantitative detection of SECO, END and 
ENL was performed using a Dionex HPLC system (Sunnyvale, USA) equipped with an 
autosampler ASI-100, pump P580, STH585 column oven and UV-VIS detector UVD340S. A 
Genesis C18 column (150 x 4.6 mm, 4 µm) (Jones Chromatography, UK) was used in 
combination with a gradient composed of solvent A (methanol/acetonitrile (2:1) acidified with 
0.1 % acetic acid) and solvent B (water acidified with 0.1 % acetic acid). Gradient profile: 0-
2.5 min: 60 % B, 5-22.5 min: 55 % B, 25-30 min: 60 % B. The injection volume was 20 µL, 
the flow-rate 0.7 mL/min, and the column temperature 25 °C. SECO, END en ENL were 
detected at 280 nm. Peaks were identified by comparison of the retention times with those of 
authentic isolated reference compounds and external calibration curves were established for 
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SECO, END and ENL (Sigma-Aldrich, St. Louis, Missouri, USA). Chromatograms were 
analyzed with the Chromeleon® software (Dionex, Sunnyvale, USA). 
Samples incubated with IX: Quantitative analyses were effected by high-performance 
liquid chromatography (HPLC) using a Waters 2695 Alliance Separations Module (Waters, 
Milford, USA) equipped with a Waters 996 Photodiode Array Detector and Waters Millenium 
Software v3.20 (Possemiers et al., 2005). 
 
Microbial analysis 
Real time PCR quantification 
Liquid samples from freshly homogenized fecal samples were collected and frozen at -20 
°C for subsequent analysis. Total DNA extractions of 1 mL liquid sample were performed 
using the method described by Boon et al. (2003). Using an ABI Prism SDS 7000 instrument 
(Applied Biosystems, Foster City, USA), 10 times diluted general bacterial DNA as well as 
specific DNA from MPB, SRB and the C. coccoides - E. rectale group were quantified by 
Real Time PCR. DNA from the latter group was quantified using the qPCR® core kit for Sybr® 
Green I (Eurogentec, Liege, Belgium), whereas for the other protocols the PCR Master Mix 
(2x) SYBR® Green kit (Applied Biosystems, Foster City, USA) was used. 
The 16S rRNA genes for all members of the bacteria were amplified using primer 
PRBA338f and P518r (Boon et al., 2003). Real time PCR analysis of the SRB was performed 
using the primers Et3F (5’ AACAACATHGARTTYATG 3’) and Et3R (5’ 
TAGCAGTTACCRCARTACAT 3’) specific for dsrB gene (patent number MI2002A002479, 
by EniTecnologie S.p.A.). After 2 min at 50 °C, initial denaturation for 10 min at 95 °C was 
followed by 40 cycles consisting of denaturation at 94 °C for 30 sec, annealing at 50 °C for 
30 sec, extension at 60 °C for 50 sec and a 83 °C for 15 sec step to avoid primer dimer 
problems. DNA from MPB was quantified using primers ME3F (5’ 
GGTGGHGTMGGWTTCACACA and ME2R (5’ TCATKGCRTAGTTDGGRTAGT) specific for 
the mcrA gene (Hales et al., 1996). The protocol consisted of 2 min at 50 °C; 10 min at 95 
°C; 40 cycles of 40 s at 94 °C, 50 s at 55 °C and 50 s at 60 °C. For the C. coccoides - E. 
rectale group, primer set, annealing temperature and Mg concentration were described by 
Rinttilä et al. (2004) and adapted according to Possemiers et al. (2006). Standard curves 
were constructed with cloned PCR products in a concentration range from 1010 to 102 DNA 
copies/µL and DNA from at least 10 non-target species was used as negative control to test 
amplification specificity. 
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β-glucosidase activity 
Unfrozen fecal suspensions were centrifuged at 5000 × g for 5 min and diluted five times 
in phosphate buffer (0.5 mol/L, pH 7) (Hoey et al., 2004). For the assessment of β-
glucosidase activity, the suspensions were incubated aerobically for 30 min at 37 °C with p-
nitrophenyl-β-D-glucopyranoside (2.5 mmol/L). Release of p-nitrophenol was recorded with a 
Tecan SunriseTM absorbance reader (Tecan Benelux, Mechelen, Belgium) at 405 nm before 
and after incubation. The absorbance of a series of different concentrations of p-nitrophenol 
was used to calculate the enzymatic activities, according to the method of Berg et al. (1978). 
 
Statistical analysis 
All extractions and analyses were performed in triplicate. The statistical package for the 
social sciences for Windows version 12.0 (SPSS Inc., Chicago, Illinois, USA) was used to 
carry out all statistical analyses. Data were calculated as percentage metabolite produced 
relative to the amount of incubated precursor. Normality of the data was assessed using the 
Kolmogorov-Smirnov test. Comparison of means of non-normally distributed data was 
evaluated with the non-parametric Kruskal-Wallis test. Correlations between non-normally 
distributed data of the percentage production of two metabolites were calculated as two-
tailed Spearman correlations. Individuals were clustered into high, moderate and low 
producers of a specific metabolite, based on TwoStep clustering. To do this, data were 
transformed into the log10-ratio of concentrations of the metabolite to its specific precursor as 
proposed by Setchell and Cole (Setchell and Cole, 2006). Percentage of individuals 
clustered in each group are presented. Cross-classification analysis calculated the 
agreement between the different producer phenotypes. Inter-rater agreement has also been 
assessed using the weighted κ statistic, calculated with a linear set of weights (Altman, 
1991). The κ value can be interpreted as follows: < 0.20 = poor; 0.21-0.40 = fair; 0.41-0.60 = 
moderate; 0.61-0.80 = good; 0.81-1.00 = very good (Altman, 1991).  
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RESULTS 
Intestinal bacterial production of phytoestrogen metabolites 
After incubation of 100 fresh fecal samples with 4 g/L SoyLife® EXTRA (510 µmol/L 
daidzein), large interindividual differences were noted in the production of O-DMA and equol 
(Figure 4.1). For each metabolite, the data could be clustered into three clusters with 
significantly different means. This led to the separation of the samples into 23 % and 33 % 
low, 51 % and 25 % moderate and 26 % and 42 % high O-DMA and equol producers 
respectively.  
 
 
Figure 4.1. O-Desmethylangolensin (O-DMA) and equol production after incubation of 100 fecal 
samples with 4 g/L SoyLife® EXTRA (mean dose % ± SE). Individuals were clustered into high, 
moderate and low O-DMA and equol producers based on TwoStep clustering. To do this, data were 
transformed into the log10-ratio of O-DMA and equol concentrations to its precursor daidzein as 
proposed by Setchell and Cole (2006). Percentage of individuals clustered in each group are 
presented in the figure. 
 
Similarly, after incubation of the fecal samples with 2 g/L LinumLife™ EXTRA (630 µmol/L 
SECO), the production of END and ENL strongly differed between individuals (Figure 4.2). 
Whereas varying amounts of END were produced in 3/4 of the samples (51 % moderate and 
12 % high producers), ENL was only produced in 39 % of the samples (31 % moderate and 8 
% high producers). Finally, incubation with 70 µmol/L IX led to the production of 8-PN (Figure 
4.3). Clustering separated individuals in 30 % low, 55 % moderate and 15 % high 8-PN 
producers. 
 
   Chapter 4 
 99 
 
Figure 4.2. Enterodiol (END) and enterolactone (ENL) production after incubation of 100 fecal 
samples with 2 g/L LinumLife™ EXTRA (mean dose % ± SE). Individuals were clustered into high, 
moderate and low END and ENL producers based on TwoStep clustering. To do this, data were 
transformed into the log10-ratio of END and ENL concentrations to its precursor secoisolariciresinol as 
proposed by Setchell and Cole (2006). Percentage of individuals clustered in each group are 
presented in the figure. 
 
 
Figure 4.3. 8-Prenylnaringenin (8-PN) production after incubation of 100 fecal samples with 70 µmol/L 
isoxanthohumol (IX) (mean dose % ± SE). Individuals were clustered into high, moderate and low 8-
PN producers based on TwoStep clustering. To do this, data were transformed into the log10-ratio of 8-
PN concentrations to its precursor IX as proposed by Setchell and Cole (2006). Percentage of 
individuals clustered in each group are presented in the figure. 
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Relation between the production of different metabolites 
In order to evaluate whether a producer phenotype of one metabolite coincides with high 
probability with a specific producer phenotype of other metabolites, the relation between the 
production of different metabolites was statistically analyzed (Table 4.1). 
 
Table 4.1. Relation between the production of different phytoestrogen metabolites within individuals 
(n=100), by fecal sample incubation a. 
  8-PN O-DMA Equol END ENL 
8-PN Rho b  0.003 0.049 0.004 0.185 
 κ c  0.04 
(-0.12;0.19) 
-0.02 
(-0.15;0.11) 
0.06 
(-0.11;0.23) 
-0.02 
(-0.15;0.11) 
O-DMA Rho 0.003  -0.199* 0.146 0.011 
 κ 0.04 
(-0.12;0.19) 
 0.34 
(0.20;0.47) 
0.08 
(-0.08;0.24) 
0.04 
(-0.10;0.17) 
Equol Rho 0.049 -0.199*  0.069 -0.063 
 κ -0.02 
(-0.15;0.11) 
0.34 
(0.20;0.47) 
 0.05 
(-0.08;0.18) 
-0.02 
(-0.15;0.11) 
END Rho 0.004 0.146 0.069  0.430** 
 κ 0.06 
(-0.11;0.23) 
0.08 
(-0.08;0.24) 
0.05 
(-0.08;0.18) 
 0.43 
(0.28;0.58) 
ENL Rho 0.185 0.011 -0.063 0.430**  
 κ -0.02 
(-0.15;0.11) 
0.04 
(-0.10;0.17) 
-0.02 
(-0.15;0.11) 
0.43 
(0.28;0.58) 
 
a For each evaluation, the correlation between the percentage production of the metabolites are presented, 
as well as the weighted κ values, calculated after cross-classification of the high, moderate and low producers of 
two specific metabolites. The 95 % confidence intervals are presented between brackets. b As data are not 
normally distributed, two-tailed Spearman Correlations were calculated (Rho). c The κ value can be interpreted as 
follows: < 0.20 = poor; 0.21-0.40 = fair; 0.41-0.60 = moderate; 0.61-0.80 = good; 0.81-1.00 = very good (Altman, 
1991). * Correlation is significant at the 0.05 level (2-tailed). ** Correlation is significant at the 0.01 level (2-tailed) 
 
Based on the non-parametric Spearman Correlation, no correlation was found between 
the production of metabolites from the different groups of phytoestrogens, i.e. isoflavones, 
lignans and prenylflavonoids. Yet, O-DMA was negatively correlated with the percentage 
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equol production. The strongest correlation was found between END and ENL production 
with P<0.01, indicating that high ENL production coincided with high END production. 
These correlations were confirmed by cross-classification analysis using weighted κ 
values. These values were calculated to investigate whether people having a specific 
producer phenotype of one metabolite (high, moderate or low) would share the same 
producer phenotype of the second metabolite. The highest κ value again was found for END 
and ENL production. In this test, equol production also fairly coincided with O-DMA 
production. However, when taking the crosstabulation into account (Table 4.2), it is clear that 
O-DMA and equol production should in fact be seen as two separate processes. The fair κ 
values were mainly due to the fact that 92 % of high O-DMA producers were also high equol 
producers. In contrast, for instance 72 % of low equol producers produced O-DMA and 61 % 
of low O-DMA producers produced equol. 
 
Table 4.2. Cross-classification of the O-desmethylangolensin (O-DMA) and equol producer 
phenotypes based on the incubation of 99 fecal samples with 4 g/L SoyLife® EXTRA (510 µmol/L 
daidzein). 
  O-DMA producer phenotype Total 
  High Moderate Low  
High 24 15 3 42 
Moderate 1 13 11 25 
Equol 
producer 
phenotype 
Low 1 22 9 32 
Total  26 50 23 99 
 
Finally, the Kruskal Wallis test was used to evaluate whether specific phenotypes of one 
metabolite (low, moderate or high) had significantly different mean productions of other 
metabolites (data not shown). Again, low, moderate or high END producers showed 
significantly (P<0.01) different mean ENL production and vice versa and the O-DMA 
phenotypes showed different percentage equol production (P<0.01). In contrast, equol 
phenotypes had no significantly different O-DMA production. 
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Influence of microbial community composition and activity 
To evaluate the relation between the production of specific phytoestrogen metabolites 
and the microbial community composition and activity, a number of microbial parameters 
were assessed on the fresh fecal samples. Counts of bacteria belonging to the C. coccoides 
- E. rectale cluster varied between 2.2 × 107 and 4.5 × 1011/g wet weight (average: 2.1 × 
1010/g wet weight or 20 % of the total bacterial population), the numbers of MPB varied 
between < 5.0 × 103 and 2.2 × 109/g wet weight (average: 1.9 108/g wet weight or 0.3 % of 
the total) and the counts of SRB were between < 5.0 × 103 and 5.0 × 1010/g wet weight 
(average: 1.9 × 109/g wet weight or 1.9 % of the total). The intestinal β-glucosidase activity 
varied between 0.24 and 108.7 µmol/h/g (average 26.1 µmol/h/g). These absolute counts 
were correlated with the production of each metabolite, using the non-parametric Spearman 
Correlation (Table 4.3).  
 
Table 4.3. Correlation between the intestinal bacterial production of a specific phytoestrogen 
metabolite and the abundance of the C. coccoides – E. rectale cluster, methane producing (MPB) and 
sulfate reducing (SRB) bacteria and with the intestinal β-glucosidase. 
  8-PN O-DMA Equol END ENL 
Rho a 0.129 -0.005 -0.159 -0.277** -0.078 C. coccoides – 
E. rectale Sig. 0.202 0.958 0.118 0.006 0.445 
SRB Rho -0.001 -0.036 0.262** -0.027 -0.039 
 Sig. 0.992 0.725 0.009 0.788 0.700 
MPB Rho -0.074 0.209* -0.032 0.078 0.128 
 Sig. 0.469 0.039 0.756 0.444 0.210 
β-glucosidase Rho -0.092 0.116 -0.041 0.189 0.169 
 Sig. 0.363 0.256 0.690 0.062 0.096 
a As data are not normally distributed (Kolmogorov-Smirnov), two-tailed Spearman Correlations were calculated 
(Rho). * Correlation is significant at the 0.05 level (2-tailed). ** Correlation is significant at the 0.01 level (2-tailed) 
 
This showed that END production was negatively correlated with the abundance of the 
C. coccoides – E. rectale cluster (P<0.01). O-DMA and equol production were positively 
correlated with the abundance of respectively MPB (P<0.05) and SRB (P<0.01). Although 
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not significant, β-glucosidase activity showed a positive trend (P<0.1) with the production of 
both END and ENL. 
Next to absolute counts of bacterial concentrations, Spearman Correlations were also 
used to relate the production of a specific phytoestrogen metabolite with the abundance of 
the bacterial groups, relative to the total bacterial counts (data not shown). In this case, the 
results were similar, except for the fact that the percentage ENL production was now also 
positively correlated with the relative abundance of MPB (P<0.05).   
Finally, the Kruskal Wallis test was used to evaluate whether specific phenotypes of one 
metabolite (low, moderate or high) had significantly different mean concentrations of the 
bacterial groups and rates of β-glucosidase activity (data not shown). Again, low, moderate 
or high END producers had significantly (P<0.01) different mean C. coccoides – E. rectale 
counts and the equol phenotypes showed different counts of sulfate reducing bacteria 
(P<0.05). Since these two relations were the most consistent in the different statistical tests, 
these two were the most important results found in this experiment.  
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DISCUSSION 
After incubation of 100 fecal samples with SoyLife® EXTRA, Linumlife™ EXTRA or IX, the 
production of O-DMA, equol, END, ENL and 8-PN showed substantial interindividual 
variation, separating individuals for each metabolite into high, moderate and low producers. 
Correlations were found between O-DMA and equol (negative) and between END and ENL 
(positive) production. Moreover, the production of some metabolites could be related with 
specific intestinal conditions. 
 Recently, a new data processing method to define the equol-producer status was 
proposed by Setchell and Cole (Setchell and Cole, 2006). In the past, differentiation of equol 
producers from non-producers often was based on arbitrary cutoff values (Lampe et al., 
1998; Setchell et al., 2002), stressing the need for a universal approach independent of 
precursor intake (Setchell and Cole, 2006). However, after data transformation, these 
authors still defined an arbitrary cutoff value to validate their method. In this study, we 
combined their data processing method with statistical TwoStep cluster analysis, providing a 
more unbiased tool to define the producer phenotype of the relevant bacterial metabolites. 
Moreover, in the past, producer phenotypes were mostly defined as producer or non-
producer (Setchell et al., 1984; Lampe et al., 1998; Rowland et al., 2000). However, it is clear 
that for most metabolites the production for many individuals has intermediate values instead 
of a clear yes or no trend. Thus, this method better represents the data, separating 
individuals into 3 clusters, in high, moderate or low producers. 
The findings of interindividual variation in 8-PN production are consistent with previous 
experiments (Possemiers et al., 2006), in which 16 % high producers were found. In the 
present study, the abundance of moderate 8-PN producers was higher, because of 
differences in the data processing method. This resulted in grouping individuals with 8-PN 
production below 20 % with non-producers in the former study (Possemiers et al., 2006), 
whereas these individuals were now identified as moderate. Still, the results were very 
similar with about 60 % converting less than 20 % IX. 
Variations in the production of O-DMA and equol are also in agreement with literature, 
with the difference that data were now grouped in 3 producer phenotypes. Equol production 
is reported to occur in 20 to 35 % of individuals (Kelly et al., 1993; Lampe et al., 1998; 
Duncan et al., 2000; Rowland et al., 2000; Setchell et al., 2002; Blakesmith et al., 2005) with 
a higher frequency among vegetarians (Setchell and Cole, 2006) and in Asian populations 
(Akaza et al., 2004; Song et al., 2006). A number of studies indicate that most subjects 
produce O-DMA (80-90 %) (Kelly et al., 1993; Arai et al., 2000; Blakesmith et al., 2005; Song 
et al., 2006), which is in accordance to the 77 % noted in this study. Neither O-DMA or equol 
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production was correlated with the production of lignans or 8-PN, indicating that the factors 
determining the metabolic fate of daidzein differ from the factors influencing 8-PN, END or 
ENL production. Some previous studies reported a reciprocal relationship between excretion 
of O-DMA and equol (Hutchins et al., 1995; Kelly et al., 1995; Arai et al., 2000), whereas 
other studies found no relation (Lampe et al., 1998; Rowland et al., 2000; Blakesmith et al., 
2005). In this study, we found a negative correlation (P<0.05) between O-DMA and equol 
production, explained by the fact that both metabolites are derived from the same precursor. 
However, the rather low O-DMA production (~20 % for many high producers) made 
coexistence of high producer phenotypes of both metabolites still possible, explaining the fair 
κ value. Yet, analysis of Table 4.2 indicates that both processes probably do not exclude 
each other. 
Many studies have also reported substantial variation in intestinal lignan metabolism 
(Lampe et al., 1994; Hutchins et al., 2000; Rowland et al., 2000; Atkinson et al., 2006). 
Whereas some studies report that END is the most abundant enterolignan (Thompson et al., 
1991; Cunnane et al., 1995; Nesbitt et al., 1999; Clavel et al., 2005), other studies found 
higher ENL concentrations (Lampe et al., 1994; Hutchins et al., 2000; Rowland et al., 2000; 
Taylor and Al-Azzawi, 2000). In this study, we confirmed that END is formed from flaxseed in 
more individuals and in higher percentages than ENL (Figure 4.2). Furthermore, there was a 
significant correlation between ENL and END production and a moderate κ value. This 
confirms the previously proposed pathway of SECO metabolism, the most abundant 
precursor in flax and present in food as SECO-diglucoside (SDG), showing that END is an 
intermediate in ENL formation (Borriello et al., 1985; Wang et al., 2000). A significant 
negative correlation was noted between END production and the abundance of the C. 
coccoides – E. rectale cluster. The counts of this dominant cluster (20 % of total population) 
are similar to previously reported data (Clavel et al., 2005). Although some bacteria which 
are involved in the production of END belong to this cluster (Clavel et al., 2005), high counts 
of this group might have negative effects on END production. Further research is needed to 
elucidate the biological significance. Finally, a trend was noted between increasing β-
glucosidase activity and increased END and ENL production, which can be explained by the 
fact that SDG needs deglycosylation before further metabolism occurs.  
A very interesting finding was the significance of the correlations between the abundance 
of SRB and MPB and respectively equol and O-DMA production. In the gut, fermentative H2 
is a central metabolite (Cummings and Englyst, 1987), but it must be removed to allow a 
more complete oxidation of substrates (Miller and Wolin, 1981; Miller and Wolin, 1983). MPB 
and SRB have a key role in this process, competing for H2 to produce CH4 or H2S (Miller and 
Wolin, 1983; Gibson et al., 1988; Gibson et al., 1993; Dore et al., 1995). It is well known that 
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H2 plays an important role in the production of O-DMA and equol (Joannou et al., 1995; 
Heinonen et al., 1999; Decroos et al., 2005). In this process, one H2 is needed in the first 
transformation, in which daidzein is hydrogenated into dihydrodaidzein (DHD). This DHD can 
then be isomerized into O-DMA or may be converted into equol, requiring two extra H2. 
Although further research is needed to explain this interaction between the intestinal 
hydrogen transfer pathways and the transformation of daidzein, some hypotheses can be 
postulated.  
Firstly, MPB and SRB may be directly involved in the production of respectively O-DMA 
and equol. However, to our knowledge intestinal methanogens have never been reported to 
use alternative electron acceptors (e.g. daidzein) instead of CO2 (Miller and Wolin, 1986) and 
the versatility of SRB is located at the donor site (Gibson et al., 1988). Hence, a second 
hypothesis may be that O-DMA and equol producing bacteria can interact with the specific 
interspecies H2 transfer to MPB or SRB in the gut (Robert et al., 2001) to use it for their own 
transformations. This is confirmed by recent work which showed that an equol-producing 
consortium (Decroos et al., 2005) is able to compete in vitro with MPB and SRB for H2. High 
counts of MPB or SRB could thus indicate high interspecies H2 transfer, facilitating other 
bacteria to derive some for their own process. Finally, MPB are predominant in 30-50 % of 
individuals (McKay et al., 1985) and are now seen as markers of a specific colonic 
environment (Florin et al., 2000; Levitt et al., 2006). This would include slower transit time 
(ElOufir et al., 1996), higher pH (Stephen et al., 1986) and higher acetate production 
(Fernandes et al., 2000) and these conditions may be linked to a less favorable environment 
(Melcher et al., 1991) and clinical states (Fernandes et al., 1998; Levitt et al., 2006). In this 
study, production of the less active O-DMA was related with MPB. Similarly, high SRB counts 
may be markers for a colonic environment favoring equol producing bacteria. Interestingly, a 
recent study showed that non-equol excreting individuals had higher dietary protein intakes 
(Blakesmith et al., 2005), conditions increasing pH, exposure to less desirable products and 
favoring MPB. This again indicates the importance of a specific environment for equol 
production, warranting further investigation. 
In conclusion, the intestinal activation of the dietary phytoestrogens, i.e. isoflavones, 
lignans and prenylflavonoids showed substantial interindividual variation, with intra class but 
not inter class correlations. Knowledge about these variations may help to better evaluate the 
final dietary exposure to phytoestrogens. Moreover, we report for the first time the relation 
between the production of the different metabolites and the relation with specific intestinal 
environmental conditions, which may increase our understanding of the factors influencing 
this variation.   
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CHAPTER 5 
Application of Eubacterium limosum in the SHIME and in human 
microbiota-associated rats for the intestinal activation of 
isoxanthohumol  
ABSTRACT 
Recently, it was shown that the exposure to the potent hop phytoestrogen 8-
prenylnaringenin depends on intestinal bacterial activation of isoxanthohumol, but this occurs 
in only 1/3 of the population. As the butyrate-producing Eubacterium limosum can produce 8-
PN from IX, a probiotic strategy was investigated to increase 8-PN production in low 8-PN 
producers, balancing estrogen exposure in all individuals. With fecal samples from a high 
and low 8-PN-producing individual, a high and low IX-converting dynamic intestinal model 
was constructed. In parallel, high and low 8-PN-producing gnotobiotic rats were designed, 
germ-free rats acting as negative controls. To intestinal model and rats, first IX and then IX + 
E. limosum were dosed and changes in 8-PN production and exposure were assessed. After 
dosing IX, 80 % 8-PN was produced in the high IX-converting model and highest 8-PN 
production, plasma concentrations and urinary and fecal excretion occurred in the high 8-PN-
producing rats. Only in these rats, 8-PN was detected in organ samples. Administration of 
the probiotic increased butyrate production in all rats and 8-PN production in the low-IX-
converting model and low 8-PN-producing and germ-free rats. As result, 8-PN excretion was 
similar in all rats and 8-PN was detected in organs from all rats. Plasma 8-PN reached 1.7 ± 
0.2 µmol/L after 5-day IX uptake (5.6 µmol/kg). In conclusion, it was conclusively shown that 
intestinal bacteria determine 8-PN exposure after hop consumption. Moreover, E. limosum 
reached the colon where it produced butyrate and increased 8-PN production in low 
producers, resulting in similar final estrogen exposure in all individuals.    
 
Keywords: Phytoestrogens, 8-prenylnaringenin, Eubacterium limosum, probiotics, gut 
bacteria 
 
Redrafted after: Possemiers S., S. Rabot, J.C. Espín, A. Bruneau, C. Philippe, A. González-Sarrías, 
A. Heyerick, F.A. Tomás-Barberán, D. De Keukeleire and W. Verstraete (2007). Application of 
Eubacterium limosum in the SHIME and in human microbiota-associated rats for the intestinal 
activation of isoxanthohumol from hop (Humulus lupulus L.) into the potent phytoestrogen 8-
prenylnaringenin. Submitted to Applied and Environmental Microbiology (+ extra data included). 
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INTRODUCTION 
Eubacterium limosum is identified as an anaerobic Gram-positive rod and is considered 
to be present in the colon of most humans (Wang et al., 1996). Over the last years, this 
bacterium has gained increased attention because of its beneficial effects on the colonic 
environment in inflammatory bowel disease (IBD), possibly attributed to its butyrate-
producing capacity (Kanauchi et al., 2002; Kanauchi et al., 2005). Butyrate is known to 
modulate epithelial cell proliferation and differentiation and has protective effects on IBD 
(Sengupta et al., 2006), but oral butyrate treatment did not prove efficient because of the 
difficulty of delivering butyrate to the colon (Steinhart et al., 1996). Therefore, a good 
alternative to deliver butyrate in the colon would be to administer butyrate-producing 
probiotics, such as Clostridium butyricum or E. limosum (Gionchetti et al., 2003). The 
promising application of E. limosum was recently shown when the probiotic ameliorated 
experimental colonic inflammation in mice (Kanauchi et al., 2006). 
Moreover, in addition to improving the colonic environment, the latter probiotic could 
possibly also be used for other applications, e.g. the production of health beneficial 
compounds. Recently, this metabolically versatile bacterium was shown to activate 
proestrogens from hop (Possemiers et al., 2005). Hop has been identified as a source of 
xanthohumol (X), a strong cancer preventive agent (Vanhoecke et al., 2005; Monteiro et al., 
2006) and the potent phytoestrogen 8-prenylnaringenin (8-PN) (Milligan et al., 1999; Milligan 
et al., 2002), which has been indicated to exert many biological activities (Zierau et al., 2003; 
Diel et al., 2004; Pepper et al., 2004; Effenberger et al., 2005; Hümpel et al., 2005) and hop 
extracts are now used to relieve menopausal complaints (Heyerick et al., 2006). Recently, 
we have shown that the final exposure to 8-PN may not only depend on the presence of 8-
PN itself in hop products, but rather on the combined presence in the plant of a much more 
abundant precursor, isoxanthohumol (IX), and the metabolic potential of the intestinal 
microbiota (Possemiers et al., 2005; Possemiers et al., 2006). Intestinal bacteria were shown 
to demethylate IX into 8-PN, thereby easily tenfold increasing the 8-PN exposure. However, 
due to interindividual intestinal variability, only about 1/3 of the humans were found capable 
of efficiently performing this transformation, leading to large differences in 8-PN exposure 
and thus possible health effects after hop consumption. 
As we selected before an efficient 8-PN-producing strain of E. limosum (Possemiers et 
al., 2006), and because of its previously mentioned probiotic potential, the combined uptake 
of E. limosum and hop extracts could therefore lead to increased health effects by improving 
both the colonic environment (e.g. cancer preventive effect of X and bacterial butyrate 
production) and the activation of IX into 8-PN in humans who lack the appropriate intestinal 
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metabolic potential. The hypothesis of increased 8-PN and butyrate production by the 
probiotic was investigated in vitro in a dynamic model of the intestine (Figure 5.1), followed 
by an in vivo trial with germ-free and human microbiota-associated (HMA) rats. 
 
 
Figure 5.1. Design of the TWINSHIME setup in which two dynamic SHIME (Simulator of the Human 
Intestinal Microbial Ecosystem) models were combined in parallel. 
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MATERIALS AND METHODS 
Chemicals 
The isolation of xanthohumol (X), isomerisation of X into IX and chemical 8-PN synthesis 
were performed as described earlier by (Possemiers et al., 2005). Stock solutions of IX and 
8-PN were prepared in ethanol (5 g/L).  
 
Preparation of the Eubacterium limosum inocula 
The 8-PN-producing E. limosum strain LMG P-23546 (Possemiers et al., 2005) was 
grown in Brain Heart Infusion (BHI) broth (Oxoid, Drongen, Belgium) with 0.5 g/L L-cystein 
HCl, 5 g/L yeast extract and 5 mg/L haemin, at 37 °C in an anaerobic glove box. After dilution 
to a log 9 CFU/mL concentration, 15 mL was centrifuged (15 min, 15000 × g) and 
resuspended in 15 mL saline (0.9 g/L NaCl). This suspension was immediately used for 
administration of the bacterium to the SHIME or to the rats by oral gavage. 
 
Identification of high and low 8-PN producing human fecal 
microbiota 
Twelve human volunteers delivered a fecal sample for incubation purposes. The samples 
were prepared and incubated with 25 mg/L IX according to Possemiers et al. (2005). Based 
on these results, a high and a low 8-PN-producing individual were selected. To confirm their 
8-PN production status, a capsule containing on average 5.59 ± 0.97 mg IX, was 
administered for four consecutive days. On day 4, a 24 h urine sample was collected and the 
relative 8-PN excretion was quantified. After confirmation of their status, the high and low 8-
PN producer were asked to deliver fecal samples for inoculating the SHIME and germ-free 
rats. 
 
Simulator of the Human Intestinal Microbial Ecosystem 
The reactor setup was adapted from the SHIME (Molly et al., 1993), consisting of five 
successive reactors, simulating the stomach, small intestine, ascending, transverse and 
descending colon. The microbial community in the last 3 reactors is derived from a selected 
fresh fecal sample. The reactor setup, inoculum preparation, and reactor feed composition 
were previously described (Possemiers et al., 2004).  
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For this experiment, a new TWINSHIME setup was developed by operating two systems 
in parallel at the same time (Figure 5.1). Identical environmental conditions for both systems 
were obtained by identical pH and temperature control and by using 2-headed pumps for 
liquid transfer between the respective reactors. The systems were inoculated with a fecal 
sample from the identified high and low 8-PN producers and designated respectively Hop+ 
and Hop- compartment. After reactor start up and a three-week stabilization period 
(Possemiers et al., 2004), 25 mg/L IX was administered for 4 weeks to the SHIME feed 
entering both systems (experiment 1). After 2 weeks, log 9 E. limosum was dosed daily to 
the ascending colon of both systems for 2 weeks (experiment 2). 
 
Experiment with germ-free and HMA rats 
Animals 
Eighteen male and 18 female Fischer 344 rats were used. They were born germ-free and 
bred in germ-free conditions in the Germ-Free Rodent Breeding Facilities of the Unit on 
Ecology and Physiology of the Digestive Tract (INRA, Jouy-en-Josas, France) according to 
established methods (Coates, 1968). Rats were aged 5-7 weeks at the start of the 
experiment. They were randomly separated into 3 groups of 12 animals each (6 males and 6 
females per group) housed in 3 sterile isolators (La Calhène, Vendôme, France). Within each 
isolator, male and female rats were kept separately in threes in standard macrolon cages 
containing a bed of wood shavings. They were given free access to autoclaved tap water and 
a pelleted semi-synthetic diet (SAFE, Augy, France) sterilised by γ-irradiation at 45 kGy (IBA 
Mediris, Fleurus, Belgium). To reproduce the diversity of a human type diet, the food 
contained lipids and proteins of plant and animal origins, sucrose and cooked starch. 
Throughout the study, isolators were maintained in controlled conditions of light (07.00–19.00 
hours), temperature (20-22 °C) and humidity (45-55 %). 
Design of the Animal Experiment 
Rats from two groups were orally administered with 1 mL of a fecal suspension freshly 
made from the stools of the high (Hop+ group) and the low (Hop- group) 8-PN producers, 
respectively. To do this, fresh stools were transferred in the anaerobic glove box and 
dispersed in BHI broth (1 % w/v); the suspensions were subsequently transferred in the 
isolators and given to rats using a stainless-steel stomach tube. The HMA rats were given 3 
weeks to allow the microbiota to settle in the digestive tract and the rat physiology to adapt to 
the new bacterial status. The third group of rats was maintained germ-free (GF group), to act 
as a negative control. The total duration of the experiment was 6 weeks. In a first period (wks 
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1 to 4, experiment 1), all animals were treated with IX. Half of them were then sacrificed for 
collection of blood and organs for biochemical analyses, and of intestinal contents for 
incubation purposes. The remaining half entered a second period of experiment (wks 5 to 6, 
experiment 2) during which they were treated with IX and the E. limosum strain, before being 
sacrificed. On day 1 of wk 1, 3 males of each group were weighed and placed in individual 
metabolism cages to allow for separate collection of daily urinary and fecal outputs (Figure 
5.2). To protect the urine samples from bacterial contamination, 200 µL of 0.4 % sodium 
azide solution (v/v) was added every day to the urine collection receptacles. Subsequently to 
the first daily urine and feces collection (blank samples), the rats were gavaged every day 
from day 2 to day 5 with a sterile solution of 2 mg IX/kg BW in 50 % ethanol/propylene glycol 
(v/v). Urinary and fecal outputs collected on day 5 and 6 were used for analysis of IX and 8-
PN excretion. Furthermore, fresh feces were collected on day 1 and stored at -80 °C until 
molecular analysis of the microbiota. Rats were returned to their collective cages on day 6 of 
wk 1. On wk 2, the same protocol was applied to 3 female rats of each group. Eventually, it 
was run with the 3 remaining subsets of male and female rats on wks 3 and 4 respectively. 
At the end of their treatment wks, these animals were anaesthetised with isoflurane 
(Aerrane®, Baxter, Lessines, Belgium) and blood was collected from the inferior vena cava 
on heparinized tubes. Blood samples were centrifuged (10 min, 10000 × g) and the plasmatic 
supernatants were stored at -80 °C until analysis of IX and metabolites. Rats were sacrificed 
by section of the abdominal aorta and liver, kidneys, brain, and uterus in females were 
dissected, frozen in liquid nitrogen and stored at –80 °C until analysis of IX and metabolites. 
Cecal and colon contents were also collected; they were immediately transferred into the 
anaerobic glove box, 5-fold diluted in BHI broth and thoroughly homogenized with an ultra-
Turrax blender for incubation experiments as described below. Prior to this treatment, an 
aliquot of the cecal content was stored at –80 °C for molecular analysis of the microbiota and 
for butyrate assays.  
Rats that had been treated with IX in the course of wks 1 and 2 were treated with both IX 
and the E. limosum strain after a 3-wk washout period, i.e. on wks 5 and 6 respectively. The 
same procedure as in the first period of the experiment was followed, except that the rats 
were now gavaged with IX every morning and E. limosum every afternoon. Furthermore, E. 
limosum administration started 2 days prior to the initial dosing with IX. At the end of their 
treatment week, animals were sacrificed and blood, organs and intestinal contents were 
collected as described above. All procedures were carried out in accordance with the 
European guidelines for the care and use of laboratory animals. 
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Figure 5.2. Design of the animal experiment. At the start of each experiment, three rats from each 
treatment group were transported from their collective cages (1) to the experimental isolators (2). After 
weighing the rats (3), each rat was housed in individual metabolism cages for the duration of the 
experiment and daily urine and feces were collected. At the end of the experiment, rats were 
anaesthetized and organs were collected.  
 
Incubation experiment with the rat intestinal contents 
All fermentation experiments were performed in BHI broth with 0.5 g/L L-cystein HCl, 5 
g/L yeast extract and 5 mg/L haemin. The medium bottle was placed in the anaerobic glove 
box at least 48 h prior to the start of the incubations to remove traces of oxygen. The 
homogenized cecal and colon suspensions of the sacrificed rats were incubated at 10 % 
(v/v) in the BHI broth supplemented with 25 mg/L IX and incubated at 37 °C for 72 h. After 
this, a 5 mL sample was collected from each incubation for HPLC analysis.    
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Chemical analysis 
Extraction of urine, feces and plasma 
Sampling and extraction of prenylflavonoids from the colon compartments of both 
systems were described previously (Possemiers et al., 2006). Extraction and quantification of 
butyrate in the SHIME samples and rat cecal content was also previously described 
(Possemiers et al., 2006). 
Immediately after collection, the volume of urinary output was measured and samples 
were clarified by centrifugation (5 min, 8000 × g). The fecal samples were lyophilized, 
weighed and finely grinded in an electric coffee grinder. To 1 mL urine, 1 mL sodium acetate 
buffer (0.1 mol/L, pH 5) and 50 µL β-glucuronidase/arylsulfatase (10000/330 units/mL) 
(Sigma-Aldrich, St. Louis, Missouri, USA) were added to release the sulfo- and/or glucurono-
conjugated forms of the prenylflavonoids. Similarly, to 500 mg feces, 9.5 mL sodium acetate 
buffer and 250 µL β-glucuronidase/arylsulfatase were added. The samples were vortexed 
and incubated overnight at 37 °C. The prenylflavonoids were extracted by liquid/liquid 
extraction with ethyl acetate as solvent (Possemiers et al., 2005). To 2 mL sample, 3 mL H2O 
acidified with HCl (pH 2) and 5 mL ethyl acetate were added. 4-Hydroxybenzophenon was 
added as internal standard. After the extraction, the extracts were dried under nitrogen, 
dissolved in 250 µL H2O/methanol (1:1 + 0.025 % formic acid) and transferred into HPLC 
vials.  
To 300 µL plasma, 1.7 mL sodium acetate buffer (0.1 mol/L, pH 5.0) and 50 µL β-
glucuronidase/arylsulfatase (10000/330 units/mL) were added. The samples were vortexed 
and incubated overnight at 37 °C. The prenylflavonoids were then extracted by liquid/liquid 
extraction with ethyl acetate and hexane as solvent. To the 2 mL sample, 3 mL H2O acidified 
with HCl (pH 2), 5 mL ethyl acetate and 1 mL hexane were added in a test tube. 4-
Hydroxybenzophenon was added as internal standard. After vortexing, the samples were 
centrifuged (10 min, 8000 × g) and 4 mL supernatant was transferred to a new 10 mL tube. A 
second extraction was performed in the same conditions, 5 mL supernatant was transferred 
to the same tube and the sample was dried under nitrogen. Finally, the extracts were 
dissolved in 250 µL H2O/methanol (1:1 + 0.025 % formic acid) and transferred into HPLC 
vials. All extractions were performed in triplicate. 
To test possible deconjugation of liver phase II metabolites in the rat excreta due to 
sample processing (freezing and extraction with acidified H2O), an experiment with p-
nitrophenyl-β-D-glucuronide (Sigma-Aldrich) was designed. In a first part, a 2.5 mmol/L 
solution in saline was frozen and thawed in three consecutive cycles and before, in between 
and after the absorbance was measured at 405 nm with a Tecan SunriseTM absorbance 
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reader (Tecan Benelux, Mechelen, Belgium). In a second part, a 2.5 mmol/L solution was 
prepared in acidified H2O and absorbance at 405 nm was measured before and after 20 min 
incubation at room temperature.  
Organs (2 g liver, 0.7 g kidney, 0.6 g brain and 0.15 g uterus) collected from each rat and 
extra organ samples from control rats without initial IX supplementation, were homogenized 
with 10 mL (5 mL in the case of uteri) methanol:HCl:H20 (79.9:0.1:20) with continuous stirring 
for 30 minutes and further incubated in a water bath for ultrasound exposure. Afterwards, the 
samples were centrifuged at 14000 × g for 10 min, and the supernatants were concentrated 
under reduced pressure and further filtered through a previously activated reverse phase 
C18 Sep-Pak cartridge. Afterwards, the cartridges were washed with 2 mL of MeOH. The 
samples were concentrated at 40 ºC under reduced pressure, filtered through a 0.45 µm 
Millex-HV13 filter and then analyzed by LC-MS/MS as described below. By following this 
protocol, approximately 85 % of both IX and 8PN standards were recovered when 1 µmol/L 
of each compound was added to the initial mixture. In addition, extracts were treated with 40 
units/mL β-glucuronidase from bovine liver (1000 units/g solid, Sigma-Aldrich) and 0.3 
units/mL sulfatase from Helix pomatia (10000 units/g solid, Sigma-Aldrich) to determine the 
possible conjugation to sulfate and/or glucuronide moieties upon metabolism of 
prenylflavonoids by cells.  
Analysis of prenylflavonoids in the rat biological fluids and tissues 
Quantitative analyses of urine, feces and plasma were effected by high-performance 
liquid chromatography (HPLC) using a Waters 2690 and 2695 Alliance Separations Module 
(Waters, Milford, Massachusetts, USA) equipped with a Waters 996 Photodiode Array 
Detector and Waters Millenium Software v3.20 (Possemiers et al., 2005). An extra 
confirmation of the identity of the compounds in the samples was achieved by LC-MS/MS 
analysis using a Waters Quattro micro with electrospray ionization (Stevens et al., 1997). 
Organ samples were analyzed by LC-MS/MS. The HPLC-DAD system was equipped 
with a mass detector in series (Agilent Technologies, Waldbronn, Germany). The mass 
detector was an ion-trap mass spectrometer equipped with an electrospray ionization (ESI) 
system (capillary voltage, 4 kV; dry temperature, 350 ºC). Mass scan (MS) and MS/MS 
daughter spectra were measured from m/z 100 up to 800 m/z. Collision-induced 
fragmentation experiments were performed in the ion trap using helium as collision gas, and 
the collision energy was set at 50 %. Mass spectrometry data were acquired in the negative 
ionization mode.  
Chromatographic separations of organ samples were carried out on a reverse phase 
C18 LiChrospher column (25 cm x 0.4 cm, particle size 5 µm, Merck, Darmstadt, Germany) 
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using water:acetic acid (99:1, v/v) (A) and acetonitrile (B) as the mobile phases at a flow rate 
of 1 mL/min. The gradient started with 5 % B in A to reach 55 % B in A at 15 min; 55 % B in 
A at 15 min and remaining 55 % for 5 min; 60 % B in A at 25 min, 85 % B in A at 26 min for 5 
min. UV chromatograms were recorded at 280 and 295 nm. IX, 8-PN and their corresponding 
derived metabolites were identified according to their UV and MS spectra as well as MS/MS 
fragments.  
 
Molecular analysis 
PCR-DGGE fingerprinting of the fecal and cecal bacterial 
communities 
DNA extractions of the collected SHIME material and rat fecal and cecal samples were 
performed as described by Boon et al. (2003). The 16S rRNA genes for all bacteria were 
amplified by PCR using the primers PRBA338f and P518r (Ovreas et al., 1997), and a 40 bp 
GC-clamp was added to the forward primer. DGGE was performed on amplified DNA 
samples from the rat intestinal content using the Bio-Rad D gene system (Bio-Rad, Hercules, 
California, USA) with 8 % (w/v) polyacrylamide gels and with denaturing gradients ranging 
from 45 to 60 % (Possemiers et al., 2004). The DGGE patterns were subsequently 
normalized and analyzed with the BioNumerics software v. 2.0 (Applied Maths, Sint-Martens-
Latem, Belgium). Pearson correlation and the Unweighted Pair Group Method with Arithmetic 
mean (UPGMA) were used for clustering and Multidimensional Scaling. 
Real time PCR quantification of Eubacterium limosum 
A real time PCR protocol specific for E. limosum was developed based on the method of 
Kageyama et al. (2001). Amplification was performed with an ABI Prism SDS 7000 
instrument with the PCR Master Mix (2x) SYBR® Green kit (Applied Biosystems, Foster City, 
California, USA). The primers LimoF (TGG-ATC-CTT-CGG-GTG-ACA-TT) and LimoR ( 
CTC-ATT-GGG-TAC-CGT-CAT-TC) were used at a concentration of 300 nmol/L and the 
protocol consisted of 2 min at 50 °C; 10 min at 95 °C; 40 cycles of 30 s at 94 °C, 30 s at 63 
°C and 30 s at 72 °C. Standard curves were constructed with cloned 16s rRNA genes from 
E. limosum in a concentration range from log 10 to log 2 DNA copies/µL and DNA from at 
least 10 non-target species was used as negative control to test amplification specificity. To 
avoid PCR inhibition, DNA was diluted 100 x prior to amplification. Because of this, the 
quantification limit of the protocol was log 5 DNA-copies/g or mL.  
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Statistical analysis 
The effects of bacterial status (Hop+, Hop- and GF) and sex (male and female) on the 
quantities of IX and 8-PN in plasma, urine and feces, and on the fecal counts of E. limosum, 
were analysed using a 2-way ANOVA. The effects of bacterial status (Hop+ and Hop-) and 
colon compartment on the quantities of IX and 8-PN and E. limosum counts in samples from 
the TWINSHIME experiment were also analysed using 2-way ANOVA. When ANOVA 
indicated significant differences, groups were compared in pairs with the Student-Newman-
Keuls multiple comparison test. Non-normally distributed data, namely relative organ weights 
(g/100 g BW) and proportions of 8-PN to the overall amounts of IX and 8-PN in plasma, urine 
and feces, and in the cecal and colonic content incubations, were analysed using non 
parametric tests (Kruskall-Wallis for the effect of bacterial status, Mann-Whitney for the effect 
of sex). Finally, animals were compared before (experiment 1) and after (experiment 2) E. 
limosum consumption; paired data were compared using an ANOVA for repeated 
measurements (quantities of IX and 8-PN in urine and feces) or the non-parametric Wilcoxon 
test (proportions of 8-PN to the overall amounts of IX and 8-PN in urine and feces). Unpaired 
data were compared with a 1-way ANOVA (quantities of IX and 8-PN in plasma) or the non-
parametric Mann-Whitney test (proportions of 8-PN to the overall amounts of IX and 8-PN in 
plasma and in cecal and colonic content incubations). Statistical significance was set at 
P<0.05. Calculations were performed using the Statview software (version 5.0; SAS Institute, 
Cary, NC, USA). All data were expressed as mean values with their standard errors (n = 3 or 
6). 
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RESULTS 
Effect of bacterial status and the presence of E. limosum on the in 
vitro conversion of IX into 8-PN 
In the colon compartments of the SHIME model 
The possibility to use E. limosum as a probiotic to increase the activation of IX into 8-PN 
was first tested in vitro in the dynamic TWINSHIME model. The steady state 8-PN production 
in each colon reactor before (experiment 1) and after (experiment 2) the administration of E. 
limosum were quantified (Table 5.1). When only IX was dosed to both models, no 8-PN 
production was noted in the Hop- compartment, i.e. the simulated intestine inoculated with 
intestinal microbiota derived from the low 8-PN-producing individual. In contrast, IX was 
partially converted in both the transverse and descending colon reactors of the Hop+ 
compartment, i.e. the intestinal model inoculated with intestinal microbiota derived from the 
high 8-PN-producing individual, leading to 78.4 % conversion of IX into 8-PN after complete 
passage through the simulated intestine. After administration of E. limosum, the 8-PN 
production did not significantly increase in the transverse and descending colon of the Hop+ 
compartment, whereas in the Hop- compartment, the 8-PN production reached 40 % in the 
descending colon reactor due to the administration of the strain. In parallel, the 
administration of E. limosum significantly increased the butyric acid production in the 
ascending colon from both the Hop+ and Hop- compartment respectively from 5.7 and 2.3 
mmol/L to 10.8 and 4.5 mmol/L. 
In incubations of cecal and colonic contents from GF and HMA rats 
To assess the ability of the cecum and colon contents of the individual rats to produce 8-
PN from IX, the cecum and colon contents of each rat were collected after rats' sacrifice and 
incubated in vitro with IX. After 72 h of incubation, the conversion of IX into 8-PN was 
quantified in each sample (Table 5.1). In the in vitro incubations of the intestinal contents 
from rats which were not treated with E. limosum, the 8-PN production significantly depended 
on the bacterial status of the rats (Hop+ > Hop- > GF). Whereas approximately 35 % of the in 
vitro dosed IX was converted into 8-PN in the cecal and colon incubations of the Hop+ rats, 
only very low 8-PN production was noted in the contents derived from the Hop- rats and no 
8-PN was produced in the incubations of the GF rat contents. For neither the Hop+ or Hop- 
rats, the 8-PN production significantly differed between incubations of cecal and colon 
contents. In the in vitro incubations of intestinal samples from rats which were treated before 
with E. limosum, a significantly higher 8-PN production was noted for the Hop-, but not for 
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the Hop+, bacterial status, compared to samples from non-treated rats. The intestine of the 
GF rats now contained only E. limosum, leading to 100 % 8-PN production. No significant 
differences occurred between cecum and colon incubations. 
 
Table 5.1. Percentage conversion of isoxanthohumol (IX) into 8-prenylnaringenin (8-PN) and 
concentration of Eubacterium limosum in the colon compartments of the Simulator of the Human 
Intestinal Microbial Ecosystem (SHIME) and in in vitro incubations of rat cecum and colon contents, 
depending on bacterial status Hop+, Hop- or germ-free (GF). Data are presented as average (SEM, 
n=3). 
 Only IX IX + E.limosum 
  % 8-PN/(IX+8-PN) 
E. lim 
log(#)/mL 
% 8-PN/(IX+8-PN) 
E. lim 
Log(#)/g 
+ 0.0 (0.0) n.d. 0.0 (0.0) 7.77 (3.95) Ascending 
colon - 0.0 (0.0) n.d. 0.0 (0.0) 7.82 (4.51) 
+ 38.6 (8.5)a* n.d. 53.7 (11.2)a* 7.56 (4.36) Transverse 
colon - 0.0 (0.0)b n.d. 0.0 (0.0)b 8.06 (4.12) 
+ 78.4 (5.7)a+ n.d. 90.1 (6.9)a+ 7.84 (4.28) 
S
H
I
M
E 
Descending 
colon - 0.0 (0.0)b n.d. 40.2 (2.4)b* 7.52 (4.27) 
Cecum + 32.7 (15.2)a n.d. 54.6 (10.7)a 5.58 (2.32)a 
 - 2.7 (1.2)b n.d. 9.0 (1.5)b 6.48 (2.65)a 
 GF 0.0 (0.0)c n.d. 100.0 (0.0)c 8.95 (3.65)b 
Colon + 38.4 (16.1)a / 44.3 (9.9)a / 
 - 1.6 (0.9)b / 28.9 (15.3)a / 
R
A
T
S 
 GF 0.0 (0.0)c / 100.0 (0.0)b / 
Statistical differences are indicated as follows: bold numbers: statistical difference between experiment 1 and 2. a, 
b, c: statistical difference between bacterial status Hop+, Hop- or GF (only for rats), within each experiment and 
intestinal compartment. *, +: statistical difference between intestinal compartments within each experiment and 
bacterial status. N.d.: Not detected. /: Not performed 
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Excretion of IX and 8-PN in feces and urine of GF and HMA rats 
As the excretion on day 5 and 6 were significantly correlated (r ranging from 0.62 to 0.82; 
P<0.001), the mean excretion of the 2 days was used as a new variable. 
After administration of only IX to the rats (experiment 1), no 8-PN was detected in the 
feces of the GF rats and the IX concentrations were significantly higher in the feces of these 
rats compared to the Hop+ and Hop- rats (Table 5.2). For the latter two groups, the fecal 
excretion of IX and 8-PN was not significantly different. After administration of both IX and E. 
limosum (experiment 2), the fecal 8-PN excretion increased in all rats but did no longer 
depend on the bacterial status, as no differences were noted in 8-PN excretion between the 
Hop+, Hop- and GF rats. Consistently, the excretion of IX in the GF feces decreased and IX 
excretion was similar in all rats. For both IX and 8-PN, the excretion was consistently higher 
in the males than the females when only IX was dosed, but not when IX and E. limosum 
were administered.  
In experiment 1, the bacterial status influenced the urinary 8-PN excretion (Hop+ > Hop- 
> GF) but the IX excretion was similar in all rats. The exposure to E. limosum in experiment 2 
increased the 8-PN excretion in the Hop- and GF rats but did not influence the Hop+ rats, 
resulting in similar excretions in all rats. Now, the IX excretion differed (Hop+ > Hop- > GF). 
Sex effects noted in the IX excretion in experiment 1 persisted in experiment 2. 
The relative 8-PN excretion showed similar trends (Figure 5.3). In experiment 1 (black 
bars), the bacterial status influenced the relative 8-PN excretion in both feces (Hop+ & - > 
GF) and urine (Hop+ > Hop- > GF), whereas the relative 8-PN excretion was similar in all 
rats after the bacterial treatment in experiment 2 (grey bars). This was the consequence of 
the increase by E. limosum of the fecal and urinary % 8-PN in the GF rats and, to a lesser 
extent, in the Hop- rats.  
After the treatment with E. limosum, a 35 % increase (P<0.05) in butyrate was detected 
in the feces of both Hop+ and Hop- rats to levels of 3.6 and 3.7 µmol/g. The GF rats now 
produced 1.8 ± 0.6 µmol butyrate /g. 
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Figure 5.3. Relative percentage recovery of 8-prenylnaringenin (8-PN) in the feces, urine and plasma 
of the rats after a 4-day treatment with 2 mg/kg BW IX (experiment 1) or 2 mg/kg BW IX + log 9 
Eubacterium limosum (experiment 2). Data are separately presented for each bacterial status Hop+, 
Hop- and germ-free (GF). Statistical differences are presented as follows: *: Statistical difference 
between experiment 1 and 2. a, b, c: Statistical difference between bacterial status Hop+, Hop- or GF in 
experiment 1. 1, 2: Statistical difference between bacterial status Hop+, Hop- or GF in experiment 2. 
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Concentrations of IX and 8-PN in rat plasma and different organs 
In experiment 1, the absolute plasma IX concentrations were similar for all rats whereas 
the bacterial status influenced the 8-PN concentration (Hop+ > Hop- > GF) (Table 5.15.1). 
Only in the GF rats a significant effect of E. limosum was noted on the 8-PN concentration, 
which was now similar in all rats. No sex effects were noted. The relative 8-PN 
concentrations depended on the bacterial status in experiment 1 (Hop+ & - > GF) and 2 (GF 
> Hop+ & -) (Figure 5.3). A significant effect of E. limosum was seen for both the Hop- and 
GF rats. 
All rats were weighed before and after each treatment and all organs were weighed after 
collection. Body and organ weight were not influenced by the bacterial status. No 
unconjugated IX or 8-PN was detected in any tissue. The glucuronides (IX-glucuronide, m/z- 
529; 8-PN-glucuronide, m/z- 515) were the only metabolites detected (Table 5.3). 
 
Table 5.3. Relative abundance of isoxanthohumol-glucuronide (IX-glc) and 8-prenylnaringenin-
glucuronide (8-PN-glc) in liver, kidney and uteri tissues. No metabolites were detected in brain a. 
  Only IX IX + E. limosum 
  IX-glc 8-PN-glc IX-glc 8-PN-glc 
  Male Female Male Female Male Female Male Female
+   ++ b ++ ++ ++ ++ ++ ++ ++ 
- ++ ++ - - ++ ++ +++ +++ Liver 
GF +++ +++ - - +++ ++ ++ ++ 
+ + + - + ++ ++ - ++ 
- + + - - + ++ + ++ Kidney 
GF + + - - + - + - 
+  -  +  -  + 
-  -  -  -  - Uterus 
GF  ++  -  +  + 
a The ions were extracted using the Extracted Ion Chromatogram mode and the corresponding areas were 
integrated. b Values were scored as follows: high, +++; medium, ++; low, +; not detected, -. 
 
The glucuronidase treatment of the tissue removed the glucuronides but the 
corresponding aglycones could not be detected (below detection limit because the aglycones 
showed lower ionization than their corresponding glucuronides). The quantification of the 
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peaks could not be approached because most of the UV signals were below the 
quantification limit and no glucuronide standards were available for quantification in the mass 
spectrometer.  
No metabolites were detected in brain tissues. IX-glucuronide was detected in 
approximately 95 % of rats although for individual organs the detection of the compound was 
different (recovered in 97 %, 60 % and 50 % of liver, kidney and uteri tissues analyzed, 
respectively). In experiment 1, no 8-PN metabolites were detected neither in GF or Hop- rats 
whereas 8-PN-glucuronide was detected in the 85 % of the Hop+ rats. After treatment with E. 
limosum in experiment 2, 8-PN metabolites were detected in 100 % of rats. However, the 
detection of 8-PN-glucuronide was different depending on the tissue (recovered in 89 %, 33 
% and 28 % of liver, kidney and uteri tissues analyzed, respectively). 
 
Bioavailability of IX and 8-PN in the GF rats 
From the GF rats from wks 3, 4, 5 and 6, urinary and fecal samples from all experiment 
days were collected and analyzed for IX and 8-PN, with and without enzymatic treatment. 
This allowed to assess 2 other important factors determining the bioavailability of IX and 8-
PN, i.e. the dynamics of IX and 8-PN absorption and the fraction of aglycones present in 
urine and feces. The analysis was performed on excreta from the GF rats as no bacteria with 
deconjugating activity are present in the latter rats’ intestine, allowing to assess the 
importance of enterohepatic circulation. Plasma samples of the rats were also analyzed for 
liver phase I and II metabolites. 
In experiment 1, the GF rats excreted 24.9 ± 7.6 % and 0.44 ± 0.14 % of the ingested 
dose in the first 24 h sample of respectively feces and urine (Figure 5.4). This corresponds to 
the excretion after a single oral dose of 2 mg IX/kg BW. After a five-day treatment with IX, the 
excretion in 24 h fecal and urine samples relative to the daily dose increased to respectively 
34.9 ± 10.4 % and 2.3 ± 0.7 %. In none of the samples, 8-PN could be detected. In 
experiment 2, the gavaging of the GF rats with log 9 E. limosum started 2 d before the 
administration of IX to allow the bacterium to colonize their gut. After one administration of 
IX, this led to a relative excretion of IX in feces and urine of 14.4 ± 3.1 % and 0.96 ± 0.16 %. 
However, after a single administration, 7.6 ± 3.1 % and 0.14 ± 0.03 % of ingested IX was 
already excreted in respectively feces and urine as 8-PN. At the end of the experiment, 24 h 
fecal and urine samples contained 8.4 ± 3.6 % and 1.3 ± 0.3 % of IX and 19.4 ± 4.4 % and 
0.92 ± 0.31 % of 8-PN relative to the daily dose. 
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Figure 5.4. Daily excretion of isoxanthohumol (IX) and 8-prenylnaringenin (8-PN) after five-day 
administration to germ-free rats of 2 mg IX/kg body weight (only IX) or 2 mg IX/kg body weight in 
combination with log 9 Eubacterium limosum (IX + E. limosum) (n=6).  
 
The presence of liver phase II conjugates in feces and urine was assessed by 
quantifying the amounts of IX and 8-PN recovered without enzyme treatment, relative to the 
total IX and 8-PN amounts, obtained after treatment of the samples with β-
glucuronidase/arylsulfatase from Helix pomatia. Samples from day 5 and 6 were analyzed 
and the percentage of aglycones in feces and urine are presented in Table 5.4. Statistical 
analysis showed that for both experiments, the feces contained higher percentage of IX 
aglycones and in experiment 2, the fraction of 8-PN aglycones was higher in the feces than 
in urine. Administration of E. limosum (experiment 2) led to a significant increase in free 8-PN 
excretion and in the feces, but not in urine, the fraction of IX aglycones decreased. In both 
feces and urine, the fraction of 8-PN aglycones was higher compared to the fraction of IX 
aglycones. 
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Table 5.4. Percentage aglycones of isoxanthohumol (IX) and 8-prenylnaringenin (8-PN) recovered 
from urine and feces from germ-free rats treated with 2 mg IX/kg body weight (experiment 1) or 2 mg 
IX/kg body weight in combination with log 9 Eubacterium limosum (experiment 2) (n=6) a. 
 Urine Feces 
 IX 8-PN IX 8-PN 
Experiment 1 30.6 (6.9) n.d. b 47.2 (13.1) n.d. 
Experiment 2 32.9 (7.2) 45.8 (7.2) ** 37.4 (7.8) * 68.8 (9.7) ** 
a Data were obtained by quantification of IX and 8-PN in urine and feces without and with treatment of the 
samples with β-glucuronidase/arylsulfatase from Helix pomatia. b N.d.: Not detected. * Statistical difference 
between experiment 1 and 2 at the 0.05 level (Student’s T-test, 2-tailed). ** Statistical difference between 
experiment 1 and 2 at the 0.01 level (Student’s T-test, 2-tailed).  
 
Finally, plasma samples of the GF rats from wks 5 and 6, collected at the end of the 
treatment, were investigated for the presence of free aglycones and both phase I and II liver 
metabolites. Whereas only low concentrations of aglycones were detected, IX and 8-PN 
mainly circulated as phase II glucuronides. Moreover very low quantities of metabolites with 
the same molecular mass as IX- and 8-PN-alcohols were detected, but the fragmentation 
was not completely clear. Urine samples also contained ions with similar mass as IX-glycine 
and 8-PN-alcohol, but final structure elucidation of phase I metabolites in plasma and urine 
requires further investigation. As high fractions of aglycones were found in the rat excreta, 
the possibility that a part of the conjugates present in the samples were hydrolyzed during 
the sample processing, a short experiment with p-nitrophenyl-β-D-glucuronide was 
performed. Deconjugation due to freezing-thawing or acidifying the samples with acidified 
H2O was assessed by comparing absorbance before and after the experiment. However, no 
deconjugation was observed in this experiment, indicating that the detected aglycone 
amounts in the biological samples were no artifact. 
 
E. limosum concentrations and bacterial community composition 
When only IX was dosed, the bacterium could not be detected in neither the SHIME or 
the rat cecal community (Table 5.1). After administration of the bacterium to the TWINSHIME 
model, E. limosum was detected in similar concentrations in all colon reactors of both the 
Hop+ and Hop- compartments. In experiment 2 of the rat trial, the cecal contents contained 2 
to 3 log higher concentrations for the GF compared to the Hop+ and Hop- rats.  
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The bacterial intestinal community in the rats was analyzed by multidimensional scaling 
(MDS) (Figure 5.5). In experiment 1, the community profiles in the rat feces, collected at the 
end of the IX administration, grouped based on their bacterial status. Within each cluster, the 
profiles grouped per 3, relating to the fact that the rats were housed per 3. Even though all 
GF rats had identical bacterial status, i.e. germ-free, there profiles did not group completely 
together. This is inherent to the band-based analysis technique of DGGE profiles. When no 
bands are present, i.e. in case of the GF rats, even minor color differences in the DGGE gel 
result in differences in the clustering of the profiles. In experiment 2, the community profiles 
in the feces before the administration of E. limosum and the profiles in the cecum after the 
treatment were analyzed. In both feces and cecum, clustering depending on bacterial status 
was noted, with different profiles in the feces and cecum. All ceacal profiles from the GF rats 
were identical, related with the presence of only E. limosum.  
 
 
Figure 5.5. Multi dimensional scaling comparison (based on Pearson correlation and Unweighted Pair 
Group Method with Arithmetic mean (UPGMA)) of general bacterial DGGE profiles of the microbial 
community in the rat feces and cecum. Panel A presents the fecal community profiles after a 4-day 
treatment with 2 mg/kg BW IX (experiment 1). Panel B presents the fecal and cecal community profiles 
respectively before and after a 4-day treatment with 2 mg/kg BW IX + log 9 E. limosum (experiment 2). 
Different bacterial status is indicated by different colors. 
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DISCUSSION 
Until now, the application of probiotics to improve the intestinal microbial community 
composition has mainly been limited to strains belonging to a few genera, such as 
bifidobacteria and lactobacilli (Chermesh and Eliakim, 2006). However, the human gut is 
colonized by hundreds of species and many perform important metabolic reactions or exert 
biological activities which might translate into clinical benefits (Limdi et al., 2006). Therefore, 
other bacterial groups now gain increasing interest as probiotics to improve the intestinal 
environment, e.g. butyrate producers (Takahashi et al., 2004; Kanauchi et al., 2006). In this 
research we showed that these obligate anaerobes might not only be interesting because of 
the butyrate production, but also because of their specific metabolic potential. E. limosum 
was shown in vitro and in rats to effectively reduce interindividual variability in phytoestrogen 
metabolism and exposure. 
Interindividual variation in phytoestrogen metabolism was reported by several authors 
(Lampe et al., 1998; Rowland et al., 1999) and the bacterial origin of this metabolism was 
shown by the lack of transformations noted in germ-free rats (Bowey et al., 2003). Recently 
we found that this is also true for phytoestrogens derived from hops (Possemiers et al., 2005; 
Possemiers et al., 2006). The final exposure to the active substance 8-PN may depend on 
the capacity of the intestinal microbiota to demethylate IX, a process which would only occur 
in 1/3 of the humans. The results from this study definitively show the crucial role of the 
intestinal microbiota in the production of 8-PN from IX, as 8-PN could not be detected in any 
of the biological samples from the germ-free rats after dosing IX. Colonization of germ-free 
rats with fecal microbiota from subjects with a high (Hop+) or a low (Hop-) 8PN-production 
status, also resulted in rats with different 8-PN production and excretion and inoculation of 
the TWINSHIME with these samples resulted in an 8-PN-producing (Hop+) and non-
producing (Hop-) compartment. This shows that differences in the intestinal microbiota 
determine the 8-PN production and further confirms that both the in vitro SHIME model and 
HMA rats are good models to study intestinal processes (Bowey et al., 2003; Decroos et al., 
2006), as the intestinal functionality of interest could be transferred to both models.  
Moreover, a strong correlation was found between the ability of rat intestinal contents to 
produce 8-PN from IX in vitro and the 8-PN recovery in rat excreta. Especially the 
observation that 8-PN was only detected in organs of the Hop+ rats after IX administration, 
can be considered as a definitive proof that differences in the intestinal metabolic potential 
not only determine the 8-PN production, but also the 8-PN exposure after hop consumption. 
Due to the administration of low, but physiologically relevant, IX doses to the rats, the organ 
concentrations were very low. Both liver and kidney are highly blood irrigated organs, 
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explaining the highest presence of both IX- and 8-PN-glucuronides in these organs. The 
accumulation of metabolites in the brain is hampered by the blood-brain barrier, although 
previous reports suggest that 8-PN might reach the brain (Christoffel et al., 2006). In the 
case of uteri, the presence of these metabolites is interesting because of their potential in 
vivo estrogenic or anti-estrogenic activity, as previously reported for genistein (Diel et al., 
2001).     
As differences in phytoestrogen exposure due to different intestinal metabolism may 
hamper its therapeutic applicability, E. limosum was used as probiotic to equilibrate the 8-PN 
exposure. When only IX was dosed to the TWINSHIME, no IX was activated in the Hop- 
compartment, whereas 8-PN production in the Hop+ SHIME mainly occurred in the distal 
regions, with up to 80 % conversion. After dosing the probiotic to the ascending colon of both 
SHIME compartments, high bacterial concentrations were quantified in the different colon 
regions, coinciding with 40 % 8-PN production in the distal region of the Hop- compartment. 
Moreover, the butyrate production in the ascending colon doubled, also leading to increased 
butyrate concentrations in the rest of the intestine. The survival of probiotics in the SHIME 
(Nollet et al., 1997; Kontula et al., 1998; Alander et al., 1999) has been tested several times 
and recently the efficacy of a probiotic microbial consortium to increase equol production was 
shown (Decroos et al., 2006). Our results further indicate the usefulness of the SHIME. 
Similarly, the Hop+ rats basically produced much more 8-PN compared to the Hop- rats. 
Administration of the probiotic increased the IX activation in the rat colon, as shown by the in 
vitro incubations of the rat intestinal contents. This led to a similar in vitro production of 8-PN 
in both groups of HMA rats. The GF rats were now only colonized with E. limosum, leading to 
100% in vitro 8-PN production. Molecular analysis confirmed the efficacy of the treatment. E. 
limosum could be recovered in all cecum samples, with the highest titers in the GF rats, due 
to the lack of competition with indigenous bacteria in these rats.  
Without taking bacterial status into account, the 24 h total prenylflavonoid excretion 
relatively to the daily dose reached at the end of the experiment 35.0 ± 6.6 % and 2.4 ± 0.6 
% respectively in the feces and urine. More specific data were obtained by the analysis of all 
fecal and urine samples of the GF rats. Although no pharmacokinetic data of IX are available, 
these data correspond with the few available data on 8-PN excretion. In the GF experiment, 
24 % and 0.44 % of IX was excreted in respectively feces and urine within 24 h after the first 
oral administration of IX. After single oral administration of 50 mg 8-PN to postmenopausal 
women, 23 % and 8 % were excreted within 48h respectively in feces and urine (Rad et al., 
2006). Plasma levels were also well within the range of plasma 8-PN concentrations (14.5 
µmol/L) detected after 3-month oral treatment of 6.8 mg 8-PN/kg to rats (Christoffel et al., 
2006). Finally, the 24 h urinary recoveries were similar compared to other phytoestrogens, 
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e.g. genistein (5 – 30 %) and daidzein (6 – 49 %) (Setchell et al., 2003; Blakesmith et al., 
2005).  
In experiment 1, the urinary 8-PN excretion and plasma concentrations were the highest 
in the Hop+ rats and no 8-PN was found in the GF group. This shows that intestinally 
produced 8-PN efficiently could be absorbed and enter the bloodstream. Interestingly, GF 
feces IX concentrations were much higher due to a lack of conversion, but urine and plasma 
concentrations were not. Pharmacological studies need to be performed to explain this but, 
based on data from 8-PN distribution (Rad et al., 2006), this may indicate that after 
absorption from the small or large intestine, a first-liver-pass effect and enterohepatic 
circulation occur, through which low plasma IX concentrations are regulated, resulting in high 
fecal IX concentrations. Here, 8-PN production and absorption can occur. Differences in 
pharmacokinetics between males and females may explain the sex effects noted in some 
samples and need to be studied further. 
 The assessment of phase I and II metabolites in the biological samples from the GF rats 
further confirms the importance of enterohepatic circulation of prenylflavonoids. Being a good 
model to study enterohepatic circulation of ingested compounds, due to the absence of 
deconjugating bacteria, 53 % of IX-glucuronides were recovered from the GF rats’ feces after 
the oral administration of IX. This further shows that a major part of IX is first absorbed and 
then excreted back in the intestine by the liver and is in accordance with the general scheme 
of flavonoid absorption and distribution (Liu et al., 2003; Walle, 2004). In experiment 2, 8-PN 
excretion was already observed in the GF rats within 24h after the first dose. Interestingly, 
21% of the 8-PN excreted in the feces was bound to glucuronic acid. Further research is 
needed to assess whether this was due to absorption of 8-PN followed by glucuronidation 
and recirculation. Alternatively, E. limosum might also be able to demethylate IX-
glucuronides directly. The fact that the percentage aglycones of IX decreased in experiment 
2 suggests a preference of the bacterium to demethylate free IX compared to IX-
glucuronides, but does not exclude the possibility that the latter are also demethylated. Yet, 
one important difference with previous literature data should be noted. When reviewing data 
on for instance naringenin bioavailability, the general conclusion is that hardly any free 
aglycones can be detected because of a high degree of phase II metabolism (Erlund et al., 
2001; Bugianesi et al., 2002; Manach et al., 2003; Manach and Donovan, 2004; Wang et al., 
2006). In this research however, 30 % of IX excreted in urine were aglycones and for 8-PN 
this increased even to 46 %. As we confirmed that deconjugation did not occur during 
sample processing, IX and 8-PN are not subjected to phase II metabolism to the same 
degree compared to other flavonoids, with the important consequence that the bioavailability 
of the original compound might be higher compared to other flavonoids which mainly 
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circulate as phase II metabolites. Whereas some researchers have shown that the 
administration of flavonoids through oral gavage may decrease phase II metabolism 
(Manach and Donovan, 2004), an alternative explanation is that the presence of the prenyl 
chain limits the occurrence of phase II metabolism.  
After treatment with E. limosum the % 8-PN excretion in both feces and urine were 
similar for all rats, due to a significant increase of the intestinal 8-PN production in the Hop- 
and GF rats. In the GF rat plasma, 8-PN levels were now even the highest due to very high 
8-PN production. Coincidently, butyrate concentrations increased in the feces of all rats. This 
shows that the probiotic can survive the stomach and small intestinal environment and 
equilibrates the 8-PN exposure by increasing the IX activation in low 8-PN producers to the 
levels found in high producers. This is further confirmed by the fact that the phytoestrogen 
was now detected in the organs of all rats. 
In conclusion, this work shows the promising potential of a new type of probiotics which 
improve the intestinal environment and coincidently perform interesting metabolic reactions, 
leading to the activation of specific food compounds. Orally dosed E. limosum reached the 
colon, increased the butyrate production in the SHIME and HMA rats and increased the 8-PN 
production in the distal colon of low-producing individuals. This way, the final exposure to 
hop phytoestrogens is well balanced, leading to similar possible health effects in all 
individuals.   
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CHAPTER 6 
General discussion and perspectives 
6.1 General research outcomes 
6.1.1 Positioning of this research 
The human bowel is populated by a large number of bacteria which cooperate as a 
microbial partnership and thereby fulfill a range of important functions for the human host, 
such as vitamin production and the stimulation of our immune system. Moreover, they can 
convert substances from our food or medicines, which may strongly influence their eventual 
functional activity. Therefore, the favorable impact of a food product or medicine is frequently 
not only stipulated by the original composition, but by the way the bowel bacteria convert 
biologically active components.  
People are increasingly becoming aware of the importance of this relation and the role of 
intestinal microbiota in maintaining human health. This is illustrated by the rapid expansion of 
the functional food market in the last decennium, e.g. in 2005 the European probiotic yoghurt 
market valued 1.25 billion Euro. As new developments in the scientific world now for instance 
also point out an important role of intestinal bacteria in the onset of obesity (Backhed et al., 
2004; Cani et al., 2006), future interest in intestinal microbiology and health will only 
increase. 
One of the best examples of the important food and health interaction and the impact of 
microbial transformations is the lower incidence of (hormone-related) cancers and CVD in 
countries as Korea, China and Japan, which would be linked to a high dietary intake of soy 
products (Parkin et al., 2005). Indeed, a recent meta-analysis reported that men who 
regularly consumed soy products had a 30 % lower risk of prostate cancer (Yan and 
Spitznagel, 2005). This observation has led to an extensive research for potential health-
beneficial properties related to soy intake and in many cases studies focused on a specific 
group of soybean constituents, the isoflavone phytoestrogens. This has given soy a very 
healthy image and its consumption has strongly increased, with for instance a doubling of the 
US soy market in the last five years. In this process, intestinal microbiota are believed to play 
an important role as a number of researchers now relate positive health aspects of soy intake 
to the microbial production of the active metabolite equol.  
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Next to soy, a number of other dietary products are also a source of phytoestrogens with 
possible beneficial health effects. Lignans are present in a variety of foods, such as 
beverages, vegetables and bread (Milder et al., 2005) and microbial activation reactions in 
the intestine have been shown to be crucial for final biological activity. Recently, a third group 
was added to this list, the prenylflavonoids from hops, which are mainly present in beers.  
In addition to their presence in foods, the attribution of health effects to phytoestrogens 
has led to specific applications such as the production of food supplements, where these 
compounds are claimed to relieve menopausal complaints. As the Western population is 
rapidly ageing, this market is also rapidly expanding. In Belgium, the percentage of elderly 
people (60+) is believed to increase from approximately 20 % in 2000 up to 30 % in 2030. 
Consequently, the number of women having menopausal complaints will also strongly 
increase. As it is estimated that approximately 75 % of the women between 50 and 60 years 
will have serious complaints as a result of the menopause, their number is expected to 
increase from 690,000 in 2005, up to 760,000 in 2015, indicating that the market of 
pharmaceutical products which relieve menopausal complaints will also further increase. In 
2006, the menopause segment was 11 % of the Belgian supplement market with a turnover 
of 11 million Euro. As example, Menohop, the first standardized 8-PN based supplement in 
Belgium, had a turnover of about 5 % of the menopause segment of the Belgian supplement 
market. This shows that, despite the lack of extensive knowledge on the bioavailability of this 
new group of phytoestrogens, hop is already quite extensively used as dietary supplements.  
 
6.1.2 Bioavailability of prenylflavonoids 
The aim of this work was to investigate the possible influence of intestinal microbiota on 
the bioavailability and biological activity of prenylflavonoids from hops. It was known that the 
bioavailability and biological effects of phytoestrogens belonging to the isoflavones and 
lignans greatly depends on the highly variable intestinal microbial metabolism. Yet, by 
focusing on this topic, we entered a highly unexplored field of research, as clearly shown by 
a short search in the available literature (Figure 6.1). Comparing the number of hits found for 
the keywords isoflavones, lignans or prenylflavonoids showed that research on 
prenylflavonoids has only recently started to expand. The important role of the intestinal 
microbiota in relation to the final biological activity of the former two groups is shown by the 
substantial number of hits for the most important bacterial metabolites of these two groups of 
phytoestrogens, i.e. equol and enterolactone. For the prenylflavonoids however, no other 
research group ever linked 8-PN with intestinal bacterial metabolism up to date. In addition, 
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despite the fact that some researchers reported in vitro data about liver phase I and II 
metabolism, the importance of these reactions in vivo remained to be elucidated. 
Therefore, an integrated approach of combining in vitro and in vivo research was 
followed to explore this research area. Starting from simple in vitro batch incubations with 
fecal samples, the most important research findings were further investigated in the dynamic 
SHIME model and finally in vivo animal models and a preliminary human intervention trial 
were set up to validate and show the importance of our in vitro findings.  
   
 
Figure 6.1. Number of hits in Web of Science when searching for isoflavones, lignans and 
prenylflavonoids and the relation with bacterial metabolism in the intestine (http://portal. 
isiknowledge.com). 
 
6.1.3 Main research outcomes 
The major accomplishments of this work can be separated into three parts and 
summarized as follows (Figure 6.2): 
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 First description of the role of isoxanthohumol as a proestrogen. For the first time, 
the intestinal metabolism of the prenylflavonoids xanthohumol, isoxanthohumol and 8-
prenylnaringenin from hops was investigated. Upon in vitro incubation of fecal samples, it 
was shown that intestinal bacteria can O-demethylate IX into the potent phytoestrogen 8-
PN (chapter 2). Based on experiments with the dynamic SHIME model, prenylflavonoids 
were shown to pass unmodified through stomach and small intestine and 8-PN 
production occurs in the distal colon regions (chapter 3 and 5). Uptake of IX by human 
volunteers led to urinary excretion of 8-PN, showing that intestinal IX activation leads to 
8-PN excretion in humans (chapter 3). As no 8-PN production was noted in germ-free 
rats, intestinal bacteria have a crucial role in the activation of IX. In rats harboring 8-PN 
producing intestinal microbiota, IX administration led to both 8-PN excretion and systemic 
circulation and 8-PN was found in several organs, among which the uterus. This 
indicated that intestinal IX activation leads to 8-PN exposure in vivo with possible 
biological effects (chapter 5).  
 Interindividual differences in intestinal activation of phytoestrogens. As the 
activation of IX was not detected in every fecal sample tested, the production of 8-PN 
was shown to be dependent on interindividual differences (chapter 2). An experiment 
with 51 fecal samples demonstrated that individuals can be separated in high, moderate 
and low 8-PN producers, with only 1/3 of individuals activating a major fraction of IX into 
8-PN (chapter 3). To investigate a possible relation between the activation of 
isoflavones, lignans and prenylflavonoids, a method of defining producer phenotypes was 
developed for the three groups of phytoestrogens (chapter 4). Whereas no inter-group 
correlation was found, intra-group correlations were observed in the production of 
different metabolites. Moreover correlations were found between the production of 
specific metabolites and the abundance of specific microbial groups. Finally, differences 
in intestinal 8-PN production were found to determine differences in 8-PN exposure and 
excretion in vivo as determined in human (chapter 3) and rat experiments (chapter 5). 
 Eubacterium limosum increases intestinal 8-PN production. In the search to find 
bacterial species responsible for intestinal 8-PN production, E. limosum was identified as 
capable of activation of IX into 8-PN and after strain selected we obtained a highly 
efficient 8-PN-producing strain (chapter 2). Supplementation of the strain to a non-8-PN-
producing fecal sample increased the activation of IX in the sample, showing the possible 
application of E. limosum as a probiotic to increase 8-PN production in low 8-PN-
producer phenotypes. To investigate two intestinal communities in parallel in the SHIME, 
a new TWINSHIME setup was developed (chapter 5). E. limosum increased 8-PN 
production in the model and in vivo, oral gavage of the bacterium in combination with IX 
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increased 8-PN production in germ-free and low 8-PN-producing rats, leading to a 
balanced 8-PN production, excretion and systemic exposure in all rats (chapter 5). 
 
 
Figure 6.2. Schematic overview of the main research accomplishments of this work. 
General discussion   
 144 
6.2 PART I: Contribution to scientific knowledge  
6.2.1 Activation of phytoestrogens: a microbial process 
6.2.1.1 Intestinal microbial production of phytoestrogens 
The most interesting finding of this work was the observation that intestinal microbial 
metabolism determines the exposure to the active metabolites from the three most important 
dietary groups of phytoestrogens. Microbial metabolism of the soy isoflavone daidzein into 
equol was already shown in 1932 (Marrian and Haslewood, 1932) and at present most 
researchers agree that the microbial metabolite equol has increased biological activity 
compared to daidzein (Atkinson et al., 2005). Similarly, the biological activity of lignans 
depends on bacterial activation of dietary precursors in the colon (Setchell and Adlercreutz, 
1979), leading to the production of the active phytoestrogens, i.e. END and ENL (Lampe et 
al., 2006).  
As described in chapter 2, the original goal of this dissertation was to investigate any 
possible bacterial metabolism of the most relevant prenylflavonoids from hops, i.e. X, IX and 
8-PN. In a preliminary experiment to investigate this, we separately incubated four fecal 
samples with each of the compounds. Interestingly, in this first study we found that microbial 
metabolism in the colon may also influence the biological activity of the third group of 
phytoestrogens, the prenylflavonoids from hops, and that IX acts as a proestrogen in hop 
products. Incubation of fecal samples with IX showed that intestinal bacteria are capable of 
O-demethylation of IX into the potent phytoestrogen 8-PN, which coincided with an increase 
of the estrogen response in the samples as measured with the Yeast Estrogen Screen. 
Using the dynamic in vitro SHIME model of the intestinal tract, we further unraveled this 
process and showed that IX is not metabolized in the stomach or small intestine and that 
activation of IX mainly occurs in the distal part of the colon, leading to up to 80 % 8-PN 
production (chapter 3). And whereas 8-PN was only a minor liver metabolite of IX, the only 
intestinal metabolism of the latter compound was the activation into 8-PN. Next to IX, X was 
also suggested to act as a proestrogen, as these authors reported an isomerization of X into 
IX under acid conditions of the stomach (Nikolic et al., 2004). However, no conversion of X 
into IX was noted when we tried to repeat the latter experiment. After long term incubation (8 
days) of fecal samples with X, some isomerization was noted under batch intestinal 
conditions. Yet, as this process was not observed under more relevant SHIME conditions 
(data not shown), we concluded that X probably only has a minor role as proestrogen from 
hops.   
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The important role of bacterial enzymes in this process was unequivocally shown in 
chapter 5. The production of equol and the enterolignans was shown to be performed 
uniquely by bacterial enzymes as no production of these metabolites was noted in germ-free 
rats (Bowey et al., 2003) and as the intake of antibiotics negatively influenced equol 
production (Blair et al., 2003). Similar observations were made for the activation of IX into 8-
PN. After oral administration of IX to germ-free rats, no 8-PN excretion was noted in the 
feces or urine. In a recent in vivo intervention study, IX was dosed for five days to 50 
postmenopausal women and urinary 8-PN excretion was monitored at the end of the 
administration (Bolca et al., 2007). Analysis of food frequency questionnaires filled in by the 
patients showed that recent antibiotic intake negatively influenced 8-PN excretion.  
Although some biological activities are also attributed to IX (Henderson et al., 2000; 
Miranda et al., 2000; Effenberger et al., 2005), the compound showed only very low 
estrogenic potency compared to the high activity of 8-PN (Milligan et al., 1999). We were the 
first to show that intestinal processes not only determine the final biological activity of 
isoflavones and lignans, but that this is also valid for this new group of phytoestrogens, the 
prenylflavonoids. As IX is present in beer and hop-based dietary supplements in 10- to 30-
fold higher ratios compared to 8-PN, intestinal activation of IX may increase 8-PN exposure 
at least 10-fold. 
6.2.1.2 Interindividual variability and producer phenotyping 
For isoflavones and lignans it is well known that the extent of bacterial metabolism is 
highly variable between individuals. Only about 30-50 % of humans would have the intestinal 
metabolic potential to produce equol (Atkinson et al., 2006). O-DMA production would occur 
in 80-90 % of the individuals (Kelly et al., 1993). As wide ranges in the production of the 
mammalian lignans also have been observed (Lampe et al., 1994), interindividual differences 
in the intestinal bacterial community result in interindividual differences in the exposure to 
certain phytoestrogen metabolites. 
Very similar observations were made for hop phytoestrogens. In the first preliminary 
experiment with four fecal samples, activation of IX was only detected in one of the samples, 
indicating possible interindividual differences in the capacity of the intestinal microbial 
community to convert IX into 8-PN (chapter 2). Expansion of the number of experiments to 
fecal samples from 11 and later 50 individuals (chapter 3), showed that only about 35 % of 
in vitro tested intestinal microbial communities produced medium or high amounts of 8-PN 
from IX, separating individuals in high, moderate and low 8-PN producers. In the latter 
chapter, a preliminary human intervention trial with 3 individuals was set up to investigate 
whether differences in intestinal 8-PN production would lead to differences in 8-PN excretion. 
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Indeed, 8-PN excretion was significantly higher in a high 8-PN-producing individual 
compared to urinary excretion of 8-PN in a low 8-PN producer. This was later confirmed in 
the intervention trial with 50 postmenopausal women, in which intestinal 8-PN production 
was positively correlated with urinary excretion of the compound (Bolca et al., 2007). 
In chapter 4, the number of fecal samples was further expanded to samples from 100 
individuals. These samples were incubated with precursors from the three groups of 
phytoestrogens and a new statistical analysis method was applied to define high, moderate 
and low producer phenotypes for equol, O-DMA, END, ENL and 8-PN. In the past, producer 
phenotypes were defined as producer or non-producer (Rowland et al., 2000; Setchell and 
Cole, 2006). Yet, our results show that except perhaps for equol production, individuals 
cannot easily be separated in only two phenotypes, as an important part of the population 
showed intermediate production of the active metabolite. Therefore, the concept of moderate 
producer phenotype was introduced in this chapter. Interindividual variability which was 
quantified in this chapter, was shown to be in correspondence with previous reports. The 
difference in percentage low and moderate 8-PN producers between chapter 3 and 4 was 
due to the new analysis method, as the general trends in 8-PN production were similar in 
both experiments, e.g. 60 % of individuals produced less than 20 % 8-PN.    
Interindividual differences in 8-PN production were further investigated in chapter 5 by 
using the new in vitro TWINSHIME setup and the in vivo human microbiota associated rat 
model. Both models were inoculated with fresh fecal samples from either a high (Hop+) or 
low (Hop-) 8-PN-producing individual. As previously shown for metabolism of daidzein into 
equol (Decroos et al., 2006), the functionality of the microbial ecosystem to metabolize 
phytoestrogens was conserved between the original fecal sample and the final SHIME 
microbial community. Whereas no 8-PN production was detected after administration of IX to 
the Hop- SHIME compartment, up to 80 % conversion of IX was noted in the distal region of 
the Hop+ compartment. Similarly, in vitro incubation of rat colon contents showed higher 8-
PN production in the Hop+ compared to the Hop- rats. The same was also seen in vivo as, 
after oral gavage of the rats with IX, the 8-PN excretion was higher in the Hop+ rats.  
In addition, this experiment not only showed that intestinal activation of IX determines 8-
PN excretion in vivo. Plasma concentrations in the Hop+ rats were significantly higher than in 
the Hop- rats and 8-PN metabolites were only detected in the liver, kidney and uterus of 
Hop+ rats. Therefore, it can be concluded that differences in the intestinal producer 
phenotype also for hop phytoestrogens determine the systemic exposure and possible health 
outcomes related to the consumption of IX-containing hop products. Therefore, future studies 
are needed to assess the stability of specific producer phenotypes over longer periods and to 
explore the final importance of this variability towards specific clinical effects.  
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6.2.1.3 Factors influencing phytoestrogen exposure 
Driven by the observation of the importance of interindividual differences in 
phytoestrogen metabolism, the nutritional and scientific world is highly interest to determine 
the factors influencing the producer phenotypes of the active molecules. Yet, at present a 
clear answer is not available. Given the exclusive action of the intestinal microbiota in this 
process, factors determining the production of specific metabolites should be related with the 
intestinal microbial community composition and/or activity. Next to this, the precursors need 
to reach the colon for transformation, a process which may also differ between individuals. 
A number of studies have tried to relate the production of equol and enterolignans with 
the presence of specific bacteria, finding species belonging to different genera, which were 
able to perform specific reactions in the transformation pathways (described in Clavel et al., 
(2005; 2006)). For instance, in one of these studies the number of END- and ENL-producing 
bacteria was quantified in the intestinal community (Clavel et al., 2005). Whereas END 
producers belonged to the dominant microbiota (6 × 108 CFU/g), ENL producers were less 
abundant (3 × 105 CFU/g). This confirms our observation of the higher abundance of the 
END (63 %) compared to the ENL producer phenotype (39 %). In addition, some studies 
related metabolism of phytoestrogens with shifts in bacterial populations. This was noted 
after in vitro incubation of 2 fecal samples with SDG (Lampe et al., 2006) and after 
supplementation of the diet with isoflavones in a human intervention study (Clavel et al., 
2005). In contrast, in chapter 4 we analyzed the in vivo abundance of specific bacterial 
groups, without intervention in the diet and subsequently identified the producer phenotype of 
the most important phytoestrogen metabolites. This enabled us to relate specific phenotypes 
with the composition of the normal intestinal community. Next to the negative correlation 
between END production and the E. rectale – C. coccoides cluster, the positive correlation 
between O-DMA production and MPB and between equol production and SRB were the 
most interesting results. 
Although further studies are needed to elucidate the meaning and relevance of these 
correlations, it may be hypothesized that the abundance of SRB or MPB could be seen as 
markers of a specific colonic environment. As described in the chapter 4, hydrogen 
metabolism is very important in the intestine and SRB and MPB have a key role in this 
process. Our observation of a possible link between hydrogen metabolism and equol or O-
DMA production confirms previous findings about the relation between daidzein metabolism 
and H2 availability (Decroos et al., 2005). Yet, further investigation is needed to elucidate the 
nature of this interaction and whether the MPB and SRB are directly involved in this process 
or act as markers for specific environmental conditions. Moreover, several studies showed a 
possible relation between phytoestrogen metabolism and differences in the diet (Rowland et 
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al., 2000; Blakesmith et al., 2005), which in turn may be related with specific intestinal 
conditions. 
Next to variability in exposure to 8-PN due to differences in the intestinal community 
composition or activity, individual variation in bioavailability may also be influenced by other 
factors. These factors can be both of physiological (differences in body weight, body 
composition and gastric motility) and molecular nature (differences in activity or synthesis of 
transporters or enzymes involved in biotransformation) (Kerb et al., 2001; Erlund, 2004). For 
instance, interindividual variation in biotransformation enzymes such as CYP, UGT and 
sulfotranferases have been reported frequently (Her et al., 1996; Fisher et al., 2000; Dai et 
al., 2001). In the liver, UGT1A1 was shown to be the most active enzyme involved in the 
conjugation of 8-PN (Nikolic et al., 2006). However, the rate of metabolism by this enzyme 
varies as much as 30-fold between individuals. As glucuronidation determines to a large 
extent the first-pass effect and the fraction reaching the bile, low expression of UGT1A1 
would lead to reduced clearance of the flavonoids. If liver demethylation of IX has any 
biological relevance, this may also be a source of variability as polymorphisms in the 
responsible enzyme CYP1A2 have been noted (Saito et al., 2005; Guo et al., 2006). 
Moreover, the activity of such enzymes can be influenced by environmental factors such as 
drugs, diet, alcohol consumption and smoking (Crankshaw and Hines, 1992; Zhang et al., 
2002; Czekaj et al., 2005; Iba et al., 2006). 
6.2.1.4 Identification and selection of an efficiently 8-PN-producing bacterium 
After the observation of the metabolic activation of IX in the intestine, the next step was 
to attempt identifying bacteria which may be able to perform this O-demethylation reaction. A 
number of reports described the isolation of bacteria which could perform specific metabolic 
steps in the conversion of daidzin into equol or O-DMA and recently a microbial consortium 
of four bacterial strains, capable of equol production from daidzein, was isolated at LabMET 
by anaerobic culturing and colony picking (Decroos et al., 2005). Instead of trying to isolate a 
bacterium capable of 8-PN production, we selected a number of bacterial strains which were 
previously identified as capable of O-demethylation of aromates or involved in methanol 
metabolism (see Table 1.3). Ordering of the strains from culture collections and incubation of 
the bacteria with IX gave only 2 strains which tested positive for 8-PN production, 
Eubacterium limosum and Peptostreptococcus productus (chapter 2). After strain selection 
by repeated incubation, a highly efficient 8-PN-producing strain of E. limosum was obtained, 
which is now deposited as a new strain (LMG P-23546).  
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6.2.2 Degradation of 8-PN by intestinal bacteria 
In our first report about intestinal metabolism of prenylflavonoids from hops (chapter 2), 
we showed that IX and X would have a high metabolic stability, whereas 8-PN was sensitive 
towards bacterial degradation. This could be explained based on the structure-function 
relationships predicting the sensitivity of flavonoids towards bacterial degradation, as 
described in chapter 1. 8-PN has all necessary OH groups making it a good substrate for 
bacterial enzymes, whereas the methylation of IX and X would increase the stability of both 
compounds (Simons et al., 2005). However, these preliminary conclusions were based on 
long term (8 days) batch incubations. Short term experiments under more relevant intestinal 
conditions in the SHIME (chapter 3) showed however only minor degradation of 8-PN. 
Moreover, no specific phenolic degradation products could be detected in the urine after 5-
day administration of a hop extract to postmenopausal women (Bolca et al., 2007).  
This would be in contrast with the intestinal metabolism of naringenin, the non-
prenylated counterpart of 8-PN, from which is known that it is rapidly degraded by bacterial 
enzymes (Rechner et al., 2004). In order to compare the metabolism of naringenin and 8-PN, 
a batch experiment was performed in which three fecal samples were incubated with each 
compound under conditions described by the latter authors (Figure 6.3).  
 
 
Figure 6.3. Bacterial degradation of 8-prenylnaringenin (left) and naringenin (right) in fecal samples 
from three different individuals. 
 
This shows that 8-PN indeed has a remarkably high intestinal metabolic stability 
compared to the non-prenylated naringenin, which was almost completely degraded in one of 
the incubations. Interindividual difference in the degradation of naringenin was reported 
before, separating individuals into high, moderate and low degraders (Erlund, 2004).  
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In contrast with naringenin, this means that 8-PN would hardly be degraded by bacterial 
enzymes during its passage through the intestine, possibly due to sterical hindrance and 
differences in polarity because of the prenyl chain. These results would have the important 
implication that, in contrast with easily degradable flavonoids (Rechner et al., 2004; Cermak 
et al., 2006), the fraction of 8-PN reaching the colon directly, after enterohepatic circulation or 
due to intestinal activation of IX may have an increased bioavailability, as high metabolic 
stability favors the possibility of being absorbed from the colon to exert systemic biological 
effects.  
 
6.2.3 Consequences of bioavailability on biological activity 
The new findings presented in this work about the fate of flavonoids after intake further 
highlight the importance to study the bioavailability and transformations of dietary 
compounds in order to assess the real biological activity inside the human body. In most in 
vitro studies, the main focus is the assessment of the specific biological activity of the original 
flavonoid and mostly of the aglycone, even though flavonoids mainly occur in foods as 
glycosides. Furthermore, in most cases the oral bioavailability of dietary flavonoids is 
generally very low due to extensive phase I and II metabolism in the intestinal epithelium and 
liver and microbial metabolism in the colon. Therefore, not the original flavonoids but their 
metabolites will reach systemic circulation and may exert biological effects when reaching 
specific target organs (Spencer et al., 2004; Walle, 2004; Wang et al., 2006).   
Because of the extremely diverse metabolic potential of the liver, many studies now 
focus on the influence of liver phase I metabolism towards final biological activity, mainly by 
using liver microsomes. However, although CYP-mediated metabolism of flavonoids has 
been shown in vitro in liver microsomes, its importance remains to be shown in vivo or in 
intact hepatocytes where conjugative metabolism may be expected to compete with 
oxidation (Otake et al., 2002; Walle, 2004). This was also observed for 8-PN. Whereas liver 
microsome incubations yielded a number of phase I metabolites (Nikolic et al., 2004), 80 % 
of the 8-PN metabolites produced by hepatocytes consisted of the phase II 8-PN-
glucuronides. And also in the experiment with germ-free rats (chapter 5), phase II 
metabolism dominated over phase I metabolism and the fact that almost 50 % of IX in the 
feces consisted of IX-glucuronides shows an important enterohepatic recirculation. In view of 
the exposure to 8-PN after hop consumption, one consequence of this would be that phase I 
activation only plays a minor role and that mainly IX and 8-PN conjugates can be expected 
after passage through the liver. This is confirmed by the fact that no 8-PN could be detected 
after administering IX to germ-free rats.  
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A second consequence of extensive phase II metabolism is the observation that the oral 
bioavailability of flavonoid aglycones generally is very low (Liu et al., 2003; Walle et al., 
2004). Mainly the conjugates circulate through the body and can exert systemic effects. 
Although glucuronides/sulfates sometimes remain biologically active or even have increased 
activity (Manach et al., 1998; Morand et al., 1998; Fang et al., 2003), conjugation can also 
decrease the biological activity. Glucuronides of daidzein and genistein showed 10- and 40-
fold less affinity for the estrogen receptors compared to the aglycones (Zhang et al., 1999). 
However, two remarks should be made. A number of flavonoids might already have effects in 
the intestine itself, e.g. protective effects of X against colon cancer (Gerhauser et al., 2002), 
leading to a high biological activity independent of (low) oral bioavailability (Scalbert et al., 
2002; Walle et al., 2004). Moreover, many reports now describe that both conjugation and 
deconjugation can occur in the tissues at cellular level, which may influence the amount of 
active aglycon in the tissues (Santner et al., 1984; Zhu et al., 1996; Spencer et al., 2004). 
Moreover, in the experiment with the GF rats, an important fraction of IX and especially of 8-
PN were recovered in urine as the (active) aglycones. As aglycones of 8-PN were not 
detected in plasma and organ samples, due to too low concentrations in these samples, 
further research is needed to assess whether aglycones of 8-PN also reach the target 
organs. Yet, Rad et al. (Rad et al., 2006) have also detected up to 13 % of free 8-PN in 
plasma after administration of 8-PN to postmenopausal women, indicating that 8-PN is less 
intensively conjugated than other flavonoids such as naringenin. Similar as for the lower 
intestinal degradation of 8-PN compared to naringenin, structural differences may be 
responsible for this difference.   
A last, and for hops most important, consequence of enterohepatic circulation is that a 
major fraction of the ingested flavonoids reach the colon where they become substrates for 
bacterial enzymes. A negative consequence would be that extensive colonic degradation of 
flavonoids leads to a minor importance of the fraction reaching the colon towards the 
bioavailability of the intact compound (Cermak et al., 2006), although some resulting phenolic 
metabolites would have specific activities (Kim et al., 1998). In contrast, hop prenylflavonoids 
were shown to be metabolically stable against colonic degradation, making them good 
substrates for absorption from the colon or specific metabolic processes. As our studies 
showed that the intestinal bacteria are responsible for in vivo demethylation of IX, the 
combination of an extensive liver-first-pass effect, a high metabolic stability of 
prenylflavonoids and a good absorption of 8-PN from the gut create ideal circumstances for 
efficient intestinal activation of IX and increased exposure to 8-PN after hop consumption.   
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6.2.4 Future perspectives 
In this work, the crucial role of intestinal bacteria in the activation of IX into the potent 
phytoestrogen 8-PN was elucidated. This dissertation allows to give some answers on 
questions related to why some people experience biological effects of hop intake whereas 
others do not. Yet, a lot of future research is needed to understand the whole story. 
Important questions which remain are: What is the final biological relevance of this process 
towards clinical symptoms? Is the bioavailability of orally dosed 8-PN different from 
intestinally produced 8-PN? Are interindividual differences related to the presence of specific 
bacteria or to general bacterial composition? Can E. limosum be used to change the 8-PN-
producer phenotype in humans? Can we further improve the in vitro research from this work 
to avoid animal experiments as much as possible? Only the last two questions will be 
addressed, as some preliminary experiments were already performed on these topics.       
6.2.4.1 Integration of in vitro and in vivo research: a multidisciplinary approach 
The growing awareness of the relation between food and health and the involvement of 
gastrointestinal microbiota points out the significance of conducting research in the field of 
human nutrition and intestinal microbiology related to the bioavailability of active compounds. 
Whereas in vivo epidemiological or intervention studies have the advantage of incorporating 
all physiological parameters, they have the problem of being time-consuming and costly. 
Moreover, it is very difficult to perform in-depth mechanistic studies to identify specific 
microbial processes in the gut because of limited accessibility. In vitro studies have the 
advantage of being cost effective, easy to use and allow thorough investigation of specific 
processes. Yet, simple setups such as batch systems lack physiological relevance. Simulator 
systems of the gastro-intestinal tract give a closer approximation to fermentative bacterial 
events that occur in situ and therefore can be placed at the interface between in vitro and in 
vivo research. Several in vitro models of the human gut have been developed with varying 
degree of complexity (Molly et al., 1993; Minekus et al., 1995; Hack and Selenka, 1996; 
Oomen et al., 2002). For instance, the TIM model mainly focuses on the small intestine, 
incorporating absorption from the gut, but puts less emphasis on long term culturing of 
intestinal microbiota (Minekus et al., 1999). In contrast, the SHIME is less complex and 
allows long term study of the intestinal microbial community but insufficiently simulates the 
upper intestine. 
Yet, the outcome of in vitro studies always has to be validated in vivo with animal models 
and with human studies. Therefore, as postulated by the European PASSCLAIM project Gut 
Health and Immunity (Cummings et al., 2004), the most ideal approach to identify the impact 
of intestinal microbiota on nutrition-related human health, would be to identify the process in 
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vitro in batch studies, then move up to more relevant simulator systems and finally to validate 
the results with animal models and human intervention trials. This is exactly the approach 
which was followed in this study. Starting from simple batch experiments, the activation of IX 
into 8-PN was discovered and interindividual differences were assessed (chapter 2, 3 and 
4). Then, the dynamic SHIME and later TWINSHIME were used to investigate the nature of 
this process and the application of E. limosum as a probiotic in detail (chapter 3 and 5). 
Subsequently, this in vitro research and the final role of the intestinal microbiota in the 
process were validated by performing the experiment with germ-free and HMA rats (chapter 
5). Moreover, this was also the first time that the SHIME was validated as a model and the 
very similar results obtained from the TWINSHIME and rats definitely show the usefulness of 
the SHIME to study intestinal microbial processes. Finally the biological relevance of the in 
vitro results was shown in a preliminary human intervention trial (chapter 3) and a trial with 
50 subjects was recently successfully finished (Bolca et al., 2007). 
However, further improvements of this integrated approach to study intestinal processes 
can be made in the future. Up to now, the SHIME has been combined with a number of 
physicochemical, microbiological, enzymatic and molecular tools (Possemiers et al., 2004). 
Moreover some bioassays with microorganisms are available to assess for instance the 
estrogenic or (anti-)carcinogenic properties of microbial metabolites. Therefore, the next step 
would be to combine the in vitro digestion technology of the SHIME with various cell cultures. 
Combination of SHIME suspensions with mucus secreting HT29 cells would allow the study 
of the bacterial adhesion to the intestinal wall, an intestinal process which is very important in 
vivo in the interaction with the immune system or the onset of pathogenesis (Hwang et al., 
2005; Schneeman et al., 2005). Combination with Caco-2 cells would allow to investigate 
intestinal transport processes (Nikolic et al., 2006). Finally, the use of Caco-2 (Burns and 
Rowland, 2004) or MCF-7 cells (Rasmussen and Nielsen, 2002) would allow the study of the 
biological activity of microbial metabolites in a more relevant test model compared to the 
microbial models. To show the possibility of combining the SHIME with cell cultures, samples 
from experiment 1 with the TWINSHIME (see chapter 5) are now being used to set up Caco-
2 cell culture assays, among which the COMET Assay and transport experiments, and with 
MCF-7 cells (the E-screen). These experiments are still being performed but to encourage 
further research in the field of increasing the biological relevance of SHIME experiments, a 
preliminary experiment from the E-screen is reported below. 
The MCF-7 breast cancer cell line expresses high levels of ERα as well as low levels of 
ERβ (File et al., 2005). The use of MCF-7 cells as a tool to measure the estrogenic /anti-
estrogenic activities of different compounds (E-Screen) has been widely accepted (Bryant et 
al., 2005; Larrosa et al., 2006). In a first experiment, increasing concentrations of pure 
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standards were dosed to the cell cultures and proliferation was assessed (Figure 6.4). The 
concentration required to induce half of the maximum response (IC50) was 0.9 and 3 nmol/L 
for the standards 8-PN and IX, respectively.  
 
  
Figure 6.4. Sigmoidal (estrogenic) response upon incubation of MCF-7 cells with IX and 8PN. 
Estrogenic activity was measured as the induction of cell proliferation of treated cells versus the non-
treated (control) cells. A higher induction means a higher estrogenic activity. 
 
The estrogenic activity in this assay can be expressed as the ratio of the value of 
induction of cell proliferation achieved (IF) and the concentration to needed to reach half of 
the maximum induction (IF/IC50). In this experiment, the activity of 8-PN (0.47 L/nmol) was 4-
fold higher than that of IX (1.80 L/nmol), and slightly less than previously reported due to a 
lower IF value in this experiment (Overk et al., 2005). Growth inhibition was detected from 5 
and 10 µmol/L for IX and 8-PN, respectively. This is in accordance with the dual effect of 
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phytoestrogens such as isoflavones, i.e., estrogenic/anti-estrogenic activities at low 
concentrations but anti-proliferative effect at higher concentrations (Cornwell et al., 2004). 
Then, based on the results from the TWINSHIME experiment 1, IX and 8-PN were mixed in 
proportions found in the intestine (1/1 ratio). The simultaneous incubation of MCF-7 cells with 
increasing amounts of the mixture of IX and 8-PN showed that both compounds have an 
additive rather than synergistic/antagonistic effect in the induction of cell proliferation (Figure 
6.5). The next step will be now to add SHIME samples directly to the cell cultures instead of 
mimicking the concentrations found in the reactors with standards. However, sample 
preparation is crucial and needs further to be optimized in order to remove all bacteria from 
the samples, without removal of the active compounds. 
 
 
Figure 6.5. Induction of MCF-7 cell proliferation in the presence of both IX and 8PN (in equimolar 
concentrations). Differences were evaluated over the control. *, **, *** Statistical difference at 
respectively the 0.1, 0.05 or 0.01 level. NS: Not significant. 
 
6.2.4.2 Characterization of 8-PN-producing strain P-23546 
Because the use of the in chapter 2 identified and selected strain of E. limosum may 
lead to some promising applications (see 6.4.3), a patent application was filed disclosing the 
use of the strain for the demethylation of prenylflavonoids (US60665109). Yet, in this 
research we only focused on the potential application of the strain and further research is 
needed to completely characterize the strain and identify the origin of increased 8-PN 
production compared to the original strain. Elucidation of the underlying mechanism of 
demethylation in E. limosum may also be a major step to explain the interindividual 
differences in the intestinal capacity to produce 8-PN.  
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Belonging to the group of homoacetogens and previously shown to be able to O-
demethylate isoflavonoids (Hur and Rafii, 2000), it can be postulated that E. limosum uses 
the same enzyme system for demethylation as characterized for other homoacetogens 
(Kaufmann et al., 1997; Kaufmann et al., 1998; Kaufmann et al., 1998; Engelmann et al., 
2001). This system would include four distinctive proteins and involves demethylation of the 
substrate at the cell surface, transfer of the methyl to tetrahydrofolate and finally the 
production of CO2 and acetate. Therefore, the most straightforward way to confirm that E. 
limosum uses a similar system to demethylate IX into 8-PN would be to monitor the end 
products in which the methyl group of IX has been incorporated after 8-PN production. To do 
this, chemically labeled IX was recently synthesized, which contains a 13C-methoxy group at 
the 5-position. Monitoring of 13C-CO2 and acetate will allow to investigate the 8-PN 
production pathway followed by the bacterium. 
Another point of interest is the high level of specificity of the demethylation reaction. 
Whereas a number of bacteria are known to demethylate methoxylated aromates, we only 
found two bacteria capable of 8-PN production and only E. limosum could be selected for 
increased 8-PN production. It would therefore be interesting to identify what makes E. 
limosum different from other acetogens, as this also may provide more insight in the origin of 
the interindividual difference noted in the intestinal production of 8-PN. As the upregulation of 
the 8-PN production in the selected bacterium may be related to an upregulation of the 
responsible enzyme’s expression, we performed a protein extraction and gel electrophoresis 
of a culture of the original and the selected strain (Figure 6.6). The fact that visual differences 
were observed between the profiles, warrants further investigation towards differences in 
protein expression related with the increased activation of IX into 8-PN. 
 
 
Figure 6.6. Protein profiles of the original strain of Eubacterium limosum and selected strain LMG P-
23546. To do this, proteins were extracted from exponential cultures of both strains by sonication and 
separated by 1D gel electrophoresis. Visual differences are indicated by the black rectangle. 
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6.3 Estrogenicity of beers: a new perspective 
6.3.1 Beer and health 
The relation between beer and health is subject to much debate. As a alcohol-containing 
beverage, many researchers focus on possible health effects related to alcohol intake. A 
number of studies report harmful effects such as cardiac arrest, hepatotoxicity and increased 
risk for mouth, esophageal and liver cancer (World Cancer Research Fund, 1997). On the 
other hand, epidemiological studies have convincingly demonstrated reduced mortality from 
coronary hearth diseases among moderate alcohol consumers compared to abstainers, 
supporting positive health effects of moderate consumption of alcohol containing beverages 
(Rimm et al., 1991; Gun et al., 2006; Mukamal et al., 2006; Pai et al., 2006).   
Traditionally, red wine has obtained a ‘healthy image’ despite its alcohol content, often 
referred to as the French Paradox (Kopp, 1998). In contrast, there are conflicting reports 
concerning the relationship between beer consumption and cancer risk. For example, Kato et 
al. (1990) have shown that beer drinkers have an increased risk of colorectal cancer, 
whereas Riboli et al. (1991) reported no association between beer and colon cancer. An 
inverse association between moderate beer consumption and endometrial (Swanson et al., 
1993) and prostate cancer (Jain et al., 1998), but a relationship between beer and lung 
cancer was suggested (Potter et al., 1992). Yet, several studies demonstrated that red wine 
and beer are equally beneficial in protecting against coronary hearth disease (Klatsky et al., 
1997; Innes, 1998) and a series of animal studies have shown that beer may prevent 
carcinogenesis and osteoporosis and that beer provides plasma with significant protection 
from oxidative stress (Kondo, 2004). Moreover, non-alcoholic components from beer would 
inhibit carcinogenesis induced by heterocyclic amines, found in cooked or grilled meat and 
fish (Arimoto-Kobayashi et al., 1999; Nozawa et al., 2006), giving a whole new dimension to 
drinking a beer at a barbecue.   
 
6.3.2 Estrogen exposure after beer consumption 
When reviewing the prenylflavonoid composition of beers (Table 1.2), it is clear that the 
picture about possible estrogen related effects of beer consumption now looks different. Our 
findings show that the exposure to the phytoestrogen not only depends on the original 8-PN 
concentrations, but also on the amount of IX which is transformed inside the colon. As beer 
IX concentrations often are in the range of one to a few mg/L, the amount of IX generally 
exceeds 8-PN 10 to 30 times. If IX is transformed in the intestine and if 8-PN is well 
absorbed from the colon, this process could easily tenfold increase the 8-PN exposure.  
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As further studies are needed to investigate the final biological relevance of these 
findings, one can now only postulate about whether or not regular moderate beer 
consumption could lead to exposure to biologically active 8-PN concentrations. However, 
some indications of biological activity can be given based on data from hop-based dietary 
supplements. These supplements generally contain a daily dose of about 100 µg 8-PN and 
claim specific biological effects such as alleviating menopausal discomforts. Although many 
of these claims lack thorough scientific background (Coldham and Sauer, 2001), a first 
prospective placebo controlled study was recently published which indicated that a hop 
supplement, standardized on 100 µg 8-PN/d, exerted favorable effects on menopausal 
discomforts after 6 weeks (Heyerick et al., 2006). This would mean that 8-PN concentrations 
as low as 100 µg/d might have biological relevance. However, these supplements also 
contain 10- to 20-fold higher IX concentrations. In view of the recent findings, the active 8-PN 
dose inducing the effect may be higher due to intestinal activation of IX. But nevertheless, if 
further studies show that these hop supplements really have beneficial health outcome, 
similar effects might also be expected from moderate beer consumption, as the 
prenylflavonoid composition in beers is similar as in these medicinal products (Table 1.2).  
 
6.3.3 Beer and the menopause: to your good health! 
From the brewers point of view, the valuable constituents of hops are mainly the bitter 
acids and hop oils. Normally, hops are added to the boiling wort as the α-acids isomerize 
under these conditions into the bitter iso-α-acids. As the hop oils, providing the hoppy flavour 
to beer, are evaporated or degraded during wort boiling, ‘late hopping’ (hop dosage at the 
end of the wort boiling) can be used to increase the hoppy flavor. However, in view of the 
biological activity of hop prenylflavonoids, it might also be interesting to increase the 
polyphenol content in beers to create ‘bioactive beers’. Because of the beneficial properties 
attributed to X, strategies are now being developed to increase X concentrations in beer to 
several mg X/L (Wunderlich et al., 2005). The authors state that it should even be possible to 
create beers with up to 20 mg X/L. Similarly, attempts have been made to increase the 
phytoestrogenicity of beer (Heyerick et al., 2002).  
But in the same line of thinking it would also be interesting to increase the amounts of IX 
in beers, which can be activated in the intestine. Diverse extraction methods by ethanol and 
CO2 at different pressures lead to residues that contain more than 30 % X. In commercially 
filtered beers, the elevation of X or IX levels is limited because of losses during the 
production process. However, the dosage with special X extracts after fermentation or yeast 
filtration, could increase prenylflavonoid contents (Forster et al., 2002). Using these X-
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enriched hop products, several brewing studies led to the production of beers with IX 
concentrations higher than 8 mg/L (Wunderlich et al., 2005). Beyond that, X extracts can be 
added to any kind of turbid and slightly bitter beverages, which on their part can be the basis 
of beer mix beverages (Forster et al., 2002). These strategies would of course increase the 
possible health outcome of moderate beer consumption related to 8-PN exposure. 
However, this would imply efficient intestinal conversion of IX into 8-PN and this is 
exactly hampered by interindividual differences in the intestinal transformation potential. 
Therefore, two extra strategies could be developed to ensure that everybody would be 
exposed to similar 8-PN doses. One could try to increase 8-PN concentrations in beer by 
implementing a prefermentation step in the process to convert IX with our selected bacterium 
in the hop extract or beer intermediate. An alternative would be to create a ‘probiotic beer’ by 
combining an IX-rich beer with the appropriate bacterium which can activate the IX in the 
intestine. There is currently already interest towards possible probiotic effects of beer 
consumption. Some beers still contain living yeast to which probiotic properties are now 
attributed (Kuhle et al., 2005). Moreover, some beers are produced by lactic acid 
fermentation, so there might be interest in the exploration of ‘probiotic healthy beers’. 
In conclusion, even though these recent findings may have important biological 
consequences, the final question remains whether beer will ever have a ‘healthy image’ or in 
other words: does the average beer consumer like to associate drinking a beer with health 
effects? A recent survey among menopausal women to investigate a possible market for a 
beer relieving menopausal complaints, indicated that women cannot imagine to buy or order 
a special ‘menopause beer’ but rather buy pharmaceuticals (personal communication). 
Therefore, the recent finding about intestinal activation of IX might mainly find its applications 
among the producers of hop-based dietary supplements and pharmaceuticals.  
Yet, one interesting footnote can be made. Czech people drink an average of 161 liters 
of beer each year, almost double the amount consumed in the US, and although surveys 
suggest that the number of women partaking of this ‘liquid bread’ is slowly decreasing, Czech 
women still consume more beer than the average European women. Therefore it is not 
surprising that in the Czech Republic the introduction of menopause beers in the market 
actually could work and that researchers from the Czech Republic’s Research Institute for 
Brewing and Malting recently created a low-alcoholic menopause beer that contains 10 times 
higher phytoestrogen contents. In a two-month study with 20 postmenopausal patients, a 
daily consumption of 0.3 L beer reduced acute climacteric conditions. This shows that 
menopause beers rich in IX or 8-PN indeed might find applications in countries with a long 
tradition of beer consumption among women.  
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6.4 PART II: applications and future developments 
6.4.1 Overview 
The results presented in this dissertation might also have implications for the presence or 
use of phytoestrogens in diet, dietary supplements and pharmaceuticals. In addition, the 
selection of an efficiently 8-PN-producing bacterium may lead to different practical 
applications. This can be summarized as follows (Figure 6.7):   
 
 
Figure 6.7. Schematic overview of the main practical applications of the research findings presented 
in this work. 
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6.4.2 Social relevance 
As a result of the ageing of the Western society, the number of women experiencing 
menopause-related clinical symptoms also increases. At the same time, the risk/benefit ratio 
of classical treatment strategies, i.e. hormone supplementation, are now questioned due to a 
number of negative results from recent studies. This makes the discussion about what would 
be the most optimal strategy to improve the quality of life of menopausal women, now more 
important than ever.  
After publication of the results from the Women’s Health Initiative (WHI) (Writing Group 
for the Women's Health Initiative, 2002) and Million Women Study (MWS) (Million Women 
Study, 2003), much emphasis was put on the risks of HRT and both patients and physicians 
became reluctant to prescribe and follow HRT. However, it is now clear that the results from 
these large scale studies should be carefully interpreted and not necessarily mean that the 
risks of HRT always outweigh its proven positive clinical effects (Haimov-Kochman and 
Hochner-Celnikier, 2006). This is illustrated by the official position of for instance the Belgian 
and North American menopause societies (Society, 2004) on the use of HRT, stating that 
this therapy still is an efficient and scientifically proven strategy to relieve menopausal 
complaints and to treat clinical symptoms such as osteoporosis, but the prescription should 
be considered separately for every individual patient and should be re-evaluated each year.      
The combination of available literature on phytoestrogens with the new findings show 
that such an individual evaluation for the most optimal treatment strategy would also be 
optimal in case of prescribing phytoestrogens to relieve menopausal complaints. At this 
moment, the choice for a specific phytoestrogen supplement happens more or less 
randomly. Now it is however clear that for all these supplements, the final activity depends 
into a large extent on the capacity of the intestinal microbiota to produce the active 
compound from precursors present in the supplement. As we further elucidated the important 
interindividual differences in this transformation potential, we also showed that not every 
woman will benefit equally from a specific supplement. Therefore, many women now try a 
number of different supplements before finding one that really improves their symptoms. 
However, the current knowledge about intestinal phytoestrogen production could make it 
possible to develop the most efficient treatment strategy for each women individually. By 
developing a simple test to evaluate the individual intestinal producer phenotype of each 
group of phytoestrogens, physicians could immediately decide which group of supplements 
should give the best biological effects for that individual. Therefore, an individual ‘intestinal 
production’-based instead of random selection of phytoestrogens, could be an important step 
in increasing the efficiency of phytoestrogens to relieve menopausal complaints. 
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6.4.3 Practical applications 
6.4.3.1 Production of 8-PN 
Because of their high biological activity, the potential use of prenylflavonoids in 
pharmaceutical or cosmetic preparations has gained increasing attention. Examples are the 
use of IX to prevent bone density lowering (patent WO04089359), the use of hop extracts in 
medicaments having estrogenic properties (WO02085393), and the use of IX or X in food 
products claiming anti-inflammatory or anti-aging properties (WO03090555). Moreover, the 
use of 8-PN in cosmetics for skin treatment (WO0239960) and HRT (WO05037816) has also 
been suggested. Yet, in order to use prenylflavonoids for specific applications, appropriate 
methods are required to obtain large quantities of pure compounds, which can then be 
formulated into specific products. 
X was first isolated, partially characterized and named by Power et al. (1913) and since 
then the compound has extensively been studied. Yet, although some attempts were made 
(Vandewalle, 1961), up to now a chemical synthesis procedure has not been described in 
literature, which is probably due to the unique properties of hops. The external accumulation 
of X and related prenylflavonoids in lupulin glands significantly facilitates their extraction with 
solvents such as methanol, ethanol, chloroform, acetone or ethyl acetate (Stevens et al., 
1997). From these extracts, X can further be purified using chromatographic techniques 
(Renault et al., 2006). Moreover, X-enriched products are readily available from sources 
such as supercritical CO2-extracted hops, a waste product of the hop-processing industry. 
Therefore, different procedures have now been developed specially to recover and purify X 
from hops. Examples of these extraction methods are disclosed in GB patent 2392447, US 
patent 4121040 and German patent 19939350. Synthetic routes for X production may 
however be interesting to use labelled X in in vivo studies. In one approach, 13C- or 14C-
labelled precursors were supplied to hop sprouts. This led to the incorporation of the label at 
specific positions of X, producing 13C- or 14C-labelled X by biolabelling (Berwanger et al., 
2005; Berwanger et al., 2005). 
In contrast, due to its low concentrations in hops, 8-PN is not easy to extract from hops. 
For the detection of 8-PN in hops and hop products, a variety of analytical methods can be 
used (Stevens et al., 1999; Tekel et al., 1999; Rong et al., 2000) and isolation of 8-PN from 
hops may be feasible for the production of small quantities of reference standards (Chadwick 
et al., 2005). Yet, the use of large quantities of 8-PN requires an efficient synthesis 
procedure. Because of its potential application as base material in pharmaceutical 
preparations, synthesis strategies have been developed to produce 8-PN by prenylation of 
the commercially available naringenin. The first synthesis of 8-PN was achieved by the low-
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yielding unselective direct C-prenylation of naringenin with 2-methylbut-3-en-2-ol in dioxane 
in the presence of boron trifluoride (Jain et al., 1978; Mizobuchi and Sato, 1984) or starting 
from phloroacetophenone (Sherif et al., 1982). Later, small-scale four-step chemical 
synthesis was performed by europium(III)-catalized Claisen rearrangement, with 42-45 % 
overall yield (Gester et al., 2001). Alternatively, DMX could be produced from the 
commercially available phloroacetophenone (Diller et al., 2005). 8-PN can then be produced 
by isomerization of the latter compound. Yet, in this reaction DMX will also partially be 
converted into 6-PN. 
However, at the time this research was performed, no commercially interesting method 
to produce 8-PN was available. As we obtained a highly-efficient 8-PN-producing bacterium, 
one straightforward application could therefore be the fermentative production of 8-PN by O-
demethylation of IX. The latter compound can readily be obtained by isomerization of X-
enriched extracts, e.g. in a 5 % ethanolic KOH solution (Possemiers et al., 2005). IX can then 
be purified and activated into 8-PN under anaerobic conditions. Alternatively, the isomerized 
extract as such can be used in the fermentation. After production of 8-PN, the compound 
needs to be purified from the fermentation broth in order to be used as base material. 
As proof-of-principle, a short term fed-batch fermentation experiment was designed in a 
Braun Biostat® M fermentor (2 L vessel), filled with 1.5 L Brain Heart Infusion broth (with 0.5 
g/l cystein-HCl) (Figure 6.8). The fermentor was sterilized by autoclaving and made 
anaerobic by flushing the system for 1 h with N2. After this, the reactor was inoculated with a 
2-days old E. limosum culture and 25 mg/L IX was added to the fermentation liquid. The 
fermentation was performed at 37 °C for 2 weeks, without pH control. From day 1 on, three 
times/day 200 mL anaerobic Brain Heart Infusion broth (with 0.5 g/l cystein-HCl), containing 
25 mg/L IX was dosed to the reactor at 10 mL/min and simultaneously 200 mL fermentor 
content was removed. A 10 mL sample was withdrawn from the effluent for chemical analysis 
at day 0, 1, 2 and from then on every 2 days. Respective conversion of 0 %, 43 % and 100 % 
were obtained from the samples on day 0, 1 and from day 2 until the end of the experiment.  
This experiment showed that the selected strain was able to convert IX into 8-PN in a 
fermentation based strategy. Yet, the synthesis procedure proposed by Gester et al. (2001) 
has now further been optimized for larger-scale 8-PN production and submitted as a patent 
by Schering AG (EP1524269). Moreover, an efficient chemical demethylation procedure of IX 
was recently described with scandium trifluoromethanesulfonate and potassium iodide 
without any need of protection (Wilhelm and Wessjohann, 2006) and a patent has been filed 
disclosing the production of 8-PN by chemical demethylation of IX (WO2006099914). As 
these procedures are promising to produce large amounts of 8-PN as base material, the 
application of E. limosum to produce 8-PN as such, was not further investigated in this work. 
General discussion   
 164 
 
Figure 6.8. As a proof-of-principle of the application of Eubacterium limosum to produce 8-PN from IX 
by anaerobic fermentation, a fed-batch fermentation experiment was designed in a 2-liter Braun 
Biostat® M fermentor. 
 
If this application would further be investigated in the future, growth- and conversion 
kinetics and selection of appropriate fermentation conditions require further investigation in 
order to optimize the process. Because of the low water solubility of IX and 8-PN and 
because of the antibacterial properties of 8-PN, fermentation under aquatic conditions will be 
restricted to the administration of low IX concentrations (below 50 mg/L) to the medium. As 
this would limit commercial production of large amounts of 8-PN, fermentation in biphasic 
water/organic solvent systems may be a good alternative (Leon et al., 1998). In these 
systems, the organic phase acts as a reservoir for substrates and metabolites, allowing the 
administration of much higher concentrations, and it maintains a low concentration of 
inhibitory compounds in the aqueous phase. Moreover, it enhances the in situ recovery of the 
end product (Laane et al., 1987). Finally, if the enzyme system of E. limosum responsible for 
the production of 8-PN from IX can be identified and cloned, biotechnological applications 
may enhance or facilitate the microbial production of 8-PN.  
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6.4.3.2 Prefermentation of hop supplements 
Because of the marked interindividual differences in the metabolism of and exposure to 
phytoestrogens, differences in the health outcome of phytoestrogen consumption can also be 
expected. This might especially have important consequences when producing dietary 
supplements or pharmaceuticals based on hop extracts and using these products for 
instance to relieve menopausal complaints. For example, a patent was filed for the 
production of hop extracts having estrogenic and anti-proliferative bioactivity 
(WO2005058336). These extracts are standardized on specific amounts of 8-PN in order to 
create dietary supplements with similar positive activity in all individuals. However, these 
extracts also contain IX in 10- to 20-fold higher ratio. Now it is clear that intestinal metabolism 
of IX may lead to major differences in the final active dose to which individuals are exposed. 
The variable capacity of these extracts to relieve menopausal complaints in a recent study 
(Heyerick et al., 2006) may therefore be related with variable intestinal 8-PN production. 
Unfortunately, this study was designed before the findings of this work and no relation was 
made between the response and the intestinal 8-PN-producer phenotype of the women.   
Moreover, the results from the latter study indicate that the original 8-PN dose present in 
the supplements might be too low to induce a full biological effect, as only about 50 % of the 
tested population strongly responded to a 12-week daily administration of the hop extract, 
containing 100 µg 8-PN (Heyerick et al., 2006). The results obtained from the rat experiment 
and human trial in this work show that intestinal activation of IX significantly influences the 8-
PN exposure after IX consumption. All together, this shows that extra activation of IX in the 
intestine may be necessary to induce a full response to the hop extracts and that differences 
in intestinal 8-PN production would limit their effectiveness in a part of the population. 
One strategy to overcome this variable biological effect could therefore be to remove the 
source of all variability, i.e. to remove IX by converting it into 8-PN. The most straightforward 
way to do this, is to use the selected E. limosum strain for the in vitro bioconversion of IX in 
the hop extract. Further research is needed to confirm the possible application of E. limosum 
as a whole cell biocatalyst (Cruz et al., 2004) to convert IX into 8-PN in the final hop extract 
or in one of the intermediates of the hop extraction process. The use of biphasic 
bioconversion systems could also be a solution here to enhance the efficiency of the 
process, to reduce the inhibitory effects of compounds in the extract and to facilitate further 
processing of the demethylated extract. This way, a new extract is obtained enriched in 8-PN 
which contains much less IX, leading to lower variability in the final active dose reaching the 
body, as the importance of intestinal 8-PN production is greatly reduced. This extract can 
then be used as such in food supplements or mixed with other extract, e.g. extracts rich in X, 
to obtain standardized extracts with a desired composition. 
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It is difficult to say whether the use of a fermented hop extract would be considered as a 
novel food according to the European directive EC/258/97. According to this regulation, a 
novel food cannot enter the market before it is sufficiently shown that the foods or food 
ingredients are not dangerous for the consumer or nutritionally disadvantageous by replacing 
other products to such an extent that their normal consumption is too limited. However, 
products which have a long history of safe use are excluded from this regulation. As beer has 
been consumed for many centuries and as the prenylflavonoid composition of some beers is 
very similar to the composition of the previously mentioned hop extracts, a history of safe use 
could apply for these products. As 8-PN is a naturally occurring plant substance, the 
fermentation of hop extracts could then be seen as a simple extra step to enrich 8-PN in the 
extract, similar to chemical extraction procedures, making it not a novel food. However, due 
to the new fermentation process, a product with different composition is created and as no 
food products exist which have increased 8-PN contents, demethylated extracts might be 
seen as novel foods, requiring a lot of extra research. 
A more important constraint, at least for Belgium, is the legislation on the use of herbals 
in pre-formulated dietary supplements. Whereas no limitations are set for 8-PN in foods, the 
daily 8-PN dose in hop extracts is limited to 400 µg. If all IX would be transformed into 8-PN 
in the extract itself, these limits would be crossed as they contain 1 to 2 mg IX. Therefore, in 
that case mixing of the extract would be necessary to reduce the final 8-PN content.   
6.4.3.3 Eubacterium limosum as a probiotic 
Up to now, legislation on the use of herbals does not take the aspect of bioavailability 
into account and only considers the original content of active substances in food products or 
supplements. However, in this work we showed that not the original 8-PN content in hop 
extracts, but rather the combination of the IX content and individual intestinal 8-PN-producer 
phenotype determines the final 8-PN exposure. It is now clear that the limit of 400 µg 8-PN/d 
makes no sense, as the exposure in some women might exceed this after intake of a 
supplement, due to high intestinal IX activation. Moreover, the activity probably strongly 
depends on this intestinal activation. Therefore, it has to be investigated whether dosing only 
400 µg 8-PN/d by using for instance reformulated fermented hop extracts, might be too low 
to achieve sufficient biological effects.  
In addition, 8-PN pharmacokinetics might very well be different when 8-PN is orally 
dosed and absorbed in the small intestine, compared to dosing IX and 8-PN absorption from 
the colon after intestinal production. In the rat experiment it was shown the aglycone fraction 
in urine of 8-PN (46 %) was higher compared to IX aglycones (32 %). Further research is 
needed to investigate the cause of the noted difference, but different site of absorption may 
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play a role. This would indicate that colon absorption leads to a higher bioavailability of free 
8-PN compared to small intestinal absorption. Furthermore, it is important to note that 
comparative in vitro permeability studies with small intestine and colon epithelia revealed that 
the colon epithelium is more permeable to the natural estrogen E2 than the small intestine 
epithelium (van der Bijl and van Eyk, 2003). Finally, intestinal production of 8-PN could also 
be seen as some kind of slow release formulation of the active compound. When 8-PN is 
given orally, it is rapidly absorbed from the gut, leading to a rapid peak 8-PN plasma 
concentration and subsequent elimination (Rad et al., 2006). However, when IX is given, a 
major part of the compound is absorbed from the small intestine which can reach the colon 
only after enterohepatic circulation. This leads to a longer exposure of the gut bacteria to IX, 
a subsequent 8-PN production and a prolonged exposure to 8-PN. As example, a similar 
observation was made when free naringenin was dosed to rats compared to naringenin-
rhamnoglucoside. As naringenin first needs to be released from the latter compound in the 
colon, naringenin exposure was postponed and prolonged when this compound was dosed 
(Felgines et al., 2000). 
As current regulations only look at the initial content of 8-PN, and because of possible 
differences in pharmacokinetics, it might be more interesting to convert IX into 8-PN in situ in 
the intestine, instead of prefermenting the hop extracts. Or in other words, how can one 
change the phytoestrogen metabolism status in individuals, making sure that everybody is 
exposed to increased amounts of the active metabolites? The answer could be simple: by 
introducing bacteria capable of metabolizing the precursors from food inside the intestine of 
non-producers, i.e. by using specific probiotics to increase the intestinal production of 
bioactive metabolites. 
A first attempt to apply this strategy to phytoestrogen metabolism has been made in our 
group by Decroos et al. (2005; 2006). These researchers isolated a consortium of four 
bacteria who cooperate to convert daidzein into equol. When they administered this 
consortium to a fecal sample from a non-producer or to the dynamic SHIME model, a 
significant increase in equol production was noted. These positive results encouraged us to 
apply the same strategy for hop phytoestrogens. Administration of our selected strain to a 
fecal sample from a non-producing individual increased the 8-PN production in these 
samples (chapter 2). And also in the TWINSHIME setup and in the rat experiments (chapter 
5), it was shown that the administration of E. limosum increased the 8-PN production in non- 
or low-producing intestinal communities, bringing them up to the level of the high 8-PN-
producer phenotypes. This proved that using specific probiotics may help to balance the 
exposure to bioactive compounds in all individuals, leading to a more equal exposure 
between individuals.  
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Last years, E. limosum has gained increasing attention because of its beneficial effects 
on the colonic environment in inflammatory bowel disease, possibly attributed to its butyrate-
producing capacity (Kanauchi et al., 2002; Kanauchi et al., 2005). Indeed, administration of 
the bacterium to the TWINSHIME doubled the butyrate production in the ascending colon 
compartments and a 35 % increase of butyrate excretion was noted in the feces of the rats 
treated with E. limosum. As this means that the strain increased both butyrate and 8-PN 
production, the bacterium might be a suitable candidate probiotic to increase intestinal 8-PN 
production.  
Yet, even though its application looks promising, this does not mean that it would be 
realistic to directly commercialize a hop extract combined with E. limosum as a probiotic. In 
our rats experiments, no harmful effects could be detected after a short term treatment with 
the bacterium, meaning that no effect on body or organ weight or behavior could be 
detected. Moreover, the bacterium is known as a normal inhabitant in most individuals (Wang 
et al., 1996). Still, the bacterium does not have the Generally Recognized as Safe (GRAS) 
status, and can therefore not be used for food related purposes. In a Joint FAO/WHO 
Working Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food 
(London Ontario, Canada, 2002, http://www.who.int/foodsafety/), guidelines were designed to 
define which data need to be available for the evaluation of new probiotics. These include a 
wide range of in vitro and in vivo animal and human experiments for strain identification, 
safety assessment and functional characterization. This makes that actual application of E. 
limosum as a probiotic might take several years as considerable research still needs to be 
performed. Therefore, it is important to look for alternative, putatively easier to implement 
strategies to increase in situ 8-PN production after the intake of hop-based dietary 
supplements. 
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SUMMARY 
The Western population is rapidly ageing. Consequently, the number of women having 
menopausal complaints will also strongly increase. The menopause starts when the female 
hormone balance is disturbed as result of a decrease in the production of the female 
hormone 17β-estradiol (E2) and manifests itself by symptoms such as hot flushes, insomnia 
and osteoporosis. On average, the symptoms start around the age of 51 and about 75 % of 
the women between 50 and 60 years will experience serious menopausal complaints. Since 
in Belgium alone this group is expected to increase from 690,000 in 2005, up to 760,000 in 
2015, the market of products which relieve menopausal complaints will also further increase. 
Traditionally, menopausal complaints are treated by means of so-called Hormone 
Replacement Therapy (HRT), a treatment in which semi-synthetic female hormones are 
administered. This leads to an equilibration of the hormone balance and a reduction of the 
complaints. However, recent long term scientific studies show important negative side effects 
of this therapy, such as increased risk of coronary heart disease and breast cancer. As a 
result of this negative publicity, many women now turn back to more natural alternatives, to 
food supplements which contain phytoestrogens. These natural plant components mimic the 
activity of the female sex hormone E2 and therefore could help lowering menopausal 
complaints. Moreover, less negative side effects would be associated with this therapy. Most 
commercial supplements have been developed with soy isoflavones, but the last years new 
supplements based on other groups of phytoestrogens appear, among which lignans from 
flaxseed. 
Recently however, a third group of phytoestrogens was identified. For centuries, hops 
were primarily used as essential ingredient in the beer brewing process. Yet, already in 1953 
it was suggested that hops could be a source of hormonal compounds. It was observed that 
female hop pickers frequently suffered from gynecological problems which may be related to 
long-term exposure to estrogens. This rapidly led to the use of hops in medicinal applications 
and in 1999, the most potent phytoestrogen known so far was isolated, the prenylflavonoid 8-
prenylnaringenin (8-PN). Prenylflavonoids are present in the female hop cone and besides 8-
PN, this group also includes the chalcones xanthohumol (X) and desmethylxanthohumol 
(DMX) and the flavanones isoxanthohumol (IX) and 6-prenylnaringenin (6-PN). The 
discovery of 8-PN has led to numerous studies in which several health promoting properties 
of 8-PN were suggested, such as hormonal activity and protection against osteoporosis and 
cancer. Now, some hop products are already commercially marketed for lowering 
menopausal complaints. 
Summary 
 172 
"A healthy colon is a prerequisite for good health" (Boerhave, +/- 1700). Long before 
modern science, it was commonly known that processes in the bowel have a large impact on 
health. Now it is clear that the colon is populated by a huge number of bacteria which 
cooperate as a microbial partnership and thereby fulfill a range of important functions for the 
human host, such as vitamin production and immune stimulation. Moreover, they can convert 
substances from our food or medicines, which may strongly influence their eventual 
functional activity. Therefore, the favorable impact of a food product or medicine is frequently 
not only stipulated by the original composition, but by the way the intestinal bacteria convert 
biologically active components. 
Previous research has already shown that the intestinal bacterial community has a 
crucial impact on the final biological activity of the two commonly known groups of 
phytoestrogens. Already in 1932, equol was described as a unique bacterial metabolite of the 
isoflavone daidzein and in 1979 it was shown that intestinal bacteria can convert the inactive 
plant lignans into mammalian lignans (‘enterolignans’) enterodiol (END) and enterolactone 
(ENL). As clinical studies suggest that both equol and the enterolignans would have 
increased biological activity compared to their precursors present in food, it is now commonly 
accepted that intestinal bacterial activation of isoflavones and lignans significantly influences 
health effects related to phytoestrogen intake. A restriction however, is that only 30-50 % of 
the Western population appears to have the intestinal metabolic potential to produce equol. 
As wide ranges in the production of the enterolignans also have been observed, 
interindividual differences in the intestinal bacterial community result in interindividual 
differences in the exposure to and health effects from specific phytoestrogen metabolites. 
At the time this research was started, a number of in vitro data already suggested high 
biological activity of prenylflavonoids and a first hop extract standardized on 100 µg 8-PN 
was recently marketed, claiming to relieve menopausal complaints. However, little was 
known about the fate of these compounds in the human body. It was already known for a 
long time that hops caused stronger estrogenic effects in some women compared to others, 
indicating an important role of the aspect of bioavailability towards the final biological activity. 
Yet, no data were available about the bioavailability of prenylflavonoids. As it was known that 
variable microbial metabolism determines health effects of other phytoestrogens, the main 
objective of this work was to explore the possible role of the human intestinal microbial 
community in determining the bioavailability and biological activity of prenylflavonoids from 
hop. To do this, an integrated in vitro – in vivo approach was followed, combining batch 
incubations with SHIME, rat and human studies. 
To get a first idea of possible conversions of the three most important hop 
prenylflavonoids, 8-PN, IX and X, by intestinal bacteria, a number of fecal samples were 
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incubated in vitro with each of the compounds. Possible activation or degradation of the 
compounds was assessed by LC-MS and the Yeast Estrogen Screen, a bioassay in which 
the estrogenic potency of compounds is quantified. Whereas 8-PN and X remained more or 
less stable in the batch incubations, the most interesting observation was that IX can be 
converted into 8-PN by bacterial O-demethylation. Further research demonstrated that, just 
as it is the case for the other phytoestrogens, interindividual variability in the intestinal 
microbial community determines the extent of this activation reaction. After administration of 
IX to 51 different stool samples, these could be classified in high (8/51), moderate (11/51) 
and low (32/51) 8-PN producers. 
Inside the female hop cone, X is the most important component and IX and especially 8-
PN quantities are low. However, during beer brewing or the use of hops for medicinal 
applications, most of the X is converted into IX, as a result of which IX is the most important 
substance in the final application. Because this component itself has no estrogenic activity, 
previous research focused on the 8-PN concentrations when assessing hormonal effects 
related to hop intake. For example, medicinal hop products are now standardized on a 
specific 8-PN quantity and 8-PN concentrations in beer normally are below 100 µg/L, as a 
result of which possible estrogenic effects after beer consumption were always considered 
negligible. However, since IX quantities in beer and hop products can be 10 to 50 times 
higher compared to 8-PN, the discovery of the activation of IX by intestinal bacteria can 
importantly change this vision. If all IX would be converted into 8-PN, the exposure to the 
plant hormone will also strongly increase. But because not everyone appears to have the 
correct bacteria to convert IX, only 1/3 of the population could experience this conversion. 
Therefore, this process was further examined in detail. 
To evaluate the complete passage of the prenylflavonoids from stomach to colon under 
more representative in vitro conditions, the Simulator of the Human Intestinal Microbial 
Ecosystem (SHIME) was used. By addition of IX to the feed, which enters the system 3 times 
per day, it was determined that IX passes unchanged through the stomach and small bowel 
and that more than 80 % IX was converted into 8-PN in the large intestine, with increasing 
production towards the distal colon. As this conversion was accompanied with a strong 
increase in estrogenic activity of the colon samples, it was definitively shown in vitro that the 
intake of IX might indeed lead to an important exposure to 8-PN. 
To answer the question whether differences in intestinal 8-PN production would also 
determine differences in 8-PN exposure after intake of IX in vivo, an experiment with two 
groups of human microbiota associated (HMA) rats was set up. One group of 12 rats 
harbored a high 8-PN-producing intestinal community (Hop+) whereas a second group of 12 
rats were associated with low 8-PN-producing microbiota (Hop-). A third group of 12 germ-
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free rats (GF) acted as control. After a five-day administration of 2 mg IX/kg body weight, 
three main conclusions could be made. Firstly, the unique role of intestinal bacteria in the 
activation of IX was definitively shown as GF rats produced no 8-PN. Secondly, intestinal 
activation of IX leads to both urinary excretion of 8-PN and systemic exposure to 8-PN, as 
the metabolite could be recovered in plasma, liver, kidneys and uterus of the rats. Finally, 
interindividual differences in intestinal metabolic potential to activate IX determine the final 
exposure to 8-PN, as plasma and urine 8-PN concentrations were higher in the Hop+ 
compared to the Hop- rats. 
To extrapolate these results from animals to humans, a preliminary human intervention 
trial was designed with three individuals, which were previously screened as harboring 
respectively a high, moderate and low 8-PN-producing intestinal community. Five-day 
administration of IX to these individuals confirmed that differences in intestinal 8-PN 
production determine the 8-PN exposure, as the high-producing individual also excreted 
most 8-PN in the urine.  
To our best knowledge, this is the first description that the final activity of all important 
phytoestrogens depends on metabolism by intestinal microbiota. As food contains mixtures 
of precursors from the different groups, the final exposure to phytoestrogens depends on the 
combined intestinal activation of each precursor within each individual. Therefore, we tested 
100 fecal samples for the production of equol, O-DMA (an alternative daidzein metabolite), 
END, ENL and 8-PN by separately dosing the different precursors to each sample. A new 
statistical method was used to define the producer phenotype (high, moderate or low) for 
each metabolite. To evaluate possible relations between the activation of isoflavones, lignans 
and prenylflavonoids within one individual, specific phenotypes were correlated with the 
occurrence of other phenotypes. Whereas no inter-group correlation was found, indicating 
separate pathways for the different groups, intra-group correlations were shown, i.e. a 
positive correlation between END and ENL production and negative correlation between 
equol and O-DMA. Furthermore, equol and O-DMA production were positively correlated with 
the abundance of respectively sulfate reducing bacteria and methanogens, giving a first 
indication that specific intestinal conditions, possibly related to H2 transfer, determine the 
metabolic fate of daidzein. 
The final quantity of the hop plant hormone 8-PN inside the body was thus shown to be 
determined by IX activation in the colon. As this conversion does not happen to the same 
extent for everybody, this finally explains why some people experience more effect of hop 
products than others. As this implies high variability in the efficacy of hop-based 
pharmaceuticals, the next question in this work was: What can be done to ascertain that 
everybody is exposed to similar amounts of 8-PN after consumption of hop products? To 
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answer this question, we tried to identify intestinal bacteria which are able to activate IX. A 
range of bacteria was tested and eventually Eubacterium limosum was identified and after a 
selection procedure, the bacterium now efficiently converts IX into 8-PN. Because this finding 
can imply a range of applications, its commercial use was protected by a patent application. 
A first application would be to use the bacterium as a probiotic to increase intestinal 8-PN 
production. If the bacterium could be dosed to low 8-PN-producing individuals and convert IX 
in situ in the bowel, administration of the bacterium in combination with IX could increase the 
8-PN production in these individuals, thereby also increasing the exposure to 8-PN. After 
preliminary positive indications from batch tests, a new TWINSHIME model was developed. 
This system consists of two SHIME models operated in parallel and allowed simultaneous 
investigation of high (Hop+) and low (Hop-) 8-PN-producing microbiota in the SHIME. When 
only IX was administered to both systems, 8-PN production happened only in the Hop+ 
model. In contrast, administration of both IX and E. limosum led to 8-PN production in both 
Hop+ and Hop- models. To finally assess that using E. limosum could indeed increase the 
exposure to 8-PN in vivo, the three groups of rats were used from the previously described 
experiment. Oral administration of both IX and the probiotic to all rats started 8-PN 
production in the GF rats and increased 8-PN production and systemic exposure in the Hop- 
rats up to the level of the Hop+ rats. Therefore, the possible use of E. limosum to balance the 
exposure and possible health effects of 8-PN in all individuals was definitively shown. Other 
applications which need further investigation include prefermentation of IX in the hop product 
to remove the source of variability and fermentative 8-PN production for the use of 8-PN as 
base material in pharmaceutical applications. 
In conclusion, it was demonstrated for the first time that, as noted for other 
phytoestrogens, the exposure to the potent phytoestrogen 8-PN not particularly depends on 
the initial concentration of the active component in beer or hop extracts, but rather on a 
combination of the IX concentrations present in the product and the intestinal metabolic 
potential to activate IX into 8-PN. Moreover, a E. limosum strain was selected which was 
able to O-demethylate IX into 8-PN. As interindividual differences in the microbial capacity to 
activate IX lead to differences in systemic 8-PN exposure, strategies were developed to 
balance the 8-PN exposure in all individuals. One of these strategies, in which E. limosum is 
used as a probiotic for in situ 8-PN production, was further investigated and its possible 
application was shown in vitro and in vivo.  
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SAMENVATTING 
De vergrijzing van de Westerse bevolking neemt sterk toe. Hierdoor zal ook het aantal 
vrouwen met menopauzale klachten sterk toenemen. De menopauze start gemiddeld op 51 
jaar en begint wanneer de hormoonbalans bij de vrouw verstoord wordt door vermindering 
van de productie van het vrouwelijke geslachtshormoon 17β-oestradiol (E2) en gaat gepaard 
met symptomen zoals warmteopwellingen, slapeloosheid en osteoporose. Ongeveer 75 % 
van de vrouwen tussen 50 en 60 jaar zou ernstige menopauzale klachten hebben. Vermits in 
België alleen al verwacht wordt dat de groep zal toenemen van 690.000 in 2005 tot 760.000 
in 2015, zal ook de markt van middelen die menopauzale klachten verlichten verder 
toenemen.  
Klassiek worden menopauzale klachten behandeld via de Hormoon Supplementatie 
Therapie (HST), waarbij semi-synthetische hormonen ingenomen worden. Hierdoor wordt de 
hormoonbalans in evenwicht gebracht en verminderen de klachten. Recente studies tonen 
echter belangrijke negatieve gevolgen van deze therapie, zoals toename van het risico op 
hartslagaderbreuk en borstkanker. Door al deze negatieve publiciteit grijpen steeds meer 
vrouwen nu terug naar meer natuurlijke alternatieven, naar voedingssupplementen die fyto-
oestrogenen bevatten. Dit zijn natuurlijke plantaardige componenten die de werking van E2 
nabootsen en daardoor helpen bij de verlichting van menopauzale klachten. Bovendien zou 
deze therapie minder gevaarlijke neveneffecten vertonen. De meeste voedingssupplementen 
zijn ontwikkeld op basis van isoflavonen uit soja, maar de laatste jaren verschijnen steeds 
meer supplementen op basis van de andere fyto-oestrogenen, waaronder de lignanen uit 
lijnzaad. 
Recent werd echter nog een derde groep fyto-oestrogenen geïdentificeerd. Sinds jaar 
en dag is de hopplant bekend als essentieel ingrediënt van de bierbereiding, maar al in 1953 
werd gesuggereerd dat hop ook een bron van hormonale verbindingen zou kunnen zijn. Er 
werd immers waargenomen dat hoppluksters vaak gynaecologische problemen vertoonden, 
wat te wijten kan zijn aan een langdurige blootstelling aan oestrogenen. Al snel ontstonden 
medicinale toepassingen en eind vorige eeuw werd uit hop het tot nu toe krachtigste fyto-
oestrogeen geïsoleerd, namelijk het prenylflavonoïd 8-prenylnaringenine (8-PN). Deze 
prenylflavonoïden zijn aanwezig in de vrouwelijke hopbel en de groep omvat naast het 8-PN 
ook xanthohumol (X), desmethylxanthohumol, isoxanthohumol (IX) en 6-prenylnaringenine. 
De ontdekking van 8-PN heeft geleid tot een hele reeks studies waarin aangetoond is dat 8-
PN gunstige effecten kan vertonen, zoals hormonale activiteit en bescherming tegen 
osteoporose. Nu zijn al enkele hopproducten commercieel beschikbaar voor het verzachten 
van menopauzale klachten. 
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“Een gezonde colon is essentieel voor een goede gezondheid” (Boerhave, +/-1700). 
Lang voor de moderne wetenschap, was het algemeen bekend dat wat in de darm gebeurt 
een groot effect kan hebben op de gezondheid. Nu is het duidelijk dat de darm bevolkt wordt 
door een goot aantal bacteriën die intens samenwerken en zo een reeks belangrijke functies 
vervullen voor de mens. Zo produceren ze een aantal vitamines en versterken ze ons 
immuunsysteem. Bovendien kunnen ze stoffen uit onze voeding of geneesmiddelen 
omzetten, waardoor de activiteit ervan sterk beïnvloed wordt. Hierdoor zal het gunstige effect 
van een voedings- of geneesmiddel vaak niet enkel bepaald worden door de oorspronkelijke 
samenstelling, maar door de manier waarop de darmbacteriën biologisch actieve 
componenten omzetten. 
Eerder onderzoek heeft reeds aangetoond dat de bacteriële darmgemeenschap de 
uiteindelijke activiteit van de twee bekendste groepen fyto-oestrogenen sterk beïnvloedt. Al 
in 1932 was bekend dat darmbacteriën het isoflavoon daidzein kunnen omzetten naar equol 
en in 1979 werd aangetoond dat inactieve lignanen uit de voeding omgezet worden in de 
darm in de enterolignanen enterodiol (END) en enterolacton (ENL). Aangezien klinische 
studies suggereren dat zowel equol als enterolignanen een hogere biologische activiteit 
hebben dan hun precursoren uit de voeding, wordt nu algemeen aangenomen dat activatie 
van isoflavonen en lignanen door darmbacteriën de gezondheidseffecten van deze fyto-
oestrogenen sterk beïnvloedt. Een beperking is echter dat slecht 30-50 % van de Westerse 
bevolking in staat zou zijn tot equolproductie in de darm en grote variabiliteit in de productie 
van enterolignanen werd eveneens waargenomen. Daarom blijkt dat interindividuele 
verschillen in de darmgemeenschap resulteren in een verschil in blootstelling en 
gezondheidseffect van specifieke fyto-oestrogenen. 
Op het moment dat dit project opgestart werd, waren reeds een aantal in vitro data 
beschikbaar die een hoge biologische activiteit suggereerden van de prenylflavonoïden en 
een op 100 µg 8-PN gestandaardiseerd hopextract ter verlichting van menopauzale klachten, 
was net op de markt gebracht. Ook was reeds lang geweten dat hop sterkere oestrogene 
effecten veroorzaakt in sommige vrouwen in vergelijking met anderen. Maar over het lot van 
deze componenten in het lichaam en hun biobeschikbaarheid was nog niets gekend. Omdat 
geweten was dat variabel microbieel metabolisme de gezondheidseffecten van andere fyto-
oestrogenen bepaalt, was de belangrijkste doelstelling van dit werk om na te gaan of de 
humane darmbacteriën ook een belangrijke rol spelen in de bepaling van de uiteindelijke 
biobeschikbaarheid en biologische activiteit van de prenylflavonoïden uit hop. Tijdens dit 
onderzoek werd in vitro en in vivo onderzoek geïntegreerd door combinatie van batch 
incubaties met SHIME, ratten- en humane studies. 
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Om een eerste idee te krijgen van mogelijke omzettingen van de drie belangrijkste 
prenylflavonoïden, 8-PN, IX en X, door de darmbacteriën, werden enkele fecale stalen in 
vitro geïncubeerd met elk van de componenten. Mogelijke activatie of afbraak werden 
geëvalueerd via LC-MS en de Yeast Estrogen Screen, een biotest die gebruikt wordt voor de 
bepaling van de oestrogene activiteit. Terwijl 8-PN en X stabiel bleven in de batch incubaties, 
was de interessantste vinding dat IX omgezet kan worden in 8-PN door bacteriële O-
demethylatie. Verder onderzoek leerde dat, net zoals dit geldt voor de andere fyto-
oestrogenen, interindividuele variatie in de darmbacteriën de mate waarin deze activatie 
plaatsgrijpt bepaalt. Na toediening van IX aan 51 verschillende fecale stalen konden deze 
ingedeeld worden in sterke (8/51), matige (11/51) en zwakke (32/51) 8-PN producenten. 
In de vrouwelijke hopbel is X de belangrijkste component en zijn de IX en vooral 8-PN 
hoeveelheden zeer laag. Tijdens het brouwen van bier of het gebruik van hop voor 
medicinale toepassingen wordt X echter in belangrijke mate omgezet tot IX, waardoor IX de 
belangrijkste stof is in de uiteindelijke toepassing. Omdat deze component weinig oestrogeen 
actief is, werd in het verleden enkel gekeken naar de 8-PN concentraties bij de bepaling van 
mogelijke effecten van hop opname. Zo worden medicinale hopproducten nu 
gestandaardiseerd op een specifieke hoeveelheid 8-PN en blijken de 8-PN concentraties in 
bier normaal lager dan 100 µg/L, waardoor mogelijke oestrogene effecten ten gevolge van 
bierconsumptie steeds als verwaarloosbaar beschouwd werden. Aangezien IX in 10 tot 50 
keer grotere hoeveelheden voorkomt in bier en hopproducten, zou de ontdekking van de 
activatie van IX door de darmbacteriën deze visie sterk kunnen wijzigen. Als alle IX omgezet 
wordt in 8-PN stijgt de blootstelling aan het plantenhormoon immers ook sterk. Maar omdat 
niet iedereen de juiste darmbacteriën blijkt te hebben om IX om te zetten, zou maar 1/3 van 
de bevolking deze omzetting kunnen waarnemen. Daarom werd dit proces verder in detail 
onderzocht.  
Om de volledige passage van de prenylflavonoïden doorheen het maag-darmkanaal te 
onderzoeken onder meer representatieve in vitro condities, werd de Simulator van het 
Humaan Intestinaal Microbieel Ecosysteem (SHIME) gebruikt. Door toevoeging van IX aan 
de voeding, die drie keer per dag in het systeem komt, werd gevonden dat IX onveranderd 
doorheen maag en dunne darm passeert en dat meer dan 80 % van de IX geactiveerd wordt 
in het distale deel van het colon. Dit ging gepaard met een sterke stijging van de oestrogene 
activiteit in de colonstalen, wat aantoont dat IX effectief omgezet werd in het oestrogeen 
actieve 8-PN. 
Uit deze experimenten bleek dus, althans in vitro, dat opname van IX inderdaad zou 
kunnen leiden tot blootstelling aan het krachtige fyto-oestrogeen 8-PN. Om dit nu in vivo aan 
te tonen, werd een experiment opgezet met twee groepen ratten, geassocieerd met humane 
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darmbacteriën. Eén groep van 12 ratten werd hierbij geassocieerd met sterk 8-PN-
producerende darmbacteriën (Hop+) terwijl 12 andere ratten geassocieerd werden met 
zwakke 8-PN-producerende microbiota (Hop-). Ter controle werden 12 kiemvrije ratten (KV) 
in het experiment opgenomen. Na 5-daagse toediening van 2 mg IX/kg lichaamsgewicht 
konden 3 conclusies getrokken worden. De unieke rol van de darmbacteriën in de activatie 
van IX werd definitief aangetoond, aangezien de KV ratten geen 8-PN produceerden. 
Bovendien leidde activatie van IX tot zowel urinaire excretie van als systemische blootstelling 
aan 8-PN, aangezien 8-PN teruggevonden werd in plasma, lever, nieren en uterus. Tenslotte 
bleek ook in vivo dat verschillen in de intestinale activatie van IX de finale blootstelling 
bepalen aan 8-PN, aangezien hogere urine en plasma 8-PN concentraties gevonden werden 
bij de Hop+ dan de Hop- ratten. 
Om na te gaan of dit ook geldt voor mensen, werd een beperkte interventiestudie 
opgezet met 3 individuen, waarvan de microbiële darmgemeenschap eerder geïdentificeerd 
was als respectievelijk sterke, matige en zwakke 8-PN producent. 5-daagse IX toediening 
bevestigde dat ook bij mensen verschillen in intestinale activatie van IX de blootstelling aan 
8-PN bepalen, aangezien de sterkst 8-PN-producerende persoon het meest 8-PN 
uitscheidde in de urine.  
Hiermee werd dus voor het eerst aangetoond dat de blootstelling aan alle belangrijke 
fyto-oestrogenen afhankelijk is van de capaciteit van de darmbacteriën om de actieve 
metabolieten te produceren. Omdat voeding steeds verschillende precursoren bevat, wordt 
de blootstelling aan fyto-oestrogenen dan ook bepaald door de gecombineerde activatie van 
elke precursor in 1 individu. Om dit na te gaan werden 100 fecale stalen apart geïncubeerd 
met elke precursor en werd de equol, O-DMA, END, ENL en 8-PN productie opgevolgd. Via 
een nieuwe statistische methode werd het productie fenotype (sterk, matig of zwak) 
gedefinieerd voor elk metaboliet en om mogelijke relaties tussen de activatie van 
isoflavonen, lignanen en IX te onderzoeken werd de correlatie bepaald tussen een specifiek 
fenotype van 1 metaboliet en het optreden van andere fenotypes. Terwijl geen inter-groep 
correlatie optrad, wat kan betekenen dat de groepen afzonderlijke pathways volgen, werden 
intra-groep correlaties gevonden, namelijk tussen END en ENL (positief) en tussen equol en 
O-DMA (negatief). Bovendien bleken equol en O-DMA productie positief gecorreleerd met de 
aanwezigheid van respectievelijk sulfaat reduceerders en methanogenen, wat een 
belangrijke indicatie is dat het metabool lot van daidzein in de darm bepaald wordt door 
specifieke intestinale condities, mogelijk gerelateerd met H2 transfer. 
Het feit dat de blootstelling aan 8-PN bepaald wordt door variabele intestinale activatie 
van IX, verklaart finaal waarom sommige personen meer effect van hopproducten 
waarnemen dan anderen. Omdat dit ook betekent dat de werkzaamheid van 
  Samenvatting 
 183 
geneesmiddelen op basis van hop variabel is, was de volgende vraag in dit werk: Wat kan 
gedaan worden om toch iedereen aan dezelfde dosis 8-PN bloot te stellen na 
hopconsumptie? Om hierop een antwoord te vinden, werd eerst getracht intestinale 
bacteriën te identificeren die in staat zijn tot activatie van IX. Na het testen van een reeks 
bacteriën werd uiteindelijk Eubacterium limosum geïdentificeerd en, na een 
selectieprocedure, produceert de stam nu heel efficiënt 8-PN. Omdat deze vinding een 
aantal toepassingen mogelijk maakt, werd het commercieel gebruik beschermd door een 
patent. 
Een eerste toepassing is het gebruik van de bacterie als probioticum ter verhoging van 
de 8-PN productie in de darm. Als de bacterie gedoseerd zou kunnen worden aan mensen 
en in situ in de darm IX kan omzetten, zouden ook mensen die normaal de omzetting niet 
uitvoeren nu wel meer 8-PN aanmaken en dus ook een groter effect van 8-PN ervaren. Na 
gunstige resultaten uit batch experimenten, werd het TWINSHIME model ontworpen. Dit 
model bestaat uit twee SHIME systemen in parallel, en liet toe om tegelijk sterke (Hop+) en 
zwakke (Hop-) 8-PN-producerende microbiota in de SHIME te onderzoeken. Wanneer enkel 
IX toegediend werd aan het model, trad 8-PN productie enkel op in het Hop+ model. Maar 
wanneer ook de bacterie toegediend werd, werd 8-PN nu wel geproduceerd in zowel het 
Hop+ als Hop- model. Om te onderzoeken of E. limosum ook in vivo de 8-PN blootstelling 
kan verhogen, werden de 3 groepen ratten uit het voornoemde experiment opnieuw gebruikt. 
Orale toediening van IX en probioticum leidde tot 8-PN productie in de KV ratten en 
verhoogde de productie en systemische blootstelling in de Hop- ratten tot op het niveau van 
de Hop+ ratten. Dit bevestigde dus dat E. limosum gebruikt zou kunnen worden om te 
zorgen dat iedereen in dezelfde mate blootgesteld wordt aan 8-PN en potentiële 
gezondheidseffecten. Andere mogelijke toepassingen omvatten de prefermentatie van IX in 
het hopproduct om de bron van variabiliteit te verwijderen en fermentatieve productie van 8-
PN als grondstof voor farmaceutische toepassingen. 
In conclusie, in dit werk werd voor het eerst aangetoond dat, net zoals bij andere fyto-
oestrogenen, de blootstelling aan het krachtige fyto-oestrogeen 8-PN niet zozeer afhankelijk 
is van de starthoeveelheid van 8-PN in bier of geneesmiddelen, maar eerder van de 
combinatie van de aanwezige IX hoeveelheid en het intestinaal microbieel potentieel om IX 
te activeren in 8-PN. Bovendien werd een E. limosum stam geselecteerd die in staat is tot O-
demethylatie van IX. Aangezien interindividuele verschillen in de activatie van IX leiden tot 
verschillen in blootstelling aan 8-PN, werden strategieën ontwikkeld die de blootstelling aan 
8-PN in alle individuen op het zelfde niveau kunnen brengen. Eén strategie, namelijk het 
gebruik van de stam als probioticum voor in situ 8-PN productie, werd in detail in vitro en in 
vivo aangetoond. 
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Understanding the Role of Probiotics in Health, International Yakult Symposium, 
Ghent, Belgium. 
  Curriculum vitae 
 223 
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female breast tissue of phytoestrogens”. 
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o Functionele voeding, Food2Know innovatie bij het ontbijt, Ghent, Belgium, March 2006. 
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vivo aanpak”. 
o Gut Microbiology, Research to Improve Health, Immune Response and Nutrition, 
Aberdeen, Scotland, June 2006. Lecture: “Activation of proestrogens from hops by 
intestinal bacteria; Production of 8-prenylnaringenin by Eubacterium limosum” and 1 
poster. 
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  Curriculum vitae 
 225 
Passive participation: 
o Probiotics, Leuven, symposium, Belgium, October 2003. 
o Life, a Nobel Story, symposium, Brussels, Belgium, April 2004. 
o Pre- and Probiotics, symposium, Leuven, Belgium, November 2004. 
o Bacteria and processes in the GUT: in vitro and in vivo, mini-symposium Max Planck 
Institute, Marburg, Germany, October 2005. 
o Stevia: Status and perspectives, 29th LOF symposium, Leuven, Belgium, November 
2005. 
 
 
6 SCIENTIFIC AWARDS 
 
o KVIV-ingenieursprijzen promotie 2003, Koninklijke Vlaamse Ingenieursvereniging 
(2004). Third place (€ 625) with “Bacteriofagen, de antibiotica van de toekomst?”. 
o Win a Biosprint 15 Workstation competition (2005). International competition in which 
the company Qiagen donated an automated pipetting system (€ 12000). Laureate with 
the abstract “Unraveling biotransformation and activity of phytoestrogens by gut 
microbiota”. 
o Poster prize International Yakult Symposium (2005). First place (€ 300) with “Activation 
of proestrogens  from hops (Humulus lupulus L.) by intestinal bacteria”. 
o Poster prize Gut Microbiology, Research to Improve Health, Immune Response and 
Nutrition (2006). Second place (£ 200) with “Activation of proestrogens from hops by 
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Flemish laureate with “Activatie van pro-oestrogenen uit hop in het krachtige fyto-
oestrogeen 8-prenylnaringenine door humane darmbacteriën”. 
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DANKWOORD 
Eindelijk, het dankwoord! Dat betekent dat de rest van dit boek min of meer zijn 
definitieve versie heeft bereikt… Hoog tijd dus om naar goeie gewoonte even nostalgisch 
terug te kijken naar wat tegelijk heel mooie maar ook woelige jaartjes uit mijn prille leventje 
waren en om alle mensen die een essentiële bijdrage geleverd hebben bij het tot stand 
komen van dit doctoraat te bedanken… 
…en dat zijn er heel wat… 
Als ik zo terugkijk hoe het allemaal begonnen is, denk ik dat die dag waarop ik kwam 
informeren voor een thesis bij prof. Verstraete eigenlijk de eerste aanzet moet geweest zijn. 
Ik had iets gelezen over soja fyto-oestrogenen en darmbacteriën en de SHIME wat wel 
interessant leek, maar de hele tijd werken met fecaal materiaal en een simulatie van het 
darmkanaal… mmm… Mijn eerste vraag aan prof. Verstraete was dus logischerwijze: “dat 
SHIME model, dat stinkt toch niet te hard he?” Maar na een kort bezoekje aan de 
catacomben van de faculteit (want daar stond de SHIME toen nog), was ik wel enigszins 
gerustgesteld. Hoewel velen mij zullen tegenspreken, viel de geur in het SHIME lokaal echt 
best wel mee. Uiteindelijk heb ik toen niet rond fyto-oestrogenen gewerkt maar rond 
bacteriofaagtherapie in de SHIME, maar de basis was toen al gelegd. De intrigerende wereld 
van de darmbacteriën, of ‘microbiële vennootschappen’ om het met een politiek correct 
LabMET-woord te zeggen, had mijn volledige interesse. 
Ik had dan het geluk om als aspirant bij het FWO te kunnen beginnen aan een doctoraat. 
Heel gemakkelijk want je moet maar enkele pagina’s schrijven over wat je min of meer wil 
doen tijdens die vier jaar, maar tegelijk ook heel moeilijk omdat je zonder werkplan totaal 
onvoorbereid begint te werken en als aspirant verwacht wordt om je eigen weg te zoeken. 
De eerste mensen die ik daarom moet bedanken zijn mijn twee promotoren, prof. Verstraete 
en prof. Van Camp, die mij met raad een daad bijgestaan hebben tijdens deze zoektocht. 
John, we hebben vooral het eerste jaar samenwerkt toen we probeerden het bacterieel 
metabolisme van sfingolipiden onder de loep te nemen. Hoewel we daar uiteindelijk maar 
gedeeltelijk in geslaagd zijn, heb ik toch veel steun gehad van u en Roeland en ook daarna 
kon ik altijd terecht op je bureau voor een gesprek of een duwtje in de rug. Bedankt 
daarvoor! En prof. Verstraete, Willy, bedankt voor je allomtegenwoordige enthousiasme, 
gekke en nog gekkere ideeën, de vrijheid die je me gaf bij het uitstippelen van mijn pad 
omdat je erin geloofde dat ik er wel zou geraken, maar tegelijk ook het steunpunt waar ik 
altijd terecht kon, … Maar vooral bedankt voor het delen van je ervaring op het gebied van 
mensenkennis en het managen van contacten met bedrijven. We zijn de afgelopen jaren 
vaak samen naar vergaderingen geweest waarbij we in de auto de te volgen strategie 
uitstippelden, en ik heb zelden geweten dat we achteraf onze doelstelling niet bereikt hadden 
of zelfs met meer dan gepland terug vertrokken. Ik ben er zeker van dat die ervaringen nog 
heel belangrijk zullen zijn in een verdere carrière. 
Maar uiteindelijk ben ik dus terug terechtgekomen bij waarmee het allemaal begonnen 
was: fyto-oestrogenen en darmbacteriën en de SHIME.  
Toeval 
Dat is waarschijnlijk het meest belangrijke kernwoord van dit doctoraat. Vanuit de FFW 
kwam prof. De Keukeleire toevallig naar LabMET met het voorstel om het microbieel 
metabolisme van prenylflavonoïden uit hop te onderzoeken. De bedoeling was dat Charlotte 
B. dit ging onderzoeken in haar IWT onderzoek, maar omdat ze haar beurs toen niet haalde, 
kwam het onderzoek toevallig om mijn schoot terecht op een moment dat mijn sfingolipiden 
onderzoek moeilijk verliep. En toevallig bleken de darmbacteriën nog eens heel interessante 
dingen te doen. Toeval. En dit woord komt later nog wel eens terug… 
Dankwoord 
 230 
Door het hop onderzoek werd de FFW een beetje mijn tweede thuis en moet ik daar ook 
een aantal mensen bedanken. Denis, bedankt voor je grote input in dit doctoraat, zowel op 
wetenschappelijk gebied als na de uurtjes, waar je verborgen bowlingtalent naar boven 
kwam. Ik heb genoten van onze samenwerking. Hoewel je ons uiteindelijk verlaten hebt Ina 
(☺), was dit onderzoek nooit op tijd klaargeraakt zonder je urenlange hulp bij de extracties en 
HPLC. Nen dikke merci! Ook de rest van het labo daar natuurlijk bedankt voor jullie bijdrage. 
En ook prof. Bracke en prof. Depypere bedankt voor jullie inbreng. 
En dan zijn er nog twee mensen die ik boven iedereen moet bedanken. Ze is begonnen 
als thesisstudent, dan mee beginnen te schipperen tussen de FFW en FBW om uiteindelijk 
bij menopauzale vrouwen en zelfs in de operatiekamer terecht te komen. Selin, jouw inbreng 
heeft in belangrijke mate bijgedragen tot dit werk. En Arne, post-doc, Technology Developer 
of fuifbeest op de Gentse Feesten, ook jouw blijvende hulp en inbreng was essentieel voor 
dit doctoraat. En onze promotiereis door Amerika en Canada blijft een onvergetelijke tijd. 
Maar mijn eerste thuis was natuurlijk LabMET. Niet alleen op wetenschappelijk gebied 
een voltreffer maar verschillende (ex-)collega’s zijn meer dan enkel dat geworden en ik ben 
blij hier een nieuwe vriendenkring opgebouwd te hebben. Velen zou ik daarom zowel in de 
categorie collega’s als vrienden in dit dankwoord moeten vermelden. Dikwijls vergeten, maar 
o zo belangrijk: de drie vrouwen van het secretariaat, bedankt voor al jullie hulp bij 
administratieve en vele andere zaken. Als laatste telg van de Clermont-Ferrand SHIME 
cluster van het eerste uur zit het er voor mij ook op. Tom, Karel en Kristof, we moeten nog 
eens een Ricard-moment inlassen als herinnering aan de ‘goeie oude tijd’. Maar ook de 
mensen van de huidige SHIME groep, enorm bedankt voor al jullie inbreng. En natuurlijk den 
bureau niet te vergeten! De samenstelling is ondertussen wel al wat veranderd en zelfs het 
lokaalnummer hebben ze ons afgenomen, maar onzen bureau is er nog altijd. Ook bedankt 
voor de hulp aan mijn thesisstudentjes Selin, Charlotte, Veerle, Veerle en Caroline. Bram, 
Charlotte B, Charlotte G, Ellen E, Lynn, Nico, de laboranten Ellen VG, Petra, Siska en Greet, 
Ilse, Hilde, Wendy, Klara, Dirk, Lieven, Han, Vincent, squashmaatjes Korneel, Birgit en Lois, 
the Italian connection Massimo, al hun eventuele partners en natuurlijk alle andere LabMET 
collega’s nen dikke merci! 
  Dr. Rabot, Sylvie, you and all the people in your lab deserve a special thank you for the 
very nice cooperation and hospitality during my stay in Jouy-en-Josas. In the 6 weeks I 
stayed there, I could perform some of the most interesting experiments of this entire book 
and was able, in between climbing the Eiffel Tower or visiting the Louvre, to learn many new 
techniques. Merci! And I hope we can continue the cooperation in the future. 
I would also like to thank all jury members, prof. J. Lampe, dr. E. Vaughan, dr. S. Rabot, 
prof. P. Vandamme, prof. D. De Keukeleire, prof. B. De Meulenaer and prof. W. Steurbaut for 
their willingness to evaluate this work as members of the examination committee. Verder 
wens ik ook het FWO – Vlaanderen te bedanken voor de financiering van dit doctoraat. 
Natuurlijk moet er al eens wat ontspannen worden bij een frisse pint of lekkere barbecue, 
een stevige skireis of andere trip, of een van de vele trouwpartijen. Zonder jullie zou ik hier 
nooit geraakt zijn (al heb ik natuurlijk volgens de meesten de laatste 4 jaar niet echt moeten 
werken als doctoraatstudent). Nele en Pieter, Delphine en Wouter, Cassandra en Gijs, Tine 
en Fre, Karen en Nicolai, Benedicte en Bruno, Sara en Stijn, Tine en Hans, Charlotte en 
Bernd, Sarah en Johan: merci. Alleen al gewoon om er te zijn. 
En dan nu het belangrijkste! Mamsie en papie, ik kan jullie onmogelijk voldoende 
bedanken in deze paar zinnekes. Het zou veel vaker gezegd moeten worden, het feit dat 
jullie er altijd en overal zijn voor ons, is het mooiste wat bestaat. In goede tijden of een 
moeilijke periode, ik wist steeds waar ik terecht kon. Bedankt. En natuurlijk mijn broer en zus 
niet te vergeten. Toon en Liesbeth, nog eens proficiat met jullie prille huwelijk! En mijn kleine 
zusje, onze deur staat altijd open in Gent en als je nog eens wil gaan skiën, ik ben kandidaat! 
Bomma, bedankt om er altijd voor ons geweest te zijn en ik ben fier om als kleinzoon dit 
doctoraat in uw aanwezigheid te kunnen behalen! 
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Toeval - Acaso 
 
Het ging nog een keer terugkomen in dit dankwoord, 
al zou een ander woord misschien beter gepast zijn hier 
 
Lot - Destino 
 
Six weeks in Paris, more than enough to find a Portuguese connection 
 
A minha pequenina, estou muito feliz que encontrei-te em Paris, 
E espero que vamos ficar juntos pela nossa vida fora 
O meu amor da minha vida, obrigado 
 
 
  
 
